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Chapter I  
General Introduction 
I.1. Instabilities of Protein Pharmaceuticals 
Stability during the entire lifecycle of a protein pharmaceutical is a prerequisite for the 
tolerability, efficacy, and safety of the medical treatment, as physical as well as 
chemical alterations may lead to decreased drug activity, higher toxicity and moreover 
increase the risk of unwanted immunological reactions in the patient.1-5  
This is highly relevant for biopharmaceutical development, as all stages from 
production (fermentation/expression, unfolding/refolding, purification, and formulation), 
over processing and fill-and-finish (material transfer, filtration/sterilization, filling, and 
possibly spray- or freeze-drying), to shipment, storage and administration to the patient 
have the potential to expose biopharmaceuticals to a multitude of external stress 
factors that jeopardize the stability and activity of the drug substance. These stress 
factors include, among others, changes in the solution pH and ionic strength, 
temperature variation including elevated temperatures and freeze-thaw cycles, as well 
as exposure to light, mechanical and interfacial stress (stirring, pumping, shaking, or 
pressurization).6-9 
The numerous potential instabilities of a protein pharmaceutical can be separated in 
two major groups, namely chemical modifications (I.1.1) and physical changes (I.1.2). 
As a general classification, chemical instabilities comprise a versatile number of 
reactions in which the chemical composition of the primary structure is altered via 
formation or breakage of covalent bonds, whereas physical instabilities include 
changes in the proteins secondary or higher order (tertiary, quaternary) structure.10 
Besides this idealized grouping, it is to mention that all instabilities of a protein are 
highly interrelated and therefore can be formed of or lead to degradation pathways of 
other instability classifications. In the following, these groups will be addressed in more 
detail, while exemplary degradation pathways and connections thereof will be given 
and analytical approaches are presented. 
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I.1.1. Chemical Instabilities 
Chemical instabilities occur by alteration and degradation of amino acid side chains 
and the peptide backbone under intermediate and long-term storage of 
biopharmaceuticals. The number of possible chemical reactions and degradation 
pathways is large and often highly depending on the amino acid sequence of the 
molecule of interest. Possible reactions include deamidation (mainly asparagine) and 
isomerization (aspartic acid), oxidation (sulfur atoms e.g. methionine and aromatic 
rings e.g. tryptophan), formation, breakage or exchange of disulfide bonds 
(cysteine/cystine), glycation (reducing sugars), deglycosilation and peptide backbone 
cleavage. The respective control strategy for these instabilities depends strongly on 
the underlying degradation mechanism and often includes pH and excipient 
adjustments in liquid protein formulations. However, also storage and handling 
conditions (temperature, light exposure) as well as the nature and quality of the 
chosen primary packaging material and the presence of trace amounts of impurities 
can have detrimental effects on chemical stability.10-20 
Depending on the nature of the chemical instability present, the degraded protein 
exposes a changed hydrophobicity, polarity, mass, and/or charge. Moreover, 
aggregation and/or fragmentation can potentially be induced. Thus, separation, 
identification and quantification of chemical changes are preferably performed by the 
use of liquid chromatography (reversed phase- (RP-), or ion exchange- (IEX-) HPLC), 
electrophoresis and isoelectric focusing (capillary- (cGE or cIEF) or gel- (SDS- or IEF-
PAGE) format) or mass spectrometry (MS).21-26 
I.1.2. Physical Instabilities 
The group of physical instabilities can be subdivided in protein conformational 
changes, colloidal interactions, surface and interfacial instabilities, as well as 
aggregate and precipitate/particle formation.10,13,27 In the present work, the main focus 
lies on the determination and comparative evaluation of protein unfolding parameters 
used for the high-throughput screening of protein formulations. Furthermore, the 
interplay of conformational and colloidal stabilities will be discussed in the context of 
non-native protein aggregation and precipitation as degradation endpoint. Surface and 
interfacial stability, not being an integral part of our investigations, will consequently 
not be further introduced. 
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I.1.2.1. Conformational Instability 
Conformational instabilities summarize alterations in the proteins secondary or higher 
order (tertiary/quaternary) structure, which are commonly described as protein 
unfolding or denaturation and have wide-ranging impacts on protein stability. 
Moreover, structural integrity of the labile native folded state is essential for biological 
activity and therefore efficacy of a biopharmaceutical drug.7,10 
Conformational transitions between the completely folded/native conformation of a 
protein and completely unfolded/denatured states are termed folding and unfolding. 
The native folded state typically buries hydrophobic amino acid residues in the core of 
the protein, while hydrophilic moieties are exposed to the (aqueous) solvent. This is 
called the hydrophobic effect. Intramolecular interactions as van der Waals’ forces, 
hydrophobic and ionic interactions, as well as hydrogen bonds stabilize the native 
conformation, whereas the unfolded state is strongly entropy driven. These opposing 
forces result in a small net thermodynamic stabilization of the folded state that 
corresponds to a minimum free energy. Thus, even small perturbation of the 
conformational stability, by e.g. temperature excursions, pH changes or salt addition, 
may mitigate the abovementioned intramolecular interactions, alter the three-
dimensional structure and lead to partial or complete unfolding of the protein. In further 
consequence, protein unfolding creates aggregation-prone intermediates, which 
expose hydrophobic amino acid side chains (i.e. hydrophobic patches or aggregation 
hot spots) to the solvent and hence trigger protein aggregation via random 
intermolecular self-association. A higher conformational stability or Gibbs free energy 
of unfolding will in turn favor the native state in the unfolding equilibrium and reduce 
the number of unfolded, aggregation-prone species.7,11,13,28-30 For several monoclonal 
antibodies (mAbs), mechanistic evidence is given that the aggregation-prone regions 
(APRs) that tend to interact via hydrophobic interaction upon unfolding are located in 
the antigen-binding fragments (Fab). Hence, the aggregation propensity of mAbs is 
highly dependent on the conformational stability of the Fab domains, rather than the 
least stable domain.31-34 
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The entirety of possible protein conformations (i.e. the conformational space) can be 
visualized and expressed by the use of the folding funnel model, which displays 
conformation ensembles in the overall folding energy landscape that reaches from the 
free energy minimum of the native conformation, over a multitude of folding/unfolding 
intermediate states (e.g. transition state ensembles), to the energy-rich unfolded 
states. Non-native aggregates, originating from intermolecular hydrophobic 
interactions form additional ensembles in the energy landscape, which can be 
appended to the folding funnel. In analogy to the native state, they feature additional 
free energy minima, which render non-native aggregation in biopharmaceuticals 
mostly irreversible.35-38  
In basic research and industry practice, higher-order structural changes can be 
examined by using a variety of spectroscopic techniques as UV absorbance, intrinsic 
and extrinsic fluorescence emission spectroscopy (FES), near- and far-UV circular 
dichroism (CD), as well as Fourier-transform infrared (FTIR) and Raman spectroscopy. 
Moreover, differential scanning calorimetry (DSC) is frequently used to detect 
conformational changes upon thermal unfolding and furthermore directly provides 
thermodynamic readout parameters. In addition to these established analytical 
standard approaches, more detailed structural information can be obtained by using 
highly complex assays as small-angle X-ray scattering (SAXS) or hydrogen-deuterium 
exchange (HDX) with nuclear magnetic resonance (NMR) or mass spectrometry (MS) 
readout.6,39-44 
I.1.2.2. Colloidal Instability 
Colloidal instability describes an unwanted solution condition that is caused by 
electrostatic self-interaction of proteins. The balance between repulsive, neutral and 
attractive forces is strongly influenced by the formulation pH, which in turn dictates the 
net charge of the protein in solution. At the pH of the proteins isoelectric point (pI), the 
net charge approaches zero and the electrostatic repulsion between molecules is 
minimal. At pH values far away from the pI, proteins are highly and uniformly charged, 
which leads to intra- and intermolecular electrostatic repulsion. This increases the 
colloidal stability, but may induce aggregation via the unfolding mechanism described 
in section I.1.2.1. In consequence, the ionic strength and the addition of uncharged co-
solutes generate a major impact on the manifestation of molecular interactions due to 
possible shielding of the interacting moieties. Moreover, non-uniform charge 
distribution can create dipolar interactions between molecules, which dramatically 
destabilize the system.7,11,45-48 
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The self-interaction propensity of a protein in solution can be estimated via its zeta 
potential, while interaction parameters as the osmotic second virial coefficient (B22), or 
the diffusion interaction parameter kD are used to characterize repulsive or attractive 
protein-protein interactions. Colloidal stability is favored at high (positive or negative) 
zeta potentials and positive (high) B22/kD values, both representing pronounced 
repulsive forces which inhibit the approximation and assembly of molecules.7,11,45  
While the zeta potential of a protein in solution is usually determined by evaluating the 
electrophoretic mobility of the protein in combination with laser doppler velocimetry, 
several approaches based on light scattering (SLS and DLS), analytical 
ultracentrifugation (AUC) and self-interaction chromatography (SIC) exist to determine 
B22 and/or kD.48-55 
I.1.2.3. Aggregation 
Protein aggregation and particle formation is the ubiquitous route of protein instability 
that can be described in general terms as the formation of multimeric species by self-
association. Aggregation can occur for the native protein or result from a multitude of 
chemical and physical instabilities. Thus, protein aggregation may take many different 
shapes and numerous different classifications of aggregates exist in the literature. 
These mostly rely on the preceding degradation mechanism, the reversibility of 
aggregation, the conformation or solubility of aggregates, or simply the particle size 
and morphology.7,8,56-61 
Focusing on the mechanisms of aggregation induced by physical instabilities, both 
colloidal and conformational changes are described to potentially foster aggregation. 
Whereas for colloidal interactions, changes in the solution properties (pH and salt 
concentration) and the interrelated charge alteration of the protein may promote 
association between structurally native molecules, conformational changes alter the 
native structure and hence form folding-intermediates that are presumably prone to 
aggregation. Consequently, the resulting aggregation pathways are termed native 
aggregation and non-native aggregation, depending on the structural integrity of the 
protein involved. While native aggregation is potentially reversible, non-native 
aggregation leads in many cases to irreversible aggregate formation.45,50,57  
Following the Lumry-Eyring two-state irreversible denaturation model62-66 that 
describes an aggregation mechanism from native monomers, which first undergo a 
reversible conformational change to aggregation-prone unfolded intermediates and in 
a second step irreversibly assemble to the aggregated state, the interplay and control 
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of conformational and colloidal stability are of great importance in order to effectively 
prevent the formation and growth of aggregation.29,45,67,68 
In an orthogonal classification approach, the size-differentiation spans a wide range 
from soluble aggregates/oligomers (< 100 nm, i.e. dimer, trimer etc.), over sub-micron 
(100 – 1000 nm) and subvisible particles (1 – 100 µm) to visible particles (> 100 µm). 
For all classes, the nomenclature is highly irregular and differs from one field of 
research to another.58,59 Depending on the size and nature of the aggregates/particles 
to be investigated and the specific interrogation, as for example separation, sizing, 
quantification, visualization, or discrimination based on the particulate nature, different 
analytical approaches are pursued. In practice, the aggregate and particle analytics 
applied are either used for direct sizing/counting or for indirect aggregation detection 
via characterization of the higher order structure (see section I.1.2.1). Beyond visual 
inspection according to the compendial standards for visible particles, methods based 
on light absorption or blockage (i.e. light obscuration (LO), turbidimetry/nephelopmetry, 
or optical density (OD)), microscopy (e.g. membrane microscopy or backgrounded 
membrane imaging (BMI)), flow imaging (e.g. micro-flow imaging (MFI)) or the coulter 
principle (coulter counter (CC)) are used for quantification and/or size determination of 
visible to sub-visible particles. In the sub-micron particle-range and for soluble 
aggregates, separation methods (e.g. size exclusion chromatography (SEC), analytical 
ultracentrifugation (AUC), field flow fractionation (FFF, e.g. AF4), SDS- or native 
PAGE, isoelectric focusing (IEF)) and light scattering (static and dynamic light 
scattering (SLS, DLS), nanoparticle tracking analysis (NTA)) predominate besides 
other more sophisticated approaches like electron- or atomic-force microscopy (AFM) 
and mass spectrometry (MS).8,61,69-72 
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I.2. Stabilization of Biopharmaceuticals in Solution 
As outlined in section I.1, the stability, efficacy and safety of biopharmaceuticals in 
solution is predetermined by the intrinsic properties of the protein itself, namely the 
primary amino acid sequence, the higher-order structure conformation, and post-
translational modifications. 
During protein formulation development, extrinsic environmental factors are modified 
and optimized in order to enhance the physical and chemical stability of the protein in 
solution. These factors consist of basic formulation conditions like the protein 
concentration, pH value and ionic strength, as well as a long list of possible stabilizing 
excipients that includes besides others a variety of buffer salts, sugars, polyols, amino 
acids, polymers, and surfactants. The influences on the stability of protein 
pharmaceuticals are as versatile as the mechanisms of action and will be outlined in 
the following.11,13,56,73  
The importance of the pH value for the stability of proteins is evident, as chemical and 
physical (conformational, colloidal and interfacial) stabilities are often directly 
dependent on the chosen formulation pH. The usually applicable operating range 
covers pH values between 3 and 10, while the majority of products is formulated in a 
narrower range between 5 and 7.10,11,13,74,75 In most protein formulations, the pH is 
stabilized via buffering agents, while for high concentration protein formulations the 
buffering capacity of the protein itself can be utilized.103,104  
However, the influence of ionic strength is less unambiguous and increasing the salt 
concentration can have stabilizing, destabilizing or neutral effects, mainly dependent 
on the prevalent colloidal stability properties, the composition of the protein, the pH, as 
well as the type and concentration of salt. This is due to electrostatic screening of 
intra- and intermolecular interactions by increased salt content and potential direct 
interactions with the protein. Under attractive intermolecular conditions, moderate salt 
addition stabilizes the protein in solution, while under repulsive conditions, molecular 
attraction can be provoked. An inverse effect can be derived for the de-/stabilization of 
intramolecular interactions.11,13,14,50,76,77 
For formulation components and excipients there are many stabilization mechanisms 
assumed, which describe the interaction of excipients and proteins in solution, but only 
few are well established and generally accepted. A group of mechanisms termed 
preferential interactions rank among the best investigated and are described to 
enhance the conformational stability. Thereby, stabilization can on the one hand side 
be achieved by preferential binding of the excipient to the native state of the protein. 
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According to the Wyman linkage function78, this binding leads to net-stabilization and a 
shift of the unfolding equilibrium towards the native state. On the other hand side, 
excipients can preferentially act as excluded solutes and not bind to proteins. This 
preferential exclusion/hydration mechanism was extensively investigated by Timasheff 
and coworkers79-84. Exclusion of the excipient from the vicinity of the protein increases 
the free energy of both, the native and the denatured state. Thereby, the native 
compact state is favored as the free-energy increase is larger for the solvent 
accessible unfolded state and therefore the free energy difference, i.e. free energy of 
unfolding, is enhanced. While preferential binding is the predominant stabilization 
mechanism for buffer salts and is also described for surfactants, polymers and 
cyclodextrins, non-specific preferential exclusion/hydration is known for many sugars, 
polyols and polymers.9,10,13,74,85 Though, it is to mention that both mechanisms can also 
lead to unwanted stability effects. In some cases preferential binding favors the 
denatured state over the native state, which leads to conformational destabilization. 
Moreover, the thermodynamically unfavorable preferential exclusion not only enhances 
the free energy of unfolding, but at the same time decreases the free energy of 
association, which jeopardizes the colloidal stability an may promote protein self-
assembly and aggregation.10,13,85,86  
Surfactants are traditionally used to prevent proteins from interaction with hydrophobic 
interfaces (air-water, ice-water, container-water, etc.), which can lead to subsequent 
unfolding and aggregation. Thus, they are very efficient in stabilizing proteins from 
various stresses during manufacturing, shipment and handling. The primary mode of 
action is presumably direct competition with the protein for the interfacial assembly and 
adsorption, while direct binding to hydrophobic patches of the proteins and associated 
conformational and colloidal stabilization was reported as well.85,87-92 The downside of 
non-ionic surfactant is their inherent instability against degradation by oxidation and 
hydrolysis, which in turn can induce protein aggregation under long-term storage.93-96 
As an alternative, β-cyclodextrin derivatives like hydroxypropyl-β-cyclodextrin (HP-ß-
CD) showed comparable stabilization effects by weak direct interaction to the protein 
rather than by competitive interface displacement.97,98 
In formulation practice, a detailed knowledge about the present prevailing degradation 
mechanism is a basic prerequisite for efficient screening designs. Moreover, the effect 
of excipient addition and the detailed underlying mode of action are often difficult to 
predict and the selection of excipients used for enhancing the protein stability is 
therefore mostly based on previous experience and tested in a try and error approach. 
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In a state-of-the-art formulation development approach, the colloidal and chemical 
stability is usually optimized first by screening a variety of different pH values, buffering 
agents and salt concentrations. In the next step, conformational and interfacial stability 
are improved by the addition of sugars, sugar alcohols and surfactants. Thereby, 
unfolding and aggregation during processing and storage can be reduced.11,13,56  
Beyond that, rational additive selections by computational modelling or protein-
excipient binding experiments are still rare99-101 but should be pursued more often in 
the future, in order to increase the knowledge and understanding of the underlying 
stabilization principles and thus effectively prevent degradation.102 Additional emergent 
stabilization approaches target the intrinsic protein stability already during candidate 
selection and protein engineering by introducing mutations or in vitro modifications in 
order to reduce the aggregation propensity or immunogenicity of the molecules from 
scratch.103-110 
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I.3. Analytical Approaches used for the Assessment of Protein 
Stabilities and Early Protein Formulation Screenings 
In all stages of biopharmaceutical drug product development, many approaches are 
pursued in order to enhance the R&D productivity by early risk mitigation and 
developability assessment, which goes hand in hand with an overall reduction of the 
time and cost effort.111 
During formulation development, the main attention lies on the search for fast 
approaches that surrogate the conventional candidate selection process by long-term 
stability testing under real-time conditions that match the intended storage period and 
temperature (usually up to 24 month at 2-8 °C). By establishing that, the number of 
possible formulation candidates can be narrowed down earlier and a lead formulation 
can be selected faster. The most established and ICH recommended alternatives are 
accelerated stability testing112,113 at elevated temperature and relative humidity (r.h.) 
conditions (e.g. 25 °C/60% r.h. or 40 °C/75% r.h.), as well as short-term stress 
testing6,114-116 (i.e. forced degradation) by temperature excursion, freeze-thawing, 
agitation, oxidation, light etc.. Both approaches can support formulation development 
by revealing stabilizing conditions, as well as degradation products and associated 
pathways in comparably short time of several months (e.g. one to six months) for 
accelerated stability testing down to several days (e.g. one day to one week) for short-
term stress testing. 
In order to further accelerate early formulation screenings and lead formulation 
selection, current development approaches focus on the predictive and comparative 
high-throughput determination of physical protein stabilities and aggregation pathways. 
By this means, a combination of colloidal and conformational stability parameters are 
determined for a large number of protein formulations. Subsequently, the results are 
used to derive stability trends and determine excipient combinations, which exhibit 
maximum overall stability and thus are progressed as lead formulation compositions. 
The variety of analytical techniques and assays used for such stability investigation are 
compiled in recent reviews44,67,117-119. In summary, colloidal stability is characterized via 
assessment of interaction parameters (kD or B22) as outlined in section I.1.2.2. 
Conformational stability is mainly determined by thermal ramp denaturation and 
calculation of onset- or midpoint-temperatures of unfolding (Tm,onset or Tm) as stability 
indicative surrogate parameters. Traditionally, unfolding transitions are tracked by 
highly sensitive differential scanning calorimetry (µDSC)40,120-122, which moreover 
allows for direct evaluation of thermodynamic parameters as the enthalpy (ΔH) and the 
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Gibbs free energy of unfolding (ΔG). A long-time established alternative to µDSC is 
based on circular dichroism (CD)122-124 and exploits protein unfolding induced ellipticity 
changes over temperature. Differential scanning fluorimetry (DSF)125-127, a recent 
thermal denaturation and thermal shift assay provides a much higher throughput and 
lower sample consumption. The technique is based on fluorescence enhancement of 
polarity or viscosity sensitive extrinsic fluorescence probes that are also applied to 
isothermal aggregate detection128-131. However, as it requires the addition of non-
inherent formulation additives, it exhibits limitations in terms of excipient compatibility 
or protein concentration, depending on the chosen dye.132,133 These restrictions are 
overcome with the recent development of high-throughput intrinsic fluorescence 
emission spectroscopy (FES) instrumentation that alongside thermal protein unfolding 
moreover enables the analysis of aggregation events via the associated/concomitant 
light scattering increase.134-136 Likewise, high-throughput aggregation and precipitation 
screening can also be obtained by optical density (OD) or turbidity analysis. A long-
time neglected alternative to thermal unfolding assays exists in chemical unfolding (i.e. 
isothermal chemical denaturation (ICD))137-139, which uses titration series of chaotropic 
denaturants like Urea or GuHCl to calculate the unfolding midpoint concentration (Cm) 
or determine ΔG as stability indicators. ICD is frequently used in fundamental research 
but due to the low throughput and the unknown effect of formulation manipulation by 
the denaturant addition only sparsely applied to extensive formulation screenings. 
However, the throughput was much enhanced by the introduction of high-throughput 
instrumentation for analysis (FES or CD) and the developments in automated liquid 
handling, facilitating the labor intensive dilution series preparation. Moreover, ICD, 
typically leading to fully reversible unfolding, allows for more straightforward and 
precise thermodynamic evaluation than aggregation-prone thermal unfolding that may 
be driven by aggregation kinetics and lead to deviations from the models fitted to the 
unfolding curves. The validity and sensitivity of stability assessments in the presence 
of molar concentrations of chaotropic agents still needs to be thoroughly evaluated. An 
alternative approach to investigate physical protein stabilities by making use of 
chaotropic denaturants was recently proposed by Svilenov et al.140. There, the size 
increase of monoclonal antibodies after incubation and subsequent dilution from a 
denaturing agent was investigated and found to change with different denaturant 
concentrations and formulation compositions. The straightforward approach and good 
correlation to standard assays suggests further evaluation of this method in larger 
formulation screening sets. 
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A few mechanistic case studies are reported in the literature45,50,68,141-144, which further 
investigate the impact of conformational changes and colloidal interactions on the 
overall aggregation propensity via high throughput screenings and stress testing. The 
outcome corroborates the importance and mutual dependency of both, repulsive 
electrostatic interactions and unfolding stability to support aggregation resistance and 
gather further insight in the underlying degradation mechanisms. Depending on the 
solution conditions, each degradation route can represent the rate limiting step for 
aggregation, which additionally underlines the high importance and far-reaching effect 
of the chosen formulation parameters. 
However, the overarching question for all accelerated stability approaches lies in the 
correlation and predictive power of the analytical results compared to the real-time 
quiescent storage conditions. The prediction of real-time aggregation rates or 
aggregation propensities is very challenging, as aggregation typically does not follow 
Arrhenius-like behavior. 6,145-147 Some formulation screening case studies use colloidal 
and/or conformational stability investigations to rank biopharmaceutical formulations 
according to their physical stability and compare the results to stability studies. 
Thereby, the majority of correlations are drawn to accelerated stability conditions, 
while valuable systematic comparisons to real-time stability studies as presented by 
Youssef et al.148 and Maddux et al.149 are rare. The results are diverse, ranging from a 
majority of partly predictive studies135,150-152 to some encouraging data sets showing a 
high overlap148,149,153. However, as learned from these studies, the correlation of 
accelerated stress conditions (e.g. 40 °C) to refrigerated conditions is often 
comparably weak or even worse. The reason for the excess of modest results might lie 
in the fact that protein degradation is a multifactorial process that needs to be 
examined by multiple approaches in order to gain a conclusive data set. Moreover, 
chemical changes as potential alternative degradation routes have to be kept in mind, 
which typically require longer timescales to establish and thus are only being covered 
subordinate by predictive stability approaches. In summary, the predictive power of 
high throughput screenings, as well as accelerated and stress studies needs so far to 
be assessed case by case and future development in this field is dependent on new 
analytical approaches overcoming current limitations and providing valuable insights in 
protein degradation pathways in order to aid the selection of stable formulations 
earlier.151 
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This thesis supports the quest for new orthogonal analytical approaches applicable for 
high-throughput stability assessments during early formulation screening. MicroScale 
Thermophoresis (MST) is used as a novel readout for thermal protein unfolding and 
aggregation assessments, as well as for rational excipient selection by protein-
excipient binding analyses. Furthermore, a technique termed Thermo-Optical Protein 
Characterization (TOPC) is developed as a screening tool investigating non-native 
aggregation propensities within minutes by forced thermal degradation. All results are 
compared to state-of-the-art analytical approaches and assays in the field. 
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Chapter II  
Aim and Outline of the Thesis 
The overall aim of this thesis is to develop and qualify MicroScale Thermophoresis as 
a versatile and reliable tool for the high-throughput analysis and stability prediction of 
protein pharmaceuticals. The application of MST targets three major challenges and 
objectives in the early stage development of liquid protein formulations: (i) unfolding 
stability, (ii) aggregation propensity, and (iii) protein-excipient interactions. These 
investigations simplify the workflow of formulation scientists by reducing the almost 
infinitely large number of possible formulation candidates already in early development 
phases. Moreover, thermophoresis potentially delivers new insights in physical stability 
changes and protein-excipient interactions, which would help to understand the 
underlying degradation and interaction mechanisms and to derive a protein-specific 
stabilization strategy. 
At first, an introduction to the fundamentals of MST is given (Chapter III) and the 
measurement principles, as well as standard terms are outlined for a better 
understanding of the following method and assay development phase (Chapter IV). 
Therein, the focus is on the construction and validation of multiple MST-based 
prototype measurement setups and assays suited for the abovementioned tasks in 
formulation development. Besides high precision and throughput, label- and 
immobilization-free protein analysis was a prerequisite. Moreover, routine approaches 
for straightforward data analysis and first proof-of-principle results from the prototype 
instruments are presented. In the following, the prototype setups are continuously 
improved and the implemented assays are tested and extended along several protein 
stability and formulation screening case studies. These include the investigation of 
model proteins (Chapter VI), drug candidates (Chapter V and Chapter VIII) as well as 
therapeutic biopharmaceuticals (Chapter VII). In order to work out the strengths and 
weaknesses of the developed methods and investigate the stability and interaction 
paradigms of the respective protein in greater detail, the results of the thermophoresis 
approaches are comprehensively benchmarked with established analytical methods 
and alternative assays for the respective analyses. In an overall summary and 
conclusion (Chapter IX), the results of the unfolding and aggregation investigations, 
forced degradation studies and protein-excipient interactions are reflected in order to 
derive a final estimation of the utility of thermophoresis-based formulation development 
approaches. 
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Chapter III  
MicroScale Thermophoresis (MST) 
III.1. Fundamentals of Thermophoresis 
When a temperature gradient is applied to a macromolecular aqueous solution or a 
colloidal suspension, a heat transport is evoked and molecules start to migrate 
directed in the gradient.1-3 This connection between a flow of heat and a flow of 
molecules along a temperature gradient is called thermophoresis, thermodiffusion or 
the Ludwig-Soret effect.4,5 
The molecules experience, additional to the ubiquitous Brownian motion, a steady drift 
velocity (𝑣𝑇), depending linearly on the size of the thermal gradient (∇𝑇) and the 
thermophoretic mobility, or in other words the thermal diffusion coefficient (𝐷𝑇) which 
acts as proportionality constant and hence is no diffusion coefficient in the proper 
meaning of the word (Equation 1).6,7 The resulting mass flow (𝐽) derives from the 
interplay of the Brownian diffusion coefficient (𝐷) and 𝐷𝑇(Equation 2).
2,8,9 
 
 𝑣𝑇 = − 𝐷𝑇∇𝑇  [Equation 1] 
 𝐽 = 𝐽𝐷 − 𝐽𝐷𝑇 = −𝐷∇𝑐 − 𝑐𝐷𝑇∇𝑇 [Equation 2] 
 
Since the thermal diffusion is compensated by ordinary mass diffusion a steady state 
is created. In the absence of convection, the steady-state concentration gradient (𝛻𝑐) 
is only dependent on the Soret coefficient (𝑆𝑇) and the size of the temperature gradient 
(∇𝑇) (Equation 3). Therefore, the Soret coefficient determines the magnitude of 
thermophoretic mobility in the steady-state (Equation 4).3,4,6 
 
 ∇c = −c ST∇T  [Equation 3] 
  ST =
DT
D
 [Equation 4] 
 
The orientation of the thermophoretic motion, respectively the sign of 𝐷𝑇 differs from 
one investigated system to another and is not yet predictable. While most biological 
samples show a directed movement towards the cold, termed thermophobic motion, 
there are examples of molecules displaying a flow along the temperature gradient, 
showing a thermophilic behavior. The Soret coefficient is, according to a positive 𝐷𝑇, 
by definition positive for thermophobic molecules.2,10 
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Together with the presence of a local thermodynamic equilibrium, as established by 
Duhr and Braun9, the Soret coefficient equals the negative entropy (𝑆) of the particle-
solvent system (Equation 5). Taken the contributions of the temperature-sensitive 
entropy of water hydration and the entropy of the ionic shielding into account, which 
constitute the major influence to the particle entropy in water, the expression adds up 
to Equation 6 with 𝜎𝑒𝑓𝑓 being the effective charge per surface area, 𝑠ℎ𝑦𝑑 the hydration 
entropy, 𝜀  the dielectric constant and 𝛽 its temperature derivative. Considering the 
term, the Soret coefficient (𝑆𝑇) is therefore linearly dependent on the particle surface 
(𝐴) and the Debye length ( 𝜆𝐷𝐻).
1,6,11 
 
 ST = −
S
kT
 [Equation 5] 
 ST =
A
kT
(−shyd +
βσeff
2
4εε0T
) × λDH [Equation 6] 
 
Since thermophoresis is the connection of the thermophoretic mobility (𝐷𝑇) and the 
diffusion coefficient (𝐷), it is mainly dependent on global changes in size, charge and 
the solvation entropy of the molecule, as long as the buffer conditions are maintained 
constant.4,11,12  
This indicates that changes in the extent and the direction of the thermophoretic 
movement should allow for the detection of unfolding, aggregation and binding events 
of a biopharmaceutical drug, being the main scopes of our investigations. 
III.2. Measurement Setup and Readout 
The all-optical measurement setup for MicroScale Thermophoresis, a technology 
developed at the group of Prof. D. Braun at the biophysics department of the LMU, 
which was further improved and later commercialized by the university spin-off 
company NanoTemper Technologies GmbH, is schematically represented in Figure 1. 
In this approach, a moderately focused IR-laser (1480 nm), which is strongly absorbed 
by water, is used to generate a local, precise and steep temperature gradient in the 
focal volume of glass capillaries containing the protein sample. This temperature 
increase results in thermophoretic movement of molecules which can be tracked label- 
and immobilization free via the intrinsic fluorescence of aromatic amino acids (mainly 
tryptophan and tyrosine13,14) that is excited by a UV-LED (280 nm). The combination of 
the IR-laser coupled into the same optical path as the excitation/detection unit ensures 
co-localization of temperature increase and fluorescence detection.4,11,12,15-17 
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Figure 1: MicroScale Thermophoresis measurement setup. 
Because the local temperature of the solution in the laser spot is only increased 
around 2-6 K on a micrometer scale and therefore moderate temperature gradients are 
used, the setup fulfills the requirements to apply the laws of a local thermodynamic 
equilibrium.1,6,18  
The recorded changes in fluorescence over time (i.e. fluorescence timetrace) can be 
divided in six different phases, distinguished by their respective timescales and their 
characteristic fluorescence signals dependent on the IR-Laser heating (Figure 2).4 
 
Figure 2: Typical MST timetrace, generated by measuring and normalizing intrinsic fluorescence 
over time subject to IR-laser input. Figure copied from Jerabek-Willemsen et al.4 
MICROSCALE THERMOPHORESIS (MST) 
FOR PROTEIN FORMULATION DEVELOPMENT 
28 
In the initial state before laser heating, all molecules are subject to omnipresent 
undirected Brownian motion, resulting in a uniform fluorescence readout. After 
switching on the IR-laser, the temperature in the solution is increased and two effects 
are induced which can be easily separated by their distinctive timescales. Within 
approximately 50 ms, an exponential decrease in intrinsic fluorescence is present, 
which is called temperature jump. This event is based on temperature induced 
changes in the local surrounding of the fluorophores (aromatic amino acids) and does 
not rely on molecular motion yet. On the slower timescale of diffusion, thermophoresis 
sets in only after more than 1 s and changes the fluorescence signal because of the 
molecular depletion from the heated spot. In contrast to the temperature jump, which is 
sensitive to changes in the local properties, thermophoresis is a probe of the global 
surface changes. After a timescale of 10 to 30 seconds, thermal diffusion and ordinary 
diffusion average out, which leads to a steady-state distribution of molecules. After a 
steady-state is reached, the infrared-laser is turned off, and the sample cooling evokes 
an inverted temperature jump before the molecules undergo pure mass diffusion in 
order to undo the concentration imbalance and reestablish a uniform distribution.1,4,11,12 
III.3. Data Evaluation 
The abovementioned phases of a MST timetrace are used for the calculation of the 
MST parameters thermophoresis, temperature jump, as well as the combination of 
both. All parameters can be determined from the thermophoretic signal by evaluating 
the concentration (= fluorescence) ratio of a timescale after the event (hot) and a 
timescale before the event (cold)1, which is expressed through the normalized 
fluorescence (𝐹𝑛𝑜𝑟𝑚), given in permille. Moreover, as deduced in section III.1, the 
change in concentration is linearly related to the Soret coefficient, because the 
alterations in temperature and concentration are small compared to the initial values 
(Equation 7).4,12 
 
 Fnorm =
Fhot
Fcold
≡
chot
ccold
= e−ST∆T [Equation 7] 
 
By variation of the moment in time at which 𝐹𝑐𝑜𝑙𝑑 and 𝐹ℎ𝑜𝑡 are measured, it is possible 
to distinguish between thermophoresis, the temperature jump, or the combination of 
both. Furthermore, intrinsic fluorescence can be evaluated from the raw initial 
fluorescence (Figure 3).4 
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Figure 3: Exemplary cursor settings of hot (red bars) and cold (blue bars) for the evaluation of 
thermophoresis (left – top), temperature jump (top – right), and thermophoresis with jump (bottom 
– left). Moreover, intrinsic fluorescence can be evaluated from the raw initial fluorescence, as 
indicated by the red arrow (bottom – right). 
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III.4. Protein-Excipient Interaction Analysis by using MicroScale 
Thermophoresis (MST) 
The well-established standard application of MST is the analysis of all kinds of 
biomolecular interactions, ranging from ion- or small molecule-protein interactions, 
over protein-protein, protein-DNA or protein-RNA interactions to assays investigating 
multi-component complexes as liposomes or ribosomes. This wide range of 
interactions is possible, as MST is not dependent on binding-induced size changes, 
which is a benefit over alternative approaches as fluorescence correlation 
spectroscopy (FCS) or surface plasmon resonance (SPR).4,12,16 
Moreover, the MST assay is fully immobilization-free and can be performed either 
label-free by evaluating the intrinsic fluorescence of aromatic amino acid residues, or 
by the use of an extrinsic dye, covalently attached to one of the binding partners. 
Whereas the label-free approach that we use in our studies has the advantage of 
measuring the native system without any dye artifacts (e.g. the steric hindrance of the 
fluorescent tag on the binding site), extrinsic fluorescent dyes enable the measurement 
in biological media (blood, serum, milk etc.) which can be of high interest for 
compound screenings under in vivo conditions.1,19-21 
The quantification of an interaction is usually set up as a titration experiment using 
multiple concentration ratios of the binding partners. Therefore, the concentration of 
the fluorescent binding partner is held constant and the amount of unlabeled binding 
partner is varied in a serial dilution from sub-stoichiometric concentrations to 
concentrations at least 10 times above the expected equilibrium dissociation constant 
(Kd) so that a saturation of all binding sites is ensured. By plotting the concentration of 
the added binding partner on a logarithmic scale against the change in the normalized 
fluorescence (𝛥𝐹𝑛𝑜𝑟𝑚), or the in the initial fluorescence, a sigmoidal binding curve is 
generated from which the biomolecular interaction can be easily quantified from the 
transition between the plateaus for the totally unbound (baseline) and the totally bound 
state (saturation). Typically, 𝛥𝐹𝑛𝑜𝑟𝑚 is calculated between the initial state and the 
steady-state of thermophoresis, while in some cases also the T-jump and/or the 
backdiffusion can indicate binding events and may be taken into account for binding 
analysis. It is often also possible to receive distinguishable fluorescence values if 
thermophoresis is not able to reach a steady-state within the measurement time, due 
to the slow diffusion.1,4 
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For the analysis of protein-excipient interactions, UV-LED and IR-laser settings were 
adjusted for each system, in order to get a satisfactory high initial fluorescence signal 
and thermophoretic depletion. The cursor settings for the evaluation of the MST 
parameters were kept constant and are given as a starting time and timeframe length 
for both the cold (blue) and the hot (red) region (Table 1). Additionally, intrinsic 
fluorescence was evaluated from the raw initial fluorescence emission. 
Table 1: Data evaluation settings for determining the protein-excipient interactions by using MST, 
given in relation to the start of fluorescence measurement. 
MST parameter 
Cold start 
[s] 
Cold length 
[s] 
Hot start 
[s] 
Hot length 
[s] 
Temperature jump 4.55 0.97 6.18 0.52 
Thermophoresis 6.18 0.52 34.50 0.97 
Thermophoresis with jump 4.55 0.97 34.50 0.97 
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Chapter IV  
Method and Assay Development 
In the course of this thesis, two methods for the characterization of protein stabilities 
have been developed, implemented, and thoroughly tested in comparison with 
benchmark methods and assays used in the respective field of interest. Technical 
implementation and prototype setup have been performed by NanoTemper 
Technologies GmbH (Munich, Germany). Both developed methods including all 
prototype instruments share the same origin in label-free IR-laser induced MicroScale 
Thermophoresis (MST) technology and instrumentation (Chapter III). 
In section IV.1, we describe the major development steps in order to utilize MicroScale 
Thermophoresis (MST) for unfolding and aggregation investigations of 
biopharmaceuticals. Therefore, a prototype setup was developed and steadily 
optimized in terms of enhanced automation as well as focusing and tempering 
accuracy. Moreover, the parameters for a stepped thermal ramp assay are discussed 
and an exemplary data evaluation is presented. 
A second approach is presented in section IV.2. There a method named thermo-
optical protein characterization (TOPC) was developed in order to combine classical 
forced degradation investigations with simultaneous unfolding, aggregation and 
precipitation analysis. This measurement approach distinguishes itself from standard 
MST experiments by a significantly enhanced IR-laser power applied. Apart from 
thermophoretic depletion, this modification is primarily implemented in order to rapidly 
heat up the samples by water absorption to temperatures above the respective protein 
melting temperature. Thus, forced protein aggregation is evoked, which can be 
evaluated by intrinsic fluorescence. 
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IV.1. Unfolding and Aggregation Investigations by using 
MicroScale Thermophoresis (MST) 
IV.1.1. Measurement Setup 
The determination of highly comparable and reproducible unfolding and aggregation 
parameters required several modifications of standard label-free MST measurement 
setups as the Monolith NT.LabelFree instrument (Figure 1, NanoTemper Technologies 
GmbH, Munich, Germany). Besides an overall extended accessible temperature range 
from ambient to 90 °C and highly precise temperature adjustment via a thermostated 
sample tray, the exact determination of capillary positions over the measurement time 
had to be guaranteed. These goals have been stepwise accomplished and improved 
during the development of three consecutive prototype generations (Table 2). 
The goal of extending the maximum obtainable temperature range from 45 °C to 
≥ 90 °C was already reached with a modified power adapter in the 1st generation 
prototype and continued ever since. Additionally, thermal equilibration and 
homogeneity throughout all samples had to be ensured at every temperature step. 
Before the measurement of the first sample, this was achieved by setting an initial 
delay of 15 minutes at the starting temperature.  
In the 1st prototype setup, an additional delay of 600 s was used after each stepwise 
temperature increase, which could be shortened by 90% for the 2nd and was made 
redundant for the 3rd prototype. This drastic reduction was established by first 
equipping the initially grooved aluminum sample tray (1st gen) with a temperature 
preserving lid (2nd gen). In the 3rd generation setup, the sample tray was replaced by a 
continuous silicon wafer, while the lid was adopted. The main advantage of a 
continuous tray is the full contact to the measurement region of the capillaries which 
allows for most precise and immediate temperature control. In order to preclude a 
mutual interference of the samples investigated, a capillary distance of 4.5 mm, 
matching the well-to-well spacing of a 384-well plate, was maintained for all array 
configurations. 
The focusing accuracy was increased by performing a capillary scan to determine the 
exact horizontal-/x-position of each capillary on the tray during the initial equilibration 
time. From the second generation prototype onwards, additionally the exact vertical-/y-
position was measured for every capillary at each temperature step to correct for 
thermal expansion and agitation over the measurement time. 
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Last, a precise dual-LED system was implemented in the 3rd generation prototype, 
replacing the former single wavelength detection, which covered only one relatively 
broad spectral range (330-380 nm). The measurement of two independent 
wavelengths (330 and 350 nm) extended the readout options of the MST parameters 
additionally and allowed for selecting the thermophoretic melting curves displaying the 
unfolding transition most clearly. Furthermore, this feature was used for the 
measurement of spectral shifts occurring during the unfolding transition of the protein1. 
Table 2: Overview of the three prototype generations developed for the determination of predictive 
unfolding and aggregation markers by using a stepped thermal ramp assay. 
Parameter 1st generation 2nd generation 3rd generation 
Capillary array Al-tray Al-tray with lid Si-wafer/array 
Temperature range 20-90 °C 20-90 °C 15-95 °C 
Temperature readout Manual (PT100) Automatic Automatic 
Temperature precision Low Medium High 
Equilibration delay 600 s 60 s 0 s 
Detection wavelength(s) 355 ± 25 nm 355 ± 25 nm 330 & 350 nm 
Capillary detection x-scan x- and y-scans x- and y-scans 
 
Parallel to developing the measurement prototype, the material and coating of the 
glass capillaries have been improved for our purposes and a convenient and effective 
sealing method has been developed. The initially used borosilicate glass capillaries 
(NT.LabelFree Capillaries) have been replaced by fused silica capillaries 
(NT.LabelFree Zero Background Capillaries) which drastically reduced the background 
fluorescence/capillary auto-fluorescence, which increased the measurement sensitivity 
and enabled the precise measurement of minute changes in protein conformation or 
aggregation events even at low protein concentrations. Furthermore, the standard 
treated capillaries were refined with an improved coating (MST premium coating) 
during the method development activities, in order to prevent sample adsorption to the 
inner capillary surface. The measurement of melting curves for up to 16 formulations in 
parallel made an effective and tight sealing of the capillary ends necessary in order to 
exclude changes in the protein concentration by solvent evaporation. This was realized 
in a first step by sealing the capillaries with wax and further optimized by the use of 
liquid dip gum. The details on the sealing modifications are given in section VI.2.1.1 
where the influence of capillary closure is elaborated by using the thermophoretic 
melting curves of human serum albumin. 
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IV.1.2. Measurement Assay and Parameters 
Our main goal was to derive relevant short-term stability parameters, which can be 
used for high-throughput prediction, differentiation and ranking of multiple proteins or 
formulations already in an early development stage. For this purpose, a stepped 
thermal ramp scanning assay was implemented, re-measuring MST over a set 
temperature range in defined temperature steps. Figure 4 displays the normalized 
fluorescence readout for all MST measurements in an exemplary data set, ranging 
from 35 °C to 75 °C in 1 °C steps. At every temperature increase, which is adjusted by 
heating up the capillary array, intrinsic fluorescence was recorded for 20 seconds in 
total. During this timeframe, initial fluorescence was tracked for 5 seconds, before the 
IR-laser was turned on and the subsequent temperature jump followed by the 
thermophoretic movement, both generated by the IR-laser induced temperature 
increase, were measured. 10 seconds later, equilibrium between thermal diffusion and 
ordinary mass diffusion was reached and the laser was turned off again. Immediately, 
the solution exhibits an inverse temperature jump and a subsequent back diffusion of 
molecules which were tracked for additional 5 seconds.2 
 
Figure 4: Intrinsic fluorescence timetraces measured by MST. For ease of identification, the 
fluorescence timetraces of each 5 °C step were highlighted in color. The area between the dashed 
lines represents the 10 s laser on time. The cursor positions used for calculation of the 
thermophoresis values are indicated by the blue (cold region) and red (hot region) bar. (Note: the 
original fluorescence timetraces of this measurement show a delay of 0.4 seconds to the 
theoretical laser-on time of 5 s, which has been corrected for this graph) 
  
0 5 10 15 20
0.70
0.75
0.80
0.85
0.90
0.95
1.00
 35°C
 40°C
 45°C
 50°C
 55°C
 60°C
 65°C
 70°C
 75°C
 
Time [s]
N
o
rm
a
liz
e
d
 F
lu
o
re
s
c
e
n
c
e
 [
A
.U
.]
MICROSCALE THERMOPHORESIS (MST) 
FOR PROTEIN FORMULATION DEVELOPMENT 
38 
The two fundamental measurement parameters of MST, namely LED- and IR-laser-
Power, were individually adapted for each protein examined, in order to perform all 
measurements at optimal tailor-made conditions. The UV-LED used for fluorescence 
excitation at a wavelength of 280 ± 20 nm was set to the lowest possible intensity 
which allowed for a reduction of potential photo-bleaching effects during multiple 
sample measurement but still ensured an intermediate to high starting fluorescence 
level above the background fluorescence level. To realize this tradeoff, also the 
photomultiplier recording the fluorescence emission was slightly adapted within the 
dynamic range of the system. Likewise, the IR-laser intensity had to fulfill a 
compromise between high thermophoretic depletion, resulting in an enhanced signal to 
noise ratio, and a low local temperature increase of the sample, otherwise potentially 
disturbing the native properties of the system and creating measurement artifacts.3 
 
IV.1.3. Data Evaluation 
After an intrinsic fluorescence timetrace at each single temperature step was 
measured, thermophoresis and/or temperature jump values were calculated as 
described in section III.3 and III.4, by using the cursor settings given in Table 3. It is to 
mention that the exact time point of laser activation on the absolute time scale varied 
marginally between the different prototype generations. Therefore, appropriate settings 
have been determined for exemplary timetraces on each instrument individually and 
are given in the appendix as entered in the software (IV.3). Additionally to the three 
MST derived parameters (thermophoresis, t-jump and thermophoresis with t-jump), 
intrinsic fluorescence can be evaluated from the raw initial fluorescence emission. 
Table 3: Data evaluation settings for the three MST parameters, given in relation to the moment of 
laser activation. The settings for the cold and the hot region frame the respective parameter. 
MST parameter 
Cold start 
[s] 
Cold end 
[s] 
Hot start 
[s] 
Hot end 
[s] 
Temperature jump -1.0 0.0 0.6 1.1 
Thermophoresis 0.6 1.1 9.0 10.0 
Thermophoresis with jump -1.0 0.0 9.0 10.0 
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Obtaining one data point value per temperature gives us the possibility to plot a chart 
of signal over temperature, termed melting curve (Figure 5). In all unfolding and 
aggregation measurements, thermophoresis and/or t-jump melting curves showed one 
or more distinct peaks upon protein unfolding which were assigned as apparent 
melting temperatures (Tm). In order to evaluate a melting point for each protein 
formulation, the single data points of the melting curve were smoothed and 
interpolated before the peak positions were calculated. For the intrinsic fluorescence 
data, the unfolding transitions are sigmoid curves which are analyzed by calculating 
the first derivative curve, which is in the following smoothed and interpolated before 
the peak temperatures are determined. 
 
Figure 5: Exemplary thermophoresis melting curve including smoothing and interpolation of the 
data points as well as evaluation of the apparent melting temperature (Tm). 
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IV.2. Forced Degradation Studies by using Thermo-Optical 
Protein Characterization (TOPC) 
IV.2.1. Measurement Setup 
The simultaneous forced thermal degradation of protein formulations and detection of 
changes in the intrinsic fluorescence was implemented in a prototype setup for thermo-
optical protein characterization (TOPC, Figure 6, NanoTemper Technologies GmbH, 
Munich, Germany). In our approach, thermal stress was generated by using an 
enhanced intensity IR-laser (1480 nm), which is strongly absorbed by water and allows 
for rapid heat stressing of up to 16 protein formulations pulled up into glass capillaries. 
Resultant changes in the intrinsic tryptophan fluorescence were detected at a 
wavelength of 355 ± 25 nm over time and assigned to biomolecular stability events as 
unfolding, aggregation and precipitation. For each protein investigated, the IR-laser 
power, as well as the LED power and the detection timeframe were individually 
adapted. 
 
Figure 6: Measurement setup for thermo-optical protein characterization. The protein formulations 
are pulled up in glass capillaries and positioned on a capillary array. The strong IR-laser is via a 
dichroic mirror directly focused into the center of the respective capillary to rapidly heat up the 
solution. Meanwhile, protein unfolding, aggregation and precipitation events are tracked via 
intrinsic tryptophan fluorescence. 
 
Parts of this section have been published under: Wanner R, Breitsprecher D, Duhr S, 
Baaske P, Winter G 2017. Thermo-Optical Protein Characterization for Straightforward 
Preformulation Development. Journal of Pharmaceutical Sciences  106(10):2955-
2958.  
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IV.2.2. Raw Data Interpretation 
Figure 7 exemplarily displays one set of time-resolved fluorescence measurements 
during forced thermal degradation, covering thee different formulations of the same 
mAb. The fluorescence timetrace of every single experiment can be divided into 
different sections which are explained in the following. After 5 seconds of initial 
fluorescence, the IR-laser is turned on and rapidly heats up the focal volume of the 
investigated protein formulation. The steep temperature increase leads to a 
pronounced temperature jump, thermophoretic depletion and immediate thermal 
protein denaturation. The respective unfolding transition could be seen within 15 
seconds after turning on the high-power IR-laser by a more or less pronounced peak in 
fluorescence emission. Subsequently, the timetraces spread and establish a distinct 
aggregation and precipitation pattern, indicated by the respective fluorescence level 
and the occurrence of periodic fluctuations in the fluorescence signal. Based on a 
publication by Mast and Braun4, we attribute these observations to the concurrence of 
laser-induced convective flow and accumulation of protein particles. After 155 
seconds, the laser input is terminated, the samples cool down and the fluorescence 
signal reacts with a rapid increase. This observation is on the one hand side attributed 
to the increasing quantum yield at lower temperatures and on the other hand side to 
the backdiffusion of depleted molecules to the focal area. The final fluorescence level 
is therefore related to the amount of protein particles (aggregates and precipitates) 
generated during the measurement. 
 
Figure 7: Signal types from thermo-optical protein characterization. 
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IV.2.3. Data Evaluation 
From the raw TOPC curves, a representative timeframe is chosen (Figure 7 – grey 
area) and the fluorescence level, as well as the scattering are evaluated in terms of 
mean fluorescence values and standard deviation (Figure 8). This allows for a ranking 
of aggregation and precipitation propensities among different formulations. In this 
example, the formulation that showed neither aggregation nor precipitation induced 
events upon heating for 150 seconds is described with the lowest mean and standard 
deviation levels. Increased mean fluorescence intensities are observed for the 
formulations forming soluble aggregates under heat stressing. Furthermore, the level 
of fluorescence intensity clearly distinguishes the aggregating samples from each 
other and reveals the highest aggregation propensity for the formulation displayed in 
red. Last, the scattering of the intrinsic fluorescence timetrace that yields in an 
increased standard deviation value is also clearly enhanced for this formulation 
compared to the other two. This is attributed to the induction of large, insoluble 
aggregates that did not occur under the ‘black’ and ’orange’ formulation conditions. 
 
Figure 8: Data evaluation of mean fluorescence values and the standard deviation in the timeframe 
from 125 to 150 s within the TOPC measurements. The error bars express the standard deviation 
from triplicate measurements. 
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IV.2.4. Proof-of-Principle 
In order to further strengthen our concept of combining purely IR-laser induced stress 
testing with simultaneous intrinsic fluorescence evaluation, additional proof-of-principle 
investigations have been performed. First, the influence of different concentrations on 
the TOPC readout was investigated by using a mAb formulation showing neither 
aggregation nor precipitation events. In Figure 9 (left), the respective raw fluorescence 
traces at 0.1, 0.2, 0.3, 0.4, and 0.5 mg/ml are given, which show the expected 
concentration dependent fluorescence offset but expose a highly comparable and 
parallel progression without the manifestation of any events arising from colloidal 
instabilities. This comparability is even more evident in the normalized plot (right), 
where all data points are displayed in relation to the initial fluorescence value and a 
perfect overlay of all concentrations is achieved. These findings underline the 
feasibility of normalization between varying initial fluorescence values which could 
occur due to pH or excipient variations in extensive formulation screenings. 
 
Figure 9: Raw (left) and normalized (right) fluorescence traces at different protein concentrations 
for the formulation not exposing aggregation or precipitation events (Formulation 1). 
Following this, the results were compared to a formulation with very high aggregation 
and precipitation propensity (Figure 10). Here, a completely different picture was 
apparent, showing strong differences in aggregation and especially precipitation levels. 
Stepwise decreasing the mAb concentration from 0.5 to 0.1 mg/ml, the onset of 
precipitation spikes was first shifted to later timescales, which was accompanied by a 
considerable decrease in scattering intensity (left). At the same time, also soluble 
aggregation, derived from the intrinsic fluorescence level is decreased, what is most 
prominent at 0.1 and 0.2 mg/ml and easiest derived from the normalized illustration 
(right). 
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Figure 10: Raw (left) and normalized (right) fluorescence traces at different protein concentrations 
for the formulation exposing pronounced aggregation and precipitation events (Formulation 2). 
A summarizing data evaluation of the concentration effects on the TOPC 
measurements is given in Figure 11. Formulation 1, showing neither aggregation nor 
precipitation events, was not influenced by the protein concentration. Consequently, 
the mean fluorescence, as well as the standard deviation evaluation was constant over 
changing concentrations. However, the aggregating and precipitating Formulation 2 
was strongly influenced by changes in the protein content, as higher concentrations 
led to an accumulation of soluble protein aggregates, reflected in increasing mean 
fluorescence values, and insoluble precipitates, which lead to a strong increase of 
timetrace scattering and standard deviation values. This discrepancy on the influence 
of protein content is attributed to the concentration dependency of aggregation and 
precipitation and will in the upcoming measurements be addressed with the interplay 
of protein concentration and the IR-laser heating rates. 
 
Figure 11: Concentration influence on the fluorescence intensity readout. 
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In order to elaborate in more detail on the influence of IR-laser heating we conducted 
additional measurements. In the TOPC setup, the extent of temperature increase and 
as well the heating rates are predominantly influenced by (i) the capillary diameter and 
(ii) the IR-laser intensity, which were both investigated. 
In the first experiment, a formulation showing a pronounced unfolding peak as well as 
extended precipitation under continuous laser heating was filled in capillaries of 
different inner diameters ranging from 320 – 800 µm. As Figure 12 clearly depicts, the 
capillary diameter has a large effect on the timescales and extent of unfolding, 
aggregation and precipitation. With reducing capillary diameter, the amount of water 
absorbing the IR-laser radiation in the focal volume and at the same time the 
convective transport mixing the material within the capillary decreases. In summary, 
these two effects led to a faster and more complete unfolding of the protein (right). On 
the other hand side, aggregation and precipitation was found to be more pronounced 
with increasing focal volumes (left), which is a result of the larger amount of protein 
material in the measurement area and the extended exchange with the surrounding 
volume. The convection cycle generated during a persistent measurement leads to the 
accumulation of molecules periodically flowing through the focus, a phenomenon well 
described by Braun and Libchaber5,6. As a conclusion of this pre-test, we decided to 
proceed with capillaries of 500 µm inner diameter in order to combine a complete 
unfolding of the molecule and a pronounced aggregation and precipitation. 
 
Figure 12: Comparative studies on the influence of the capillary inner diameter on unfolding , 
aggregation and precipitation during TOPC. Three different diameters were tested, which are 
shown in red (320 µm), orange (500 µm) and black (800 µm). 
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In the second experiment targeting the influence of the heating rates during TOPC, the 
IR-laser power was varied between 114% and 341% (Figure 13). Identical to the 
investigations on the inner diameters, a strong effect on conformational and 
aggregation stability was observed. Higher laser intensities lead to higher final 
temperatures within the capillary and faster heating rates. This causes a faster and 
more complete unfolding of the protein (right). The influence on the precipitation 
tendency however seems to be non-linear (left). Whereas both, the low (114%) and 
the high (341%) IR-laser power led to fluctuations in the fluorescence signal with rather 
small amplitudes, the medium setting (227%) exposes a very high scattering signal. 
However, taking a closer look at the results, additional changes in the scattering 
frequency are observed, which seem to follow a more linear behavior over increasing 
laser heating when compared to the scattering amplitudes. While the frequency of 
fluorescence timetrace scattering is expected to be proportional to the speed of 
particles flowing through the focal volume, the amplitude should increase with either a 
higher number of particles or a larger particle size. Consequently, our hypothesis to 
the observations with varying laser powers is the following. At the lowest laser 
intensity, incomplete unfolding leads to a low number of particles generated which are 
periodically flowing through the focal volume. After increasing the laser power to the 
medium value, unfolding is complete, a higher particle concentration is found and 
consequently the amplitude increases. At the highest IR-laser setting, the amount of 
particles generated is identical but the amplitude decreased. This is attributed to a 
constant increase of the convection speed over increasing laser input promoting the 
particle exchange with the surrounding out-of-focus volume which keeps the amplitude 
low, when the frequency is maximal. Defaults settings for TOPC analysis will be fixed 
to medium IR-laser intensities (227%), while fine adjustment for every single protein to 
be investigated will enable the conduction of TOPC measurements with highest 
information content on aggregation and precipitation propensities and clearly 
distinguish between stable and unstable formulations. 
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Figure 13: Comparative studies on the influence of the IR-laser power on unfolding, aggregation 
and precipitation during TOPC. Three different settings were tested, which are shown in red 
(341%), orange (227%) and black (114%). The percentage given in the figure legend corresponds to 
the IR-laser power. 
The concept presented in this method and assay development section is in the 
following benchmarked against conventional stress testing approaches and predictive 
stability screenings to prove the assumptions made from the observations under IR-
laser heating. 
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IV.3. Appendix 
Table 4: MST data evaluation settings for the 1st generation prototype unfolding and aggregation 
measurements, given in relation to the start of fluorescence measurement. 
MST parameter 
Cold start 
[s] 
Cold length 
[s] 
Hot start 
[s] 
Hot length 
[s] 
Temperature jump 3.80 1.00 5.40 0.50 
Thermophoresis 5.40 0.50 13.80 1.0 
Thermophoresis with jump 3.80 1.00 13.80 1.0 
 
Table 5: MST data evaluation settings for the 2nd generation prototype unfolding and aggregation 
measurements, given in relation to the start of fluorescence measurement. 
MST parameter 
Cold start 
[s] 
Cold length 
[s] 
Hot start 
[s] 
Hot length 
[s] 
Temperature jump 4.40 0.97 5.96 0.52 
Thermophoresis 5.96 0.52 14.46 0.97 
Thermophoresis with jump 4.40 0.97 14.46 0.97 
 
Table 6: MST data evaluation settings for the 3rd generation prototype unfolding and aggregation 
measurements, given relative to the moment of laser activation. Note: For the 3rd generation 
prototype instrument and the MO.AffinityAnalysis software, the cursor settings are given as region 
start and region end in relation to the time point of laser activation. Moreover, the cursor settings 
for t-jump and thermophoresis slightly differ from the 1st and 2nd generation prototypes. However, 
in the data presented, only thermophoresis with jump has been evaluated that complies with the 
previous data evaluations. 
MST parameters 
Cold start 
[s] 
Cold end 
[s] 
Hot start 
[s] 
Hot end 
[s] 
Temperature jump -1.00 0.00 0.50 1.50 
Thermophoresis 1.00 2.00 8.96 9.96 
Thermophoresis with jump -1.00 0.00 8.96 9.96 
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Chapter V  
Engineered Antibody Derivatives 
The sales of monoclonal antibody (mAb) drugs have been tremendously increasing 
over the past years. Together with novel antibody scaffolds like antigen-binding 
fragments (Fab), single-chain variable fragments (scFv), antibody-drug-conjugates 
(ADC), and bispecific antibodies (BsMAb), they represent the largest and fastest 
growing markets the biopharmaceutics industry with hundreds of drug candidates in 
the development pipelines. But not only innovative engineered antibody drugs are on 
the rise, also the first biosimilar antibody products have recently been approved.1-7 
Structurally, mAbs are complex Y-shaped multi-domain biomolecules forming a 
tetrameric structure with a molecular weight of 150 kDa. Each IgG antibody consist of 
two identical light chains (50 kDa each) and two identical heavy chains (25 kDa each). 
Moreover, the structure can be divided in a (constant) Fc (CH2 and CH3) and a Fab 
(with variable CDRs) region, which substantially control the overall protein stability.8-10 
The case study presented in this section is targeting the influences of chemical 
derivation on the conformational and aggregation stability of monoclonal antibodies 
(mAbs). As provided by the supplier, the antibodies investigated tend to aggregate 
during unfolding. While the unfolding of the Fc part at lower temperatures is known to 
be reversible, Fab unfolding at elevated temperatures remains irreversible and the 
expected ranking in terms of their non-native aggregation stability is Ab3, Ab4, Ab1, 
Ab2, sorted from high to low. Thus, properties of the Fab domain dictate the 
aggregation stability of the antibodies. This influence of the mAb variable region on the 
aggregation propensity is often described in literature and referred to aggregation-
prone regions (APRs) that might be exposed during Fab unfolding.9,11-14 Comparing 
Ab3 and Ab4 as well as Ab1 and Ab2, the modification reduces the aggregation 
stability. As the modified and the unmodified antibodies share the same Fab part each, 
the conformational stability of Fab unfolding remains unchanged. 
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V.1. Materials and Methods 
V.1.1. Materials 
The antibodies and antibody derivatives used in this study were kindly donated by 
Sanofi S.A. (Vitry-sur-Seine, France). An overview of the drug product (DP) materials 
including protein concentration and the composition of the used formulation buffers is 
given in Table 7. The molecular weight of all the proteins is in the range of 150 kDa. 
Table 7: Overview of the drug products used in the antibody derivatives study. 
Material 
Concentration 
[mg/ml] 
Formulation composition 
Ab1 (native/naked Ab) 10.1 
50 mM potassium phosphate, 50 mM NaCl, 
2 mM EDTA, pH 6.6 
Ab2 (modified Ab1) 5.2 
10 mM acetate, 3.75% mannitol, 2.5% sucrose, 
0.005% polysorbate 80, pH 5.5* 
Ab3 (native/naked Ab) 5.3 PBS 
Ab4 (modified Ab3) 10.8 10 mM histidine, pH 5.5 
* the percentages are given in w/V 
 
The study was conducted with DP material diluted in phosphate buffered saline (PBS). 
Therefore, 10-fold concentrated PBS stock solution pH 7.4 was diluted to 1-fold with 
deionized water. Thereafter, the four different drug products were centrifuged for at 
least 5 min at minimum 13000 rpm and subsequently volumetrically diluted with 1x 
PBS to a concentration of 1 mg/ml each. In consequence, ~ 5 or ~ 10-fold dilutions at 
mixture pH values between 5.5 and 7.4 were received, depending on the starting 
concentration and pH value of the stock DP material. 
Table 8: Overview of the materials used in the antibody derivatives study. 
Material Supplier Art.-number Lot-number 
Roti®-Stock 10x PBS 
Carl Roth GmbH & Co 
KG, Karlsruhe, Germany 
1058.1 423206137 
Water AnalaR Normapur® 
VWR International, 
Radnor, PA, USA 
102927G - 
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V.1.2. Unfolding and Aggregation Investigations 
V.1.2.1. MicroScale Thermophoresis (MST) 
The 1st generation stepped thermal ramp prototype setup (NanoTemper Technologies 
GmbH, Munich, Germany) was introduced in the course of feasibility studies for the 
execution of predictive unfolding and aggregation studies by using MST. In our assay, 
fluorescence excitation LED Power was set to 50% while an IR-laser MST Power of 
20% was used. In order to guarantee for temperature homogeneity on the tray, an 
increased delay of 600 s was used after each temperature increase. The overall 
measurement runtime was reduced by using an elevated starting temperature of 58 °C 
and increasing the temperature of the capillary tray up to 88 °C in 1 °C steps. This 
shortened temperature range covered all expected unfolding transitions and the 
aggregation event of the antibodies investigated. 
Furthermore, a control experiment monitoring potential influences of multiple IR-laser 
and UV-LED input on the thermophoretic behavior of the sample was performed. 
Therefore, the LED- and MST-settings from the stepped thermal ramp assay were 
retained, but on the contrary, the temperature was kept at a base temperature of 
30 °C. In order to obtain an increased resolution of potential signal changes, the delay 
between two measurements was decreased to 305 s. In parallel, the overall analysis 
time was extended to almost 8.5 hours by setting a 43-fold measurement of each 
sample on a full tray load containing 15 capillaries. LabelFree UI software version 
2.1.31 (NanoTemper Technologies) was used for performing the MST experiment, 
while the thermophoresis values for each sample and temperature step have been 
calculated by using NT Analysis software version 1.5.41 (NanoTemper Technologies). 
For both measurements, NT.LabelFree Standard Treated Capillaries (NanoTemper 
Technologies) were used. 
In the revised 2nd generation prototype setup, the unfolding and aggregation 
experiment was repeated for all antibody variants. NT Control software version 2.1.31 
(NanoTemper Technologies) was used to conduct the stepped thermal ramp assay by 
increasing the ambient temperature from 50 °C to 90 °C in 1 °C steps. The LED Power 
was set to 10% (PMT = 700 V) while an MST Power of 20% was used. With the 
reconstructed capillary tray all around enclosing the capillaries the equilibration time 
could be reduced to 60 s at each temperature step. In order to minimize sample 
evaporation during the temperature cycle, both capillary ends of the NT.LabelFree 
Standard Treated Capillaries (NanoTemper Technologies) were sealed with wax and 
nail polish. 
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NT Analysis Software Version 1.5.41 (NanoTemper Technologies GmbH) was used to 
derive thermophoresis values for each temperature step, before aggregation onset 
temperatures (Tagg onset) for the aggregation spikes in the resulting thermophoresis 
melting curves were calculated using Origin 8G software (OriginLab Corp., 
Northampton, MA, USA). The Tagg onset was defined as the temperature, where the 
slope of the aggregation event reaches 10% of its maximum. For data evaluation, the 
first derivative curve was calculated, smoothed (Savitzky-Golay, polynomial order 1, 
points of the window 3) and interpolated (cubic spline, 6001 points between 30 °C and 
90 °C). Afterwards, the temperature value exceeding 10% of the maximal slope was 
determined as Tagg onset. 
V.1.2.2. Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) was measured at an angle of 173° by using a Zetasizer 
Nano ZS (Malvern Instruments Ltd, Malvern, UK). Protein particle growth due to 
aggregation and precipitation after forced thermal degradation was evaluated via the 
mean intensity of the main peak. Therefore, Ab3 was diluted to 0.1 mg/ml with placebo 
buffer and subsequently heat-stressed in 2 ml conical micro-centrifuge tubes (VWR 
International LLC) for 10 min using a ThermoMixer Comfort (Eppendorf AG, Hamburg, 
Germany). The eight temperatures investigated (40, 60, 70, 75, 80, 82, 85 and 90 °C) 
were chosen from the progression of the unfolding and aggregation curve by 
thermophoresis (Figure 14). After cooling down to room temperature and overnight 
storage at 2-8 °C, the measurements were carried out in triplicates using disposable 
semi-micro PMMA cuvettes (Brand GmbH & Co. KG, Wertheim, Germany). 
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V.1.2.3. Intrinsic Fluorescence Emission Spectroscopy (intrinsic FES) 
V.1.2.3.1. Cuvette fluorimeter (Jasco FP-8300) 
A fluorescence spectrometer (FP-8300) equipped with a water thermostated 4-position 
cell changer (FCT-816) (both Jasco Deutschland GmbH, Pfungstadt, Germany) was 
used for reference measurements of stepped thermal unfolding by using intrinsic 
tryptophan fluorescence. 50 µL protein formulation was carefully pipetted in ultra-micro 
cell quartz cuvettes (Hellma GmbH & Co. KG, Muellheim, Germany). The solution was 
overlaid with 500 µL paraffin oil and the cuvette was closed with the provided plastic 
plug to minimize evaporation. Excitation was performed at 280 ± 2.5 nm and the 
emission was recorded in the range of 300-380 nm given a bandwidth of 5 nm.  
A temperature ramp from 30 °C to 90 °C was executed, measuring a full fluorescence 
spectrum of the given range in 1 °C steps. The photomultiplier (PMT) voltage was set 
to 490 V, which guaranteed high initial fluorescence levels, and the excitation path was 
opened only for the measurements, minimizing photo-bleaching to the recording times 
of the spectra. 
In order to obtain apparent melting temperatures (Tm) from the intrinsic fluorescence 
emission, the ratio of 350/330 nm was evaluated. The raw data were differentiated (1st 
derivative), smoothed (Savitzky-Golay, polynomial order 1, points of the window 5), 
interpolated (cubic spline, 6001 points between 30 °C and 90 °C) and the local 
maximum was analyzed using the included Impulse Analyzer tool (Origin 8G, 
OriginLab Corp., Northampton, MA, USA). 
V.1.2.3.2. nano Differential Scanning Fluorimetry (Prometheus NT.48) 
A Prometheus NT.48 prototype instrument (NanoTemper Technologies) was used for 
reference measurements of linear thermal unfolding by using intrinsic tryptophan 
fluorescence. In order to save sample material all samples have been diluted to 
0.5 mg/ml with PBS 1X pH 7.4 and subsequently loaded into NT.LabelFree Standard 
Treated Capillaries (NanoTemper Technologies) by pure capillary force. Sample 
evaporation from the capillaries at elevated temperatures was reduced by sealing both 
ends with liquid dip gum (Capillary Sealing Paste, NanoTemper Technologies). A 
temperature ramp from 30 °C to 100 °C was executed using a slope of 1 °C/min, while 
intrinsic protein fluorescence was measured continuously at the emission wavelengths 
of 330 nm and 350 nm. 
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A preliminary data analysis script (NanoTemper Technologies) was used to evaluate 
the raw data and assess the intrinsic fluorescence emission ratio of 350 nm/330 nm 
over increasing temperatures. Origin 8G (OriginLab Corp., Northampton, MA, USA) 
was used to calculate apparent melting temperatures (Tm) from the respective melting 
curves. Therefore, the single curves were smoothed (Savitzky-Golay, polynomial order 
1, points of the window 15) and differentiated (1st derivative). After another smoothing 
step (Savitzky-Golay, polynomial order 1, points of the window 25), the data points 
were interpolated (cubic spline, 6001 points between 30 °C and 90 °C) and the local 
maximum was determined by using the included Impulse Analyzer tool. 
V.1.2.3.3. Capillary fluorimeter (Optim 1000) 
An Optim 1000 instrument (Avacta Analytical Ltd, Wetherby, UK, now Unchained 
Labs, Pleasanton, CA, USA) was used for a comparative linear thermal unfolding and 
aggregation study. The samples were pipetted in the capillaries of a 9 µl micro-cuvette 
array (MCA), which were tightly closed with the provided silicone seals using a MCA 
frame. Using the Optim Client software V1.5.4 (Avacta Analytical) the temperature was 
linearly increased from 20 °C to 90 °C in a rate of 1 °C per minute, while a hold time of 
1 s was used at each well for recording of the fluorescence spectrum. An excitation 
wavelength of 266 nm was used to induce deep UV intrinsic fluorescence, setting a slit 
width of 100 µm and an exposure time of 1000 ms. Fluorescence emission was 
recorded from 249 to 504 nm using a center wavelength of approximately 380 nm. For 
data evaluation, the fluorescence ratio of 350/330 nm was chosen and unfolding 
temperatures (Tm) were automatically calculated by the Optim Analysis software 
V2.0.4 (Avacta Analytical). If necessary, melting temperatures were re-adjusted 
according to the maxima of the 1st derivative fluorescence curves. 
V.1.2.4. Static Light Scattering (SLS) 
Additionally to intrinsic fluorescence (section V.1.2.3.3), static light scattering intensity 
was evaluated from the Optim 1000 measurement for the UV laser at 266 nm. 
Therefore, the 90° light scattering values at 266 ± 5 nm were plotted over temperature 
and the aggregation onset temperatures (Tagg onset) were evaluated by using the Optim 
Analysis software V2.0.4 (Avacta Analytical). For calculation, a Heaviside step function 
was applied to the 1st derivative curve of static light scattering and the temperature 
corresponding to the 10% value of the maximum was determined. 
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V.2. Results and Discussion 
V.2.1. Unfolding and Aggregation Investigations 
V.2.1.1. MicroScale Thermophoresis (MST) 
Figure 14 displays an example of the thermophoresis readout over temperatures for 
the unfolding and aggregation assay. For clarity and ease of detailed evaluation, the 
thermophoresis values over temperatures are only demonstrated exemplarily for Ab3, 
the supposedly most stable antibody in the study. With increasing temperatures, two 
clear events were detectable, overlaying well for the three capillaries investigated. 
First, a very broad halo shaped peak at ~ 70 °C is apparent which can be attributed to 
the early unfolding of the Fc part. The unfolding transition is followed by a remarkably 
sharp peak at ~ 80 °C, which to our hypothesis corresponds to nascent protein 
aggregation and precipitation that seems to superimpose the Fab unfolding transition 
completely. 
 
Figure 14: Thermophoresis of Ab3 over temperature exhibits protein unfolding and aggregation 
(n = 3). 
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The results of the thermal unfolding and aggregation measurements were verified by a 
control experiment targeting the stability of the protein under repetitive IR-laser and 
UV-LED input but without an increase in temperature (Figure 15). The aim of the 
experiment was to exclude influences of the measurement principle itself and thus 
strengthen the validity of MST based unfolding and aggregation detection as a 
prerequisite of successful assay development. The depletion of molecules and 
therefore the calculated thermophoresis values remained stable in the course of 43 
consecutive measurements of the four antibody variants over more than 8.5 hours. 
This indicates that neither unfolding nor aggregation occurred in the MST setup over 
time, proving that influences by LED- and IR-radiation are negligible.  
Furthermore, distinct differences in the thermophoretic depletion of the two unmodified 
antibodies (Ab1 and Ab3) were noticeable, allowing for immediate differentiation of the 
native molecules. Derivation did not drastically change the thermophoretic behavior 
and therefore the molecule-pairs yield in analogous behavior. These observations 
match the underlying principles and dependencies of thermophoresis, which state that 
the movement of a molecule in a temperature gradient is altered by changes in its 
charge, size or hydration shell.15 Transferring this theory to our current data set, the 
two unmodified antibodies (Ab1 and Ab3) differ significantly, while the derivation was 
only very minimally and showed no influence on the thermophoretic readout. 
 
Figure 15: Stability of the thermophoretic depletion of the two antibodies (Ab1 and Ab3) and 
respective antibody-derivatives (Ab2 and Ab4) to repetitive IR-laser and UV-LED-radiation over 
time (n  3). 
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In the 2nd generation prototype setup, the unfolding and aggregation experiment of all 
antibody variants was repeated (Figure 16). As elaborately described in section IV.1, 
this revised experimental setup allows for automatic temperature readout at each step, 
enhanced and repetitive focusing accuracy, including the correction for thermal 
expansion, as well as faster thermal equilibration times by using an improved capillary 
tray. The thermophoresis results illustrate that a clustering of the molecules is possible 
with one look at the curves. In other words, unfolding of the Fc part of the mAb, as well 
as protein aggregation, which is potentially induced by Fab unfolding, appears earlier 
for Ab1 and Ab2. Therefore, Ab3 and Ab4 are considerably more stable in terms of 
conformational and aggregation stability. Moreover, derivation seems to slightly 
destabilize the unfolding of the Fc part and prepone the onset temperature of 
aggregation. 
 
Figure 16: Thermal unfolding and aggregation measurements of Ab1/2 (left) and Ab3/4 (right). 
In order to further evaluate the non-native aggregation behavior, we continued the 
investigation by calculating definite aggregation onset temperatures (Tagg onset) for the 
thermophoresis evaluation. Therefore, the Tagg onset was defined as the temperature, 
where the slope of the aggregation peak exceeds 10% of its maximum. With this 
definition, aggregation is visualized easiest in the first derivative curve of 
thermophoresis (Figure 17 – left). Inspecting the raw data as well as comparing the 
calculated Tagg onset values (Figure 17 – right) confirms the preliminary conclusions. Ab3 
and Ab4 show a higher aggregation stability compared to Ab1 and Ab2. Moreover, 
derivation promotes protein aggregation and consequently shifts the calculated 
Tagg onset to lower temperatures. With these results, the non-native aggregation stability 
ranking provided by the supplier was confirmed. 
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Figure 17: Aggregation onset determination. Left: Smoothed and interpolated first derivative 
curves of thermophoresis for Ab1 (grey), Ab2 (red), Ab3 (green) and Ab4 (black). Right: Calculated 
Tagg onset values (n = 3). 
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V.2.1.2. Dynamic Light Scattering (DLS) 
Dynamic light scattering (DLS) was measured after incubation at elevated 
temperatures in order to examine the temperature induced aggregation and thereby 
strengthen our aggregation hypothesis derived from the pronounced sharp peak in 
thermophoresis (Figure 14). Due to the large sample consumption for external 
incubation and sample analysis, this benchmark method was only investigated for Ab3. 
The DLS results exhibit an increase in size distribution over temperature with an onset 
above 75 °C. Moreover, the area of the main peak is decreasing for the samples 
 85 °C, which indicates an enhanced polydispersity due to the generation of multiple 
aggregate species. These findings are in very good agreement with the thermal 
unfolding and aggregation measurements by using MST, and confirm the detection of 
protein aggregates which was observed in the steep rise of thermophoresis values. 
Additionally, the onset of increasing particle sizes above 75 °C determined by DLS 
corresponds well to the calculated onset temperature by thermophoresis (74 °C). 
 
Figure 18: Dynamic light scattering (DLS) of Ab3 after external heating of the samples for 10 
minutes (n = 3). 
  
40 60 70 75 80 82 85 90
10
100
1000
10000
 Peak 1 Mean Intensity
 Peak 1 Area Intensity
external heating temperature [°C]
P
e
a
k
 1
 M
e
a
n
 I
n
te
n
s
it
y
 [
d
.n
m
]
0
20
40
60
80
100
P
e
a
k
 1
 A
re
a
 In
te
n
s
ity
 [%
]
 
CHAPTER V   ENGINEERED ANTIBODY DERIVATIVES 
61 
V.2.1.3. Intrinsic Fluorescence Emission Spectroscopy (intrinsic FES) 
A comparative protein unfolding study by fluorescence emission spectroscopy (FES) 
was conducted by the use of three fluorimeters, differing in the data acquisition setup, 
sample volume, and throughput. One cuvette based spectrofluorimeter (Jasco FP-
8300) and two capillary fluorimeters (Optim 1000 and Prometheus NT.48) were 
investigated, while for all methods the intrinsic fluorescence emission ratio of 
350/330 nm was evaluated. Exemplary melting curves from the Prometheus NT.48 
measurements are displayed in Figure 19. 
 
Figure 19: Exemplary melting curves for intrinsic fluorescence by nanoDSF. 
The head to head comparison of the derived Tm values for all systems yields in a 
consistent ranking of conformational stabilities among each other and in comparison to 
the thermophoresis results (Figure 20 – left). In all fluorescence measurements, the 
unmodified Ab3 turned out to be the most stable molecule in the screening, while the 
native Ab1 was substantially less stable. Derivation of both antibodies (Ab3 and Ab1) 
showed a negative effect on conformational stability, resulting in lower Tm values. This 
trend is also consistent for the additional unfolding transition (Tm1) that could be 
resolved for Ab3 and Ab4 (Figure 20 – left, white striped columns). A positive offset of 
approximately 5 °C was detected for all melting temperatures derived from the 
Prometheus NT.48 prototype measurements, showing no effect on the overall stability 
trend and the excellent correlation of the Tm2 values among the methods (Figure 20 – 
right). The offset can be attributed to an inaccurate temperature calibration in this early 
prototype stage that was corrected in later versions. 
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Figure 20: Comparison and correlation of the melting temperatures by intrinsic FES. Left: 
Comparison of melting temperatures by fluorescence emission ratio (350 nm/330 nm) for Ab1-Ab4 
using a cuvette based fluorimeter (Jasco FP-8300, n=1, black) and two capillary fluorimeters 
(Optim 1000, n=4, dark grey and Prometheus NT.48, n=3, light grey). Right: Correlation of the 
determined Tm2 values. 
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V.2.1.4. Static Light Scattering (SLS) 
The aggregation phenomenon identified in the thermophoresis melting curves and the 
thereof derived Tagg onset values of all antibodies and antibody derivatives were 
validated by comparative static light scattering measurements. Figure 21 (left) displays 
the scattering intensities at a wavelength of 266 nm over temperature. All investigated 
drug products show strong temperature dependent aggregation, which is reflected in 
increasing light scattering intensities. Furthermore, sample precipitation was indicated 
by in reverse decreasing values. While the scattering peak intensities are very 
comparable between the samples, aggregation onset temperatures differ distinctly. 
The derived aggregation onset pattern (Figure 21 – right) is congruent with the 
thermophoresis evaluation, identifying Ab3/Ab4 as the couple with the higher 
aggregation temperatures and confirming the negative effect of derivation on stability 
in both cases. 
 
Figure 21: Static light scattering at 266 nm. Left: SLS curve comparison over temperature for Ab1 
(grey), Ab2 (red), Ab3 (green) and Ab4 (black). Right: Corresponding Tagg onset values (n=4). 
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V.3. Summary and Conclusions 
In this case study, we were able to correlate events detected in thermophoresis 
melting curves to protein unfolding transitions and non-native aggregation of single 
antibody domains, qualifying MST as a predictive marker for conformational protein 
stability and aggregation propensity. 
Broad, halo shaped peaks in thermophoresis could be allocated to protein melting 
transitions. Thereby, MST showed an advanced resolution of unfolding events in 
comparison to intrinsic fluorescence evaluation, revealing the early transition of Fc 
parts (Tm1) for all investigated antibodies. In contrast, FES was merely able to resolve 
the unfolding for the Fc parts of the most stable DPs Ab3 and Ab4 (Figure 19). In 
consequence, thermophoresis offers an additional stability indicator, being crucial for 
storage at typically low temperatures. 
Very sharp peaks in thermophoresis melting curves were found to coincide with an 
increase in size distribution over temperature measured by DLS and aggregation onset 
temperatures evaluated from increasing SLS intensities at elevated temperatures. 
Thus, MST was capable of sensitively detecting protein aggregation, showing lower 
standard deviations for replicate measurements compared to reference techniques. 
Advantages of the MST approach over established methods were the low material 
consumption by minimal sample volumes and concentrations, as well as the high 
sensitivity and throughput of MST. Moreover, MST showed sensitivity to unfolding and 
aggregation events, which on the contrary limited the detection of unfolding transitions 
in the presence of aggregation events. For the methods evaluating changes in intrinsic 
fluorescence, aggregation was not observed and the detection of unfolding events was 
not impacted by simultaneous aggregation. 
Evaluating the global picture and the interplay of conformational and aggregation 
stability, our study revealed a high comparability and coincidence of Fab unfolding and 
protein aggregation events. This concurrence strengthens the hypothesis of APRs, 
present in the Fab region, being exposed during protein unfolding and consequently 
induce colloidal protein-protein interactions which result in irreversible protein 
aggregation and precipitation. 
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Chapter VI  
Human Serum Albumin (HSA) 
In this case study, a small pH screening of the model protein HSA was prepared in 
PBS to further develop thermal unfolding and aggregation investigations by using MST 
and to perform the first feasibility study of thermo-optical protein characterization 
(TOPC). First, the influence of different pH values on shape changes and shifts in 
thermophoresis and t-jump melting curves was examined and compared. The derived 
pH effects on the thermal unfolding as well as aggregation stability of HSA were then 
benchmarked by intrinsic tryptophan fluorescence and static light scattering 
measurements. Additionally, the sample set was used to evaluate different approaches 
for an effective prevention of solvent evaporation in the MST setup, setting the stage 
for more extensive formulation screenings. For TOPC, the consequences of high 
power IR-laser heating were inspected for the different formulation pH values and 
confronted with the results of the unfolding and aggregation investigations. 
VI.1. Materials and Methods 
VI.1.1. Materials 
Human serum albumin (HSA) is a 66 kDa model protein that has been extensively 
used in fundamental research including folding and unfolding studies. The molecule 
contains only one single tryptophan residue at position 214 that will be used to 
investigate the unfolding and aggregation behavior in dependency of the solution pH in 
various analytical setups and serve as a reference standards for prototype and assay 
modifications.1-4 
An overview of materials used in this study can be found in Table 9. 
Table 9: Overview of materials used in the HSA study. 
Material Supplier Art.-number Lot-number 
Albumin from human serum 
(HSA), essentially fatty-acid free 
Sigma Aldrich, St. Louis, 
MO, USA 
A3782-5G 107K75651 
Roti-Stock 10x PBS 
Carl Roth GmbH & Co 
KG, Karlsruhe, Germany 
1058.1 423206137 
Water AnalaR Normapur 
VWR International, 
Radnor, PA, USA 
102927G - 
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VI.1.2. Formulations 
A phosphate buffered saline (PBS) 10x stock solution was diluted to 1x with deionized 
water and the pH values were adjusted to the target pH values of 6.0, 6.5, 7.0 and 7.5 
by titration using NaOH or HCl respectively for each placebo solution. The pH values 
were measured by using a HI83141 pH-meter, equipped with a HI1230 electrode 
(Hanna Instruments Deutschland GmbH, Voehringen, Germany). Subsequently, 
essentially fatty-acid free Human Serum Albumin (HSA) was dissolved in the freshly 
prepared placebo solutions. After complete dissolution, the protein concentration was 
measured by absorbance using a NanoPhotometer P330 instrument equipped with 
and a NanoPhotometer P-Class Submicroliter Cell (Implen GmbH, Munich, Germany) 
and an extinction coefficient of ε(HSA)=0.531 ml*mg-1*cm-1 (at 279 nm)3. 
Subsequently, the concentration was adjusted to 0.75 mg/ml each by dilution with the 
respective placebo buffer. The formulations were aliquoted and stored at - 80 °C upon 
usage. After thawing and equilibration at room temperature, the samples were 
centrifuged for at least 5 min at 15000 rpm to remove insoluble aggregates potentially 
induced by the freeze-thaw cycle. 
VI.1.3. Unfolding and Aggregation Investigations 
VI.1.3.1. MicroScale Thermophoresis (MST) 
MST was used for predictive unfolding and aggregation studies by using the 2nd 
generation prototype setup (NanoTemper Technologies GmbH, Munich, Germany). 
The temperature was increased from 30 °C to 90 °C in 1 °C steps. Fluorescence 
excitation LED Power was set to 2% (PMT=780 V), while an MST Power of 20% was 
used. These settings optimize the signal to noise ratio while photo-bleaching effects 
can be reduced by minimal excitation LED intensities. NT.LabelFree Zero Background 
Standard Treated Capillaries (NanoTemper Technologies) were used exclusively to 
reduce the fluorescence background/capillary auto-fluorescence and therefore 
increase measurement sensitivity.  
For the pH screening experiment, the capillaries were closed with sealing wax 
(NanoTemper Technologies) on one side to reduce sample evaporation during the 
temperature cycle. In order to achieve a more effective capillary sealing, additional 
measurements were performed under the use of liquid dip gum (Capillary Sealing 
Paste, NanoTemper Technologies) applied to both capillary ends. 
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The measurements were performed by using NT Control software version 2.1.31, 
while NT Analysis software version 1.5.41 (NanoTemper Technologies) was used to 
calculate thermophoresis and t-jump values for each temperature step. Subsequently, 
Origin 8G (OriginLab Corp., Northampton, MA, USA) was used to calculate melting 
temperatures (Tm) for the respective melting curves of both data evaluations by 
smoothing (Savitzky-Golay, polynomial order 1, points of the window 3), interpolation 
(cubic spline, 6001 points between 30 °C and 90 °C) and local minimum analysis using 
the included Impulse Analyzer tool. 
VI.1.3.2. Intrinsic Fluorescence Emission Spectroscopy (intrinsic FES) 
A fluorescence spectrometer (FP-8300) equipped with a water thermostated 4-position 
cell changer (FCT-816) (both Jasco Deutschland GmbH, Pfungstadt, Germany) was 
used for reference measurements of stepped thermal unfolding by using intrinsic 
tryptophan fluorescence. 50 µL protein formulation was carefully pipetted in ultra-micro 
cell quartz cuvettes (Hellma GmbH & Co. KG, Muellheim, Germany). The solution was 
overlaid with 500 µL paraffin oil and the cuvette was closed with the provided plastic 
plug to minimize evaporation. Excitation was performed at 280 ± 2.5 nm and the 
emission was recorded in the range of 300 nm to 380 given a bandwidth of 5 nm. A 
temperature ramp from 30 °C to 90 °C was executed, measuring a full fluorescence 
spectrum of the given range in 1 °C steps. The PMT voltage was set to 540 V, which 
guaranteed high initial fluorescence levels, and the excitation path was opened only for 
the measurements, minimizing photo-bleaching to the recording times of the spectra. 
In order to obtain apparent melting temperatures (Tm), intrinsic fluorescence emission 
was evaluated in the range from 330 nm to 380 nm. The raw data were differentiated 
(1st derivative), smoothed (Savitzky-Golay, polynomial order 1, points of the window 3), 
interpolated (cubic spline, 6001 points between 30 °C and 90 °C) and the local 
minimum was analyzed using the Impulse Analyzer tool (Origin 8G, OriginLab Corp., 
Northampton, MA, USA). 
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VI.1.3.3. Static Light Scattering (SLS) 
An Optim 1000 instrument (Avacta Analytical Ltd, Wetherby, UK, now Unchained 
Labs, Pleasanton, CA, USA) was used for a comparative linear thermal aggregation 
study. The samples were pipetted in the capillaries of a 9 µl micro-cuvette array 
(MCA), which were tightly closed with the provided silicone seals using a MCA frame. 
The temperature was linearly increased from 15 °C to 90 °C in a rate of 1 °C per 
minute. Between 30 °C and 90 °C, static light scattering intensity was plotted over 
temperature and the aggregation onset temperatures (Tagg onset) were evaluated for 90° 
light scattering at 266 ± 5 nm by using the Optim Analysis software V2.0.4 (Avacta 
Analytical). For calculation, a Heaviside step function was applied to the 1st derivative 
curve of static light scattering and the temperature corresponding to the 10% value of 
the maximum was determined. 
VI.1.3.4. Thermo-Optical Particle Characterization (TOPC) 
TOPC was used for predictive thermal aggregation studies by IR-laser induced stress 
testing. The fluorescence excitation LED power was set to 2% (PMT=780 V) and heat 
stress was applied by using an IR-laser power of 170%. Changes in intrinsic 
fluorescence were detected for 175 s in total. After recording initial fluorescence for 
5 s, the effects of the IR-laser input were tracked for 150 s. Subsequently, the laser 
was turned off again and backdiffusion was measured for additional 20 s. 
In order to complement the observations and conclusions during TOPC with a well-
known assay, a standard MST experiment at a laser power of 45% was appended by 
using the same pre-stressed samples. The resulting MST timetraces were compared 
in regards of abnormalities in the curve shapes. 
All measurements were performed in singlicates at an ambient assay temperature of 
25°C by exclusively using NT.LabelFree Zero Background Standard Treated 
Capillaries (NanoTemper Technologies). NT Control software version 2.1.31 was used 
to perform the measurements, while the intrinsic fluorescence timetraces were 
normalized, exported and MST as well as T-Jump values were calculated by using NT 
Analysis software version 1.5.41 (both NanoTemper Technologies). 
The TOPC experiments were analyzed by calculating mean values and standard 
deviations for all formulations in the timeframe between 125 and 150 s. All calculations 
and data plotting were performed with Origin 8G software (OriginLab Corp., 
Northampton, MA, USA). 
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VI.2. Results and Discussion 
VI.2.1. Unfolding and Aggregation Investigations 
VI.2.1.1. MicroScale Thermophoresis (MST) 
Thermal unfolding and aggregation investigations were performed in order to further 
qualify MST for this application, by optimizing the assay and comparing the results to 
benchmark methods as well as orthogonal approaches. The resulting T-jump (Figure 
22 – left) as well as thermophoresis (Figure 22 – right) values were found to change 
dramatically with increasing temperatures, leading to melting curves with pronounced 
and broad negative peaks. These peaks were assigned to the single thermal unfolding 
event of HSA.2,5 Moreover, changing the formulation pH value led to shifts in the 
unfolding peaks for both evaluations suggesting the detection of a 
stabilizing/destabilizing effect. In detail, decreasing pH values lead to a temperature 
increase of the peak position and consequently higher apparent Tm values. This effect 
corresponds to increasing conformational stability with decreasing pH values. 
 
Figure 22: Melting curves by t-jump (left) and thermophoresis (right) for the HSA pH screening. 
pH 6.0 (grey), 6.5 (red), 7.0 (green) and 7.5 (black) (n=3). 
Figure 23 displays the Tm analysis of the negative peaks for the t-jump and 
thermophoresis evaluation, confirming the inspection from the raw data curves with 
highest conformational stability at pH 6.0. Furthermore, this illustration exhibits a 
temperature difference between the Tm values determined by t-jump and 
thermophoresis in the order of 2-3 °C. This divergence fits in direction and extent to 
the expected temperature increase induced by the IR-laser, leading to earlier 
unfolding, e.g. lower Tm values, for the thermophoresis evaluation. 
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Figure 23: Melting temperatures (Tm) for the thermophoresis and for the t-jump data evaluations. 
Evaluating the thermophoresis/t-jump melting curves (Figure 22) in more detail, 
another observation becomes apparent: In contrast to the t-jump results, 
thermophoresis melting curves show further, very sharp peaks at temperatures above 
the melting transition, additionally indicating non-native protein aggregation and/or 
precipitation. Accordingly, this clustering of single molecules affects the overall protein 
structure including the hydration shell, but not the direct surrounding of the single 
tryptophan moiety, remaining the t-jump values unchanged. At a closer look it is 
noticeable that at pH 6.0, the peaks for the different capillaries investigated occur 
simultaneously immediate after unfolding, while the appearance of additional peaks for 
the other pH values happens rather diffused and random mostly at higher 
temperatures. Our hypothesis on the random aggregation events visible at the higher 
pH values comprises solvent evaporation from the capillaries at elevated 
temperatures. The associated concentration increase might lead to molecular 
crowding and occasional protein aggregation, depending on the extent of solvent loss. 
The observance that the aggregation signal at pH 6.0 appears earlier and 
synchronized for all capillaries, leads to a different conclusion. In contrast to the 
evaporation aggregation at pH 6.5-7.5, aggregation at pH 6.0 seems to be 
independent of evaporation and might be of intrinsic origin. In consequence, low pH 
values would lead to increased conformational stability but decreased colloidal 
stability. 
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In order to further classify the evaporation and aggregation effects visible in the 
melting curves of the pH screening, an alternative sealing procedure was evaluated. 
Liquid dip gum applied to both capillary ends was tested in a head-to-head comparison 
with sealing by wax on one side. Both, pH 6.0 and pH 7.5 were investigated 
scrutinizing the prevention of evaporation and the nature of aggregation in parallel. 
Figure 24 elucidates that the peak for pH 7.5 completely vanishes by the change from 
wax to gum sealing. This suggests an effective hindrance of sample evaporation and 
inhibition of concentration dependent aggregation. At pH 6.0 the capillary sealing has 
evidently no effect on the peak formation and thus aggregation occurs concentration- 
and evaporation-independent. These findings confirm our hypothesis of aggregation 
and precipitation being favored at low pH conditions. 
 
Figure 24: Thermophoresis melting curves for comparison of capillary closure by liquid dip gum at 
both sides vs. sealing by wax at one side (n=3). 
An additional control experiment was performed proving the effective capillary sealing 
by liquid dip gum (Figure 25) The measurement represents the worst case scenario of 
a full capillary tray load (16 capillaries) combined with 300 seconds equilibration time 
at each temperature, leading to an extended total runtime of 15 hours. It impressively 
proves that the aggregation peaks in thermophoresis vanish under capillary closure by 
liquid dip gum for all eight capillaries, underlying the effective inhibition of evaporation 
and the consequent hindering of up-concentration and aggregation. 
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Figure 25: Head-to-head comparison of capillary closure by liquid dip gum at both sides vs. 
sealing wax at one side (n=8). 
VI.2.1.2. Intrinsic Fluorescence Emission Spectroscopy (intrinsic FES) 
The unfolding event of HSA followed by intrinsic tryptophan fluorescence measured in 
a standard cuvette fluorimeter is rather weak, showing one negative sigmoid unfolding 
transition (Figure 26). These findings are in contrast to the distinct peak shaped 
thermophoresis and t-jump melting curves in section VI.2.1.1. However, the resulting 
Tm values show a comparable trend of increasing unfolding temperatures when 
reducing the pH value, which results in the highest conformational stability for HSA at 
pH 6.0 (Figure 27). Moreover, the unfolding curve for HSA at pH 6.0 by intrinsic 
fluorescence shows a drop in fluorescence at approximately 80 °C that does not occur 
for higher pH values (Figure 26). This emission decrease is attributed to strong protein 
aggregation, leading to precipitation and consequently removal of sample material 
from the optical path. Therefore, the fluorimeter data confirm the stability ranking by t-
jump and thermophoresis, identifying pH 6.0 as the optimum in terms of 
conformational stability but entailing the highest risk for non-native protein aggregation 
at temperatures above the melting point. 
Overall, the data quality of the fluorescence measurements is comparable to MST, 
while the sample consumption of the cuvette fluorimeter is ~ 5-fold and the analysis 
time per sample is approximately 30% higher. Another argument for the MST 
approach is that it is parallelizable for analyzing up to 16 samples in parallel whereas 
standard fluorimeters are often limited to 4 or maximum 8 sample holders. 
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Figure 26: Melting curves of HSA by using intrinsic fluorescence (n=1). Left: Full view melting 
curves for HSA in PBS pH 6.0 (grey), 6.5 (red), 7.0 (green) and 7.5 (black). Right: Zoom of melting 
curves (lines) and corresponding smoothed and interpolated first derivative functions (dotted 
lines). 
 
Figure 27: Melting temperatures (Tm) for intrinsic fluorescence (355 ± 25 nm). 
The evaluation of initial intrinsic fluorescence over temperatures from the pH screening 
experiment in the MST setup (Figure 28) furthermore strengthens the assumption of 
increasing aggregation instabilities at low pH values due to an additional fluorescence 
decrease at temperatures above 70 °C which is potentially caused by precipitation of 
sample material. These observations are in very good alignment with the intrinsic 
fluorescence curves measured in the cuvette based fluorimeter. 
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Figure 28: Intrinsic fluorescence melting curves for comparison of capillary closure by liquid dip 
gum at both sides vs. sealing by wax at one side. 
VI.2.1.3. Static Light Scattering (SLS) 
Static light scattering measurements were carried out in order to validate the 
presumption of decreasing aggregation stabilities at lower pH values. Aggregation was 
detected at all four pH values, while a steeper slope in light scattering was found at 
lower pH values (Figure 29 – left) what leads to overall increased integrated light 
scattering values (Figure 29 – right). Therefore, SLS fully confirms the previously 
described pH dependent aggregation.  
 
Figure 29: Static light scattering (SLS) at 266 nm of 0.75 mg/ml HSA in PBS. Left: SLS comparison 
over temperatures at pH 6.0 (grey), 6.5 (red), 7.0 (green) and 7.5 (black). Right: Corresponding 
integrated static light scattering intensities. 
 
30 40 50 60 70 80 90
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
In
tr
in
s
ic
 F
lu
o
re
s
c
e
n
c
e
 [
A
.U
.]
Temperature [°C]
 pH 6.0 - gum
 pH 7.5 - gum
30 40 50 60 70 80 90
0.0
2.0x10
5
4.0x10
5
6.0x10
5
8.0x10
5
S
ta
ti
c
 L
ig
h
t 
S
c
a
tt
e
ri
n
g
 (
2
6
6
 n
m
) 
[A
.U
.]
Temperature [°C]
 pH 6.0
 pH 6.5
 pH 7.0
 pH 7.5
pH 6.0 pH 6.5 pH 7.0 pH 7.5
0.0
5.0x10
6
1.0x10
7
1.5x10
7
2.0x10
7
 
 
 
In
te
g
ra
te
d
 S
ta
ti
c
 L
ig
h
t 
S
c
a
tt
e
ri
n
g
 I
n
te
n
s
it
y
 [
A
.U
.]  266 nm
 473 nm
MICROSCALE THERMOPHORESIS (MST) 
FOR PROTEIN FORMULATION DEVELOPMENT 
76 
At the same time, the apparent aggregation onset temperatures are similar for pH 6.5 
to 7.5 and differ only for pH 6.0 where scattering increases earlier (Figure 30). 
Moreover, this formulation shows distinct precipitation at temperatures above ~ 75 °C 
which is observable in the declining scattering at higher temperatures. This is 
congruent with the emerging extra peak in the thermophoresis and t-jump melting 
curves as well as signal loss for the fluorescence measurements. 
 
Figure 30: Aggregation onset temperatures for static light scattering at 266 nm. 
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VI.2.2. Forced Degradation Studies 
Orthogonal forced degradation studies were performed in order to underline the 
consistent findings from the thermal unfolding and aggregation screening. Figure 31 
and Figure 32 display the normalized intrinsic fluorescence timetraces recorded within 
the TOPC experiments for the HSA pH screening. Large differences in the curve 
shapes are apparent with changing pH values. While the formulations at pH 7.5 and 
pH 7.0 show neither pronounced aggregation, nor precipitation indicating events under 
IR-laser heating, the formulations at pH 6.5 and especially at pH 6.0 are affected by 
heat stressing. For pH 6.5, a slight increase in fluorescence is registered that suggests 
the accumulation of protein aggregates in the focal area, without formation of insoluble 
precipitating particles. Furthermore, a much steeper increase is apparent for HSA at 
pH 6.0 that is, at later timescales, superimposed by a rise in fluorescence scattering. 
Accordingly, these observations are indicating the emergence of an even larger 
aggregate fraction or larger sized particles that precipitate under constant temperature 
input. Moreover, the deposition of precipitated material within the capillary additionally 
causes higher fluorescence levels after laser shutdown and backdiffusion of 
molecules. 
 
Figure 31: Normalized intrinsic fluorescence signal over time for thermo-optical protein 
characterization (TOPC) within the HSA pH screening. 
0 20 40 60 80 100 120 140 160 180
0.2
0.4
0.6
0.8
1.0
 
 
T
O
P
C
- 
N
o
rm
a
liz
e
d
 I
n
tr
in
s
ic
 F
lu
o
re
s
c
e
n
c
e
 [
A
.U
.]
Time [s]
 pH 6.0    pH 6.5    pH 7.0    pH 7.5
MICROSCALE THERMOPHORESIS (MST) 
FOR PROTEIN FORMULATION DEVELOPMENT 
78 
 
Figure 32: Zoom-in of the TOPC curves to highlight the differences in fluorescence level and 
scattering (left) and the timeframe between 125 and 150 s which was used for analysis (right). 
The observations from the raw data are confirmed by analysis of mean fluorescence 
and standard deviation values in the timeframe of 125-150 s (Figure 33). Again, 
soluble aggregates are anticipated to enhance the mean fluorescence values while the 
formation of insoluble aggregates increases the standard deviation. Unsurprisingly, the 
HSA formulation at pH 6.0 exhibits the highest values in both evaluations, what 
underlines the intense pH dependent aggregation and precipitation. Increasing the pH 
to 6.5 stabilizes the protein widely and only a slightly increased fluorescence level and 
standard deviation is observed. Among the higher pH values 7.0 and 7.5, the stability 
to heat exposure reaches a plateau and only marginal differences remain. 
 
Figure 33: TOPC data analysis of mean fluorescence and standard deviation in the measurement 
timeframe between 125 and 150 s. 
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Subsequently to the TOPC measurement, the same samples/capillaries were re-
investigated by means of a standard MST experiment (Figure 34). MST measurements 
with analogous settings were executed for the stepped thermal unfolding and 
aggregation investigations (Figure 22), which resulted in highly comparable 
thermophoresis and t-jump values between all investigated formulations at the starting 
temperature of 30 °C. As expected, the MST timetraces after thermal stressing in the 
TOPC setup show substantial deviations between the different pH values. For the 
formulation at pH 6.0, an overall reduced thermophoretic depletion combined with a 
non-exponential timetrace is obtained. Also in standard MST, this observation can be 
attributed to the presence of protein aggregates periodically flowing through the focal 
volume.6 In comparison to the TOPC experiment, the particulate flow occurs at a 
drastically reduced frequency, as the convective transport is reduced at the decreased 
IR-laser power and heating rate.7-9 Furthermore, a higher thermophoresis value was 
also obtained for pH 6.5, but the timetrace was found to be perfectly exponential and 
thus the absence of insoluble aggregates/particles was indicated. At pH 7.0 and 
pH 7.5 the protein was not affected by thermal stress and the MST timetraces 
remained unchanged. 
In conclusion, MST analysis of pre-stressed or stored samples can be used as 
additional measure of protein integrity and quality, when compared to unstressed or 
fresh samples. An identical application for a purely intrinsic fluorescence based 
instrument has been recently implemented by NanoTemper Technologies with the 
introduction of the Tycho NT.6. Instead of MST, this system measures the 
fluorescence ratio of 350 nm/330 nm and evaluates changes in the initial value (ratio) 
and the signal amplitude (Δ ratio) of a thermal unfolding scan. 
 
Figure 34: Standard MST measurement of the samples pre-stressed within the TOPC experiment. 
Left: Normalized MST timetraces. Right: Data analysis of the parameters thermophoresis and t-
jump.  
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VI.3. Summary and Conclusions 
MST and TOPC were able to reveal changes in conformational protein characteristics 
as well as aggregation stability facilitating a rapid stability profiling for an exemplary pH 
screening setup of HSA. 
Thermal unfolding and aggregation investigations by using MST revealed an accurate 
stability profiling, analyzing up to 16 conditions in parallel with a sample volume of only 
10 µl each. By contrast, the benchmark measurement of intrinsic fluorescence by 
using the Optim 1000 instrument exposed a very high noise level, which made the 
evaluation of unfolding temperatures with this setup impossible. In comparison to a 
standard cuvette based fluorimeter, our measurement approach required substantially 
lower sample volumes and generated a higher throughput, as in detail demonstrated 
within our publication about isothermal chemical denaturation investigations by intrinsic 
fluorescence10. Moreover, the generated stability rankings by MST and FES were 
found to be highly comparable (Figure 35) yielding a positive effect of lower pH values 
on the unfolding stability of HSA. 
 
Figure 35: Correlation of melting temperatures from intrinsic fluorescence with thermophoresis 
(black dots and line) and t-jump (red dots and line). 
Additionally, changes in non-native protein aggregation and/or precipitation were 
indicated by the occurrence of additional spikes in thermophoresis data evaluation. 
This assumption was confirmed by a prominent decrease in intrinsic fluorescence 
emission above melting temperature, not occurring for the formulations between 
pH 6.5 and 7.5 and therefore probably being related to molecular precipitation. 
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Finally, static light scattering displayed strongest aggregation for pH 6.0 and additional 
precipitation at temperatures above ~ 75 °C. 
Particularly with regard to future more extended and time consuming formulation 
screenings, an effective capillary sealing technique was implemented by the use of 
liquid dip gum that prevents sample evaporation from the capillaries for hours, even at 
elevated temperatures. 
Furthermore, TOPC and subsequent MST analysis revealed considerable differences 
between the pH values investigated. While the formulations at pH 7.5 and pH 7.0 
remain stable under continuous laser input, fluorescence values and timetrace 
scattering increases over time for pH 6.5 and especially for pH 6.0. These events are 
attributed to the formation of soluble aggregates and precipitates flowing through the 
measurement focus. With these results, the trend in colloidal stability received from the 
thermal unfolding and aggregation studies was confirmed, increasing the aggregation 
and precipitation propensity with decreasing pH values.  
In summary, model protein and formulations were well chosen because an inversely 
proportional stability trend was received for conformational and colloidal stability. In 
real formulation practice, these results would demand for a compromise between 
lowest aggregation propensity at high pH and highest thermal stability at low pH. 
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Chapter VII  
Recombinant human Granulocyte Colony 
Stimulating Factor (rh-GCSF) 
Recombinant human granulocyte colony stimulating factor (rh-GCSF) is a recombinant 
human cytokine, which stimulates the production and maturation of granulocytes, as 
well as their release to the blood circulation. rh-GCSF has several applications in the 
treatment of neutropenia and is for example used after a chemotherapeutic cancer 
treatment in order to increase the recovery rate and to prevent bacterial and fungal 
infections.1-3 On the market, GCSF is available as recombinant human drug 
(Filgrastim)4 and in PEGylated form (Pegfilgrastim)5, for which the half-life is increased 
to enable an administration once a day. Besides the originator drugs, multiple 
biosimilars are available. 
In this case study, a formulation screening investigating the effect of pH, the presence 
or absence of buffer salts, and the impact of different concentrations of a polysorbate 
and a cyclodextrin is presented. The different formulations were investigated in 
unfolding and aggregation studies by using MST and the results were compared to 
commonly used gold standard techniques like intrinsic and extrinsic fluorescence, 
calorimetry and light scattering. Furthermore, forced degradation studies were carried 
out by using TOPC and a comparative conventional stress testing approach, which 
was combined with turbidity and light obscuration readouts. 
Apart from the formulation screening, MST binding studies were performed between 
rh-GCSF and various cyclodextrins as well as the non-ionic surfactant pluronic F-127. 
The observed interactions were verified by evaluating the stability consequences by 
nanoDSF and SLS. 
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VII.1. Materials and Methods 
VII.1.1. rh-GCSF 
Recombinant human Granulocyte Colony Stimulating Factor (rh-GCSF) was a gift from 
Wacker Biotech GmbH (Jena, Germany). The growth hormone stock solution was 
formulated at a concentration of 4 mg/ml in 10 mM sodium acetate buffer pH 3.9 with 
5% sorbitol and 0.004% polysorbate 80. The E.coli expressed protein lacks 
glycosylation and consists of 174 amino acids, including two tryptophan residues in 
position 58 and 118. The theoretical molar mass sums up to 18.8 kDa, with an 
isoelectric point (pI) of 6.1.1,6,7 
VII.1.2. Excipients and Reagents 
An overview of excipients and reagents used in the formulation screening can be 
found in Table 10, while Table 11 summarized all materials used for the protein-
excipient interaction investigations. The sodium hydroxide and hydrochloric acid 
standard solutions used for pH adjustment were of analytical grade. All given pH 
values were adjusted by titration to a precision of ± 0.02. Highly purified water (ELGA 
Purelab, ELGA LabWater, Celle, Germany, now Veolia Water Technologies GmbH) 
was used exclusively for all preparation steps. 
Table 10: Overview of excipients and reagents used for the rh-GCSF formulation screening. 
Material Supplier Art.-number Lot-number 
Tween 80 (Polysorbate) 
Merck KGaA, Darmstadt, 
Germany 
8.17061.1000 
K38539861 
827 
Hydroxy-Propyl-beta-
Cyclodextrin (HP-β-CD, 
Cavasol W7 HP Pharma) 
Wacker Chemie AG, 
Burghausen, Germany 
60012210 73B014 
Citric acid, anhydrous 
Hermes Arzneimittel GmbH, 
Großhesselohe, Germany 
Raw material 
sample 
9300900 
Acetic acid, glacial LMU central supply CUP CAS: 64-19-7 - 
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Table 11: Overview of excipients and reagents used for the rh-GCSF-excipient interaction study. 
Material Supplier Art.-number Lot-number 
Acetic acid, glacial LMU central supply CUP CAS: 64-19-7 - 
Sodium dihydrogen 
phosphate dihydrate 
Applichem GmbH, Darmstadt, 
Germany 
A1939,1000 0A006917 
Alpha-Cyclodextrin (α-CD) 
CycloLab R&D Ltd, Budapest, 
Hungary 
CY-1001 CYL-2322 
Beta-Cyclodextrin (β-CD, 
Cavamax W7 Pharma) 
Wacker Chemie AG, 
Burghausen, Germany 
60006994 70P255 
Hydroxy-Propyl-beta-
Cyclodextrin (HP-β-CD, 
Cavasol W7 HP Pharma) 
Wacker Chemie AG, 
Burghausen, Germany 
60012210 73B012 
Methyl-beta-Cyclodextrin 
(M-β-CD, Cavasol W7 M 
Pharma) 
Wacker Chemie AG, 
Burghausen, Germany 
60007006 71P019 
Sulfobutyl-Ether-beta-
Cyclodextrin (Captisol  
SBE-β-CD Sodium Salt) 
CyDex Inc, Lenexa, KS, USA - 
NC-04A-
05009 
Gamma-Cyclodextrin (γ-
CD) 
CycloLab R&D Ltd, Budapest, 
Hungary 
CY-3001 CYL-1815 
Maltoheptaose 
CycloLab R&D Ltd, Budapest, 
Hungary 
CY-4004 CYL-2217/2 
Sodium Chloride (NaCl) 
Carl Roth GmbH & Co KG, 
Karlsruhe, Germany 
9265.1 - 
Pluronic F-127 
NanoTemper Technologies 
GmbH, Munich, Germany 
- - 
 
VII.1.3. Formulations 
The protein stock solution was adjusted to pH 3.5 by titration and then dialyzed to 
highly diluted hydrochloric acid solution (pH 3.5) in order to remove the buffer salt and 
the excipients, while ensuring an acid solution pH. The dialysis was performed at 2-
8 °C in three steps of 4 liter medium each, by using Slide-A-Lyzer dialysis cassettes 
(2000 MWCO, 12-30 ml capacity, Thermo Scientific, Rockford, IL, USA). The 
extensive dialysis protocol consisted of two hours dialysis, 1st buffer exchange, two 
hours dialysis, 2nd buffer exchange and overnight dialysis, which ensured a dialysis 
time of 20 hours in total. Afterwards, the solution was split into three batches and the 
pH values of the solutions were adjusted to pH 4.0, 4.5 and 5.0 by titration using HCl 
or NaOH respectively. Subsequently the respective batches were diluted to twelve 
different formulations (Table 12) using highly purified water, buffer and excipient stock 
solutions. After preparation, the pH values of the single formulations were checked 
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again and adjusted when necessary. The protein formulations were filtrated using 
0.22 µm Millex® GV PVDF syringe filter units (Merck Millipore Ltd., Tullagreen, 
Ireland). For each formulation, a reference solution missing the protein was prepared 
accordingly, which was filtrated using 0.2 µm cellulose acetate sterile syringe filters 
(VWR International LLC, Radnor, PA, USA). The pH adjustments were performed by 
using an MP220 pH meter, equipped with an InLab Expert pH electrode (Mettler-
Toledo, Greifensee, Switzerland). Protein concentrations were determined by using 
UV spectroscopy measured with a NanoDrop2000 instrument (Thermo Scientific, 
Wilmington, USA) and an extinction coefficient of ε280 nm=0.86 ml*mg-1*cm-1.1,6,8 All 
samples and references were aliquoted in 2 ml conical micro-centrifuge tubes (VWR 
International LLC, Radnor, PA, USA) with minimum headspace to reduce mechanical 
stress during sample handling and were stored at 2-8 °C upon preparation. An 
identical, randomized order was used for all analyses, in order to exclude potential 
storage and measurement time effects on the determined stability parameters. 
Table 12: Overview of the formulations prepared for the rh-GCSF formulation screening. 
ID 
GCSF 
[mg/ml] 
Buffer 
system 
pH 
Tween 80 
[%] 
HP-β-CD 
[%] 
F1 0.2 - 4.0 0.005 - 
F2 0.2 - 4.0 0.05 - 
F3 0.2 - 4.0 - 1.0 
F4 0.2 - 4.0 - 5.0 
F5 0.2 - 4.5 0.005 - 
F6 0.2 - 4.5 0.05 - 
F7 0.2 - 4.5 - 1.0 
F8 0.2 - 4.5 - 5.0 
F9 0.2 - 5.0 0.005 - 
F10 0.2 - 5.0 0.05 - 
F11 0.2 20 mM citrate 4.5 0.005 - 
F12 0.2 20 mM acetate 4.5 0.005 - 
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VII.1.4. Further Preparations 
In the course of the protein-excipient interaction study, stock solutions of the different 
excipients were prepared as stated in Table 13. Thereby, all excipients were weighed 
into 10 ml volumetric flasks with an accuracy of ± 0.1 mg to the respective target 
weight. The excipients were then dissolved in the chosen buffer by vortexing and the 
volume was filled ad 10 ml with buffer after completely dissolving the substance. 
Additional to the 20 mM acetate buffer pH 4.0 without salt, two buffer variants including 
15 mM and 3 M NaCl were prepared in order to investigate the salt dependency of the 
rh-GCSF-excipient interactions. For investigating the rh-GCSF binding to surfactants, a 
5% pluronic F-127 stock solution in water was provided by NanoTemper Technologies, 
which was pre-diluted in in 20 mM acetate buffer pH 4.0 to a concentration of 4%. 
Table 13: Overview of the excipient stock solutions prepared for the rh-GCSF protein-excipient 
binding studies. 
Stock solution 
Target 
weight 
[g] 
Buffer system 
20 mM 
acetate 
pH 4.0 
20 mM 
phosphate 
pH 4.0 
20 mM 
phosphate 
pH 7.0 
15 mM α-CD 0.1459 x x - 
15 mM β-CD 0.1703 x x - 
15 mM HP-β-CD 0.2100 x x x 
150 mM HP-β-CD 2.1000 x - x 
15 mM M-β-CD 0.1965 x x - 
15 mM SBE-β-CD 0.2138 x x x 
150 mM SBE-β-CD 2.1380 x - x 
15 mM γ-CD 0.1946 x x - 
15 mM 
Maltoheptaose 
0.1730 x x - 
15 mM NaCl 0.0088 x - - 
3 M NaCl 1.7532 x - - 
x = solution prepared; - = solution not prepared  
 
Subsequently, the previously dialyzed rh-GCSF material (0) was pre-diluted to working 
solutions (WS) of 20 µM in the three buffer systems used. After dilution, the pH values 
were checked and adjusted if necessary. The pH adjustments were performed by 
using a HI83141 pH-meter, equipped with a HI1230 electrode (Hanna Instruments 
Deutschland GmbH, Voehringen, Germany). In the next step, a 1:1 serial dilution of 
the excipient stock solution was prepared in the respective assay buffer under 
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thorough homogenization by pipetting up and down several times. Afterwards an equal 
amount of the rh-GCSF WS was added in order to reach a final protein concentration 
of 10 µM for all dilution steps. All dilution steps were performed at 4 °C on ice. After 
final homogenization, the samples were centrifuged for 10 min (15000 g, 4 °C) in order 
to remove larger aggregates. 
VII.1.5. Unfolding and Aggregation Investigations 
VII.1.5.1. MicroScale Thermophoresis (MST) 
MST was used for predictive unfolding and aggregation studies in a stepped thermal 
ramp setup by using the 2nd generation prototype setup (NanoTemper Technologies 
GmbH, Munich, Germany). Therefore, the temperature was increased from 30 °C to 
90 °C in 1 °C steps. Fluorescence excitation LED Power was set to 15% (PMT=810 V) 
using an MST Power of 20%. NT.LabelFree Zero Background Standard Treated 
Capillaries (NanoTemper Technologies) were used exclusively and sealed with liquid 
dip gum (Capillary Sealing Paste, NanoTemper Technologies) at both capillary ends. 
In order to exclude effects from prolonged thermal history of capillaries at the end of 
the sample tray, all samples were measured in quadruplicates by executing four 
consecutive runs in a randomized order with fresh capillaries each.  
The measurements were performed by using NT Control software version 2.1.31, 
while NT Analysis software version 1.5.41 (NanoTemper Technologies) was used to 
calculate thermophoresis and t-jump values for each temperature step. Melting 
temperatures (Tm) for the respective melting curves of both data evaluations were 
calculated by smoothing (Savitzky-Golay, polynomial order 1, points of the window 3), 
interpolation (cubic spline, 6001 points between 30 °C and 90 °C) and local maximum 
analysis using the included Impulse Analyzer tool (Origin 8G, OriginLab Corp., 
Northampton, MA, USA). 
VII.1.5.2. Fluorescence Emission Spectroscopy (FES) 
VII.1.5.2.1. Nano Differential Scanning Fluorimetry (nanoDSF) 
A Prometheus NT.48 prototype instrument (NanoTemper Technologies GmbH, 
Munich, Germany) was used for reference measurements of linear thermal unfolding 
by intrinsic tryptophan fluorescence. A temperature ramp was executed from 30 °C to 
90 °C by using a slope of 1 °C/min. An LED Power of 15% was used to induce intrinsic 
protein fluorescence which was continuously collected at 330 nm and 350 nm, 
enabling a data density of  11 data points per °C. All samples have been analyzed in 
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four subsequent runs using NT.LabelFree Zero Background Standard Treated 
Capillaries (NanoTemper). Evaporation of the sample material from the capillaries at 
elevated temperatures was reduced by sealing both ends with liquid dip gum (Capillary 
Sealing Paste, NanoTemper Technologies). 
In order to obtain melting temperatures (Tm) from the intrinsic fluorescence emission, 
the intensities of the single wavelengths at 330 nm and 350 nm as well as the ratio of 
350/330 nm was calculated and evaluated over temperatures. Calculation of the 
fluorescence values was conducted by using a customized Python(x,y) script (software 
version 2.7.6.0) before Tm values were determined with a hard-coded NT.Analysis tool 
(both NanoTemper Technologies). 
VII.1.5.2.2. Intrinsic Fluorescence Emission Spectroscopy (intrinsic FES) 
An Optim 1000 instrument (Avacta Analytical Ltd, Wetherby, UK, now Unchained 
Labs, Pleasanton, CA, USA) was used for a comparative linear thermal unfolding and 
aggregation study. The samples were pipetted in the capillaries of a 9 µl micro-cuvette 
array (MCA), which were tightly closed with the provided silicone seals using a MCA 
frame. Using the Optim Client software V1.5.4 (Avacta Analytical), all formulations 
were measured in quadruplicates by performing three consecutive runs with 1 MCA 
(=16 capillaries) each. Thereby, the capillary positions of the formulations within the 
MCA were changed in each run to avoid error carryover. Before each measurement, 
the thermostat temperature was set to 30 °C for a pre-scanning delay of 15 min. 
Following this equilibration time, the temperature was linearly increased from 30 °C to 
90 °C in a rate of 1 °C per minute, while a hold time of 1 s was used at each well for 
recording of the fluorescence spectrum. An excitation laser wavelength of 266 nm was 
used to induce deep UV intrinsic fluorescence, setting a slit width of 100 µm and an 
exposure time of 1000 ms. Fluorescence emission was recorded from 249 to 504 nm 
using a center wavelength of approximately 380 nm. For data evaluation, the ratio of 
350 nm/330 nm was chosen and unfolding temperatures (Tm) were automatically 
calculated by the Optim Analysis Software V2.0.4 (Avacta Analytical). If necessary, 
melting temperatures were re-adjusted according to the maxima of the 1st derivative 
fluorescence curves. 
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VII.1.5.2.3. Differential Scanning Fluorimetry (DSF) 
Differential Scanning Fluorimetry (DSF) was used for reference measurements of 
linear thermal unfolding by evaluating changes in the extrinsic fluorescence of SYPRO 
orange (SO) and 9-(2,2-dicyanovinyl)julolidine (DCVJ). 
SYPRO Orange Protein Gel Stain was purchased as a 5000x concentrated stock 
solution (SS) in DMSO (Sigma Aldrich, St. Louis, MO, USA). First, the SS was diluted 
with highly purified water (HPW) to a working solution (WS) of 21x. Subsequently, 
20 µl protein formulation or placebo reference respectively was provided in the wells of 
a skirted 96-well microplate (Biometra GmbH, Goettingen, Germany) and 1 µl WS was 
spiked in and thoroughly mixed. The resulting final volume per well was 21 µl with a 
SO concentration of 1x. For each formulation 8 wells were prepared, 6 with protein 
material and 2 with the respective placebo reference. To prevent evaporation and 
ensure proper filling of each without air bubbles, the well plate was covered with self-
adhesive optical sealing film (Biometra) and centrifuged at 2000 g for 2 minutes. 
The unfolding experiment was conducted using a qTower 2.2 UV instrument (Analytik 
Jena AG, Jena, Germany). After an initial equilibration time of 15 minutes at 30 °C, the 
temperature was stepwise increased to 90 °C following a scan rate of 1° C/min and a 
measurement interval of 1 per °C. An excitation wavelength of 490 nm was used, while 
the fluorescence emission of SO was collected at 580 nm by using the corresponding 
channel of the instrument at a gain of 5. At each temperature, three repetitive 
measurements were performed. 
Before melting temperatures (Tm) were evaluated, the placebo reference 
measurements were subtracted from the verum melting curves, in order to exclude 
effects from buffer background fluorescence. Subsequently, the background 
subtracted data were differentiated (1st derivative), smoothed (Savitzky-Golay, 
polynomial order 1, points of the window 5), interpolated (cubic spline, 6001 points 
between 30 °C and 90 °C) and the local maximum was analyzed using the included 
Impulse Analyzer tool (Origin 8G, OriginLab Corp., Northampton, MA, USA). 
9-(2,2-dicyanovinyl)julolidine (DCVJ) was purchased as solid powder from Sigma 
Aldrich (St. Louis, MO, USA) and diluted in DMSO to a stock solution (SS) of 210 mM. 
This SS was further diluted to a 2.1 mM working solution (WS) with HPW. 
Subsequently, the WS was spiked to rh-GCSF Formulation 1 in different proportions 
and thoroughly mixed, yielding final concentrations between 10 and 500 µM DCVJ. 
The wells of a Thermo-Fast 96 PCR Detection Plate (Thermo Scientific, 
Loughborough, UK) were filled with 21 µl of each preparation and sealed with 
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Adhesive Sealing Sheets (Thermo Scientific, Loughborough, UK). The well plate was 
centrifuged for 2 minutes at 2000 g to ensure filling without air bubbles. 
A 7300 real-time PCR system (Applied Biosystems, Foster City, CA, USA) was used 
for the unfolding experiment. After an initial equilibration time of 15 minutes at the 
starting temperature of 30 °C, the temperature was stepwise increased to 90 °C 
following a scan rate of 1° C/min and a measurement interval of 1 per °C. A tungsten-
halogen lamp was used for fluorescence excitation, while the emission was recorded 
at ~ 520 nm using the detection filter A. For conducting the measurement, a 7300 
System SDS Software version 1.3.1 (Applied Biosystems, Foster City, CA, USA) was 
used. 
VII.1.5.3. Differential Scanning Micro-Calorimetry (µDSC) 
A VP-DSC microcalorimeter (MicroCal Inc., Northampton, MA, USA, now Malvern 
Instruments Ltd, Malvern, UK) was used for comparative thermal unfolding studies. 
The placebo and verum formulations were degassed for approximately 5 min by using 
a ThermoVac vacuum pump (MicroCal) in order to remove potential air bubbles from 
the samples. Subsequently, 550 µl of the placebo reference was injected by using a 
2.5 ml gastight Hamilton syringe (Hamilton Company, Reno, NV, USA) at 25 °C before 
the verum material was injected accordingly. A temperature up-scan was performed 
from 30 °C to 90 °C by performing a slope of 60 °C/h. A pre-scan thermostat of 15 
minutes was set at the starting temperature to ensure thermal equilibration. During the 
measurement, a filtering period of 1 second was set without a feedback mode/gain, 
while the chamber pressure was checked to be ≥ 22 psi. After each run, the cells were 
cooled down to 30 °C again. 
Between two sample runs, a cleaning routine was performed by heating up a 50% 
(V/V) nitric acid solution under the same conditions as the samples, but using a scan 
rate of 90 °C/min and no pre-scan thermostat. Afterwards, a solution of 1% (w/V) 
sodium dodecyl sulfate (SDS) (Merck KGaA, Darmstadt, Germany) in HPW was used 
to flush each cell for 30 seconds, followed by a thorough rinse with 100 ml water per 
cell. 
The data evaluation was performed by the Origin DSC data analysis software (Origin 7 
SR2, OriginLab Corp., Northampton, MA, USA) and MicroCal VPViewer2000 version 
1.4.10 (MicroCal). The thermograms were normalized by subtracting a baseline 
measured by water vs. water scans to exclude device parameters and instrumental 
effects. Afterwards, the endothermic peaks indicating protein unfolding events (Tm) 
were determined using the included Peak Picking Tool. 
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VII.1.5.4. Static Light Scattering (SLS) 
Additionally to intrinsic fluorescence (section VII.1.5.2.2), static light scattering intensity 
over temperature was evaluated from the Optim 1000 measurement for the UV laser at 
266 nm and the blue laser at 473 nm. Therefore, 90° light scattering values were 
plotted over temperature and aggregation onset temperatures (Tagg onset) were 
evaluated for 266 nm and 473 nm, given a bandwidth of 5 nm each, by using the 
Optim Analysis software V2.0.4 (Avacta Analytical). For calculation, the software 
applied a Heaviside step function to the 1st derivative curve of static light scattering 
and the temperature corresponding to the 10% value of the maximum was determined 
automatically. 
VII.1.6. Forced Degradation Studies 
VII.1.6.1. Thermo-Optical Particle Characterization (TOPC) 
TOPC was used for predictive thermal aggregation studies by IR-laser induced stress 
testing. The fluorescence excitation LED power was set to 15% (PMT=810 V) and heat 
stress was applied by using an IR-laser power of 227%. Changes in intrinsic 
fluorescence were detected for 185 s in total. After recording the initial fluorescence for 
5 s, the laser was turned on and the effects of the IR-laser input were tracked for 
150 s, before the laser was turned off again and backdiffusion was measured for 
additional 30 s. 
All measurements were performed in singlicates following a fixed random order of 
formulations at an ambient assay temperature of 25°C by exclusively using 
NanoTemper LabelFree MST Premium Coated Zero Background Capillaries 
(NanoTemper Technologies GmbH) in order to avoid measurement artifacts from 
sample binding to the capillaries and capillary auto-fluorescence. 
NT Control software version 2.1.31 was used to perform the measurements, while the 
intrinsic fluorescence timetraces were normalized and exported by using NT Analysis 
software version 1.5.41 (both NanoTemper Technologies). The TOPC experiments 
were analyzed by calculating mean values and standard deviations for all formulations 
in the timeframe between 100 and 125 s. All calculations and data plotting were 
performed with Origin 8G software (OriginLab Corp., Northampton, MA, USA). 
  
CHAPTER VII   RECOMBINANT HUMAN GRANULOCYTE COLONY 
STIMULATING FACTOR (RH-GCSF) 
93 
VII.1.6.2. Conventional Stress Testing 
All formulations were heat- and shake-stressed in 2 ml conical micro-centrifuge tubes 
(VWR International LLC, Radnor, PA, USA) by using a filling volume of 1 ml. Heat 
stress was applied for 10 minutes at 75 °C (after 15 minutes for temperature 
equilibration) using a ThermoMixer Comfort (Eppendorf AG, Hamburg, Germany). 
Horizontal shaking was performed for 30 minutes in a Mixer 5432 (Eppendorf AG, 
Hamburg, Germany) at 1450  30 rpm as stated by the manufacturer. As a reference, 
one aliquot of each sample was stored at 4 °C for the same time. 
VII.1.6.2.1. Turbidimetry 
A Dr. Lange Nephla Turbidimeter (Hach-Lange, Duesseldorf, Germany) was used for 
measuring the turbidity of the native and stressed protein formulations. All samples 
were diluted 1:10 with filtered placebo buffer and subsequently 2 ml of each sample 
was filled in a glass cuvette. Turbidity was determined as 90° scattered light (860 nm) 
in Formazin Nephelometric Units (FNU). The measurement was carried out in 
singlicates. 
VII.1.6.2.2. Light Obscuration 
A PAMAS SVSS instrument (PAMAS GmbH, Rutesheim, Germany) was used for 
measuring the turbidity of the native and stressed protein formulations. Before 
analysis, all samples were diluted 1:10 with filtered placebo buffer. The samples were 
analyzed in three sub-runs with a total analysis volume of 0.3 ml. In between two 
sample measurements, the system was purged with highly purified water and one 
water measurement was performed to check the cleanliness of the system. The 
particle concentration is given in particles ≥ 1 µm per ml under consideration of the 
dilution factor. 
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VII.1.7. Protein-Excipient Interaction Analysis 
VII.1.7.1. MicroScale Thermophoresis (MST) 
MST was used for protein-excipient binding studies of rh-GCSF to cyclodextrins and 
pluronic F-127. All measurements were performed on a Monolith NT.LabelFree 
instrument (NanoTemper Technologies) by using a MST Power of 20%. The 
Fluorescence excitation LED Power was set individually for each measurement series 
in order to get a satisfactory high fluorescence signal. For the binding studies of rh-
GCSF to cyclodextrins, the excitation power was set to 20% for the measurements in 
20 mM acetate pH 4 and 20 mM phosphate pH 4, while for 10 mM phosphate pH 7 it 
was decreased to 7%. A value of 10% was chosen for the rh-GCSF interaction studies 
with pluronic-F127 in 20 mM acetate buffer pH 4. NT.LabelFree Zero Background MST 
Premium Coated Capillaries (NanoTemper Technologies GmbH) were used 
exclusively and the measurements were carried out at ambient room temperature. 
Only for the binding studies with pluronic F-127, the temperature was varied between 
22 and 37 °C in 5 °C steps. 
The measurements were performed by using NT Control software version 2.1.31, 
while NT Analysis software version 1.5.41 (NanoTemper Technologies) was used to 
calculate thermophoresis and intrinsic fluorescence values for each excipient 
concentration and compute equilibrium dissociation constants (Kd) by fitting a 
Boltzmann-function to the respective data. Plotting of the data was performed by using 
Origin 8G software (OriginLab Corp., Northampton, MA, USA). 
VII.1.7.2. Nano Differential Scanning Fluorimetry (nanoDSF) 
A Prometheus NT.48 instrument (NanoTemper Technologies GmbH, Munich, 
Germany) was used for linear thermal unfolding measurements of the protein-excipient 
dilution series. A temperature ramp was executed from 15 °C to 95 °C in a slope of 
1 °C/min, while protein fluorescence was continuously collected at 330 nm and 
350 nm. The fluorescence excitation power was set individually for each measurement 
series in order to get a satisfactory high fluorescence signal. For the binding studies of 
rh-GCSF to cyclodextrins, the excitation power was set to 40% (medium sensitivity) for 
the measurements in 20 mM acetate pH 4 and 20 mM phosphate pH 4. A value of 
15% (medium sensitivity) was chosen for the rh-GCSF interaction studies with 
pluronic-F127 in 20 mM acetate buffer pH 4. All titration steps have been analyzed in 
singlicate runs by using NT.LabelFree Zero Background MST Premium Coated 
Capillaries (NanoTemper Technologies). 
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In order to obtain melting temperatures (Tm) from the intrinsic fluorescence emission, 
the intensities of the single wavelengths at 330 nm and 350 nm as well as the ratio of 
350/330 nm was calculated and evaluated over temperatures by using NT.Prometheus 
Control software version 1.11 (NanoTemper Technologies). 
VII.1.7.3. Static Light Scattering (SLS) 
An Optim 1000 instrument (Avacta Analytical Ltd, Wetherby, UK, now Unchained 
Labs, Pleasanton, CA, USA) was used for a comparative linear thermal aggregation 
study of the protein-excipient dilution series. As this method is very sensitive to low 
concentrations of aggregates in solution, all buffer and excipient solutions were sterile 
filtrated using 0.2 µm cellulose acetate sterile syringe filters (VWR International, 
Darmstadt, Germany). The protein solution was filtrated using 0.22 µm Millex GV 
PVDF syringe filter units (Merck Millipore Ltd., Tullagreen, Ireland). After filtration, the 
dilution series was prepared and the samples were pipetted in the capillaries of a 9 µl 
micro-cuvette array (MCA), which were tightly closed with the provided silicone seals 
using a MCA frame. The temperature was linearly increased from 15 °C to 95 °C in a 
rate of 1 °C per minute, after maintaining the starting temperature of 15 °C for 15 
minutes in order to guarantee temperature equilibration. The static light scattering 
intensity was evaluated and plotted over temperature for 90° light scattering at 
266 ± 5 nm by using the Optim Analysis software V2.0.4 (Avacta Analytical). 
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VII.2. Results and Discussion 
VII.2.1. Unfolding and Aggregation Investigations 
VII.2.1.1. MicroScale Thermophoresis (MST) 
The melting curves of all twelve rh-GCSF formulations (see page 85) showed 
pronounced positive peaks for the evaluations of thermophoresis (Figure 36 – left), 
temperature jump (Figure 36 – right) and the combination of both (data not shown). 
Moreover, those peaks were found to shift in temperature, depending on the 
respective formulation composition and were therefore assigned as apparent unfolding 
temperatures (Tm) and used to rank the formulations in terms of conformational 
stability (Figure 37). In the Tm comparison, a strong influence of pH was found, with a 
more stable protein conformation at lower pH values. Additionally, HP-β-CD containing 
formulations showed higher melting temperatures compared to preparations including 
polysorbate 80. The stabilizing effect of HP-β-CD was independent of the 
concentration used, while higher polysorbate contents resulted in slightly decreased Tm 
values, especially at low pH values. The use of citrate (F11) and acetate (F12) as 
buffering agents at pH 4.5 resulted in negative effects on the API stability compared to 
the unbuffered solution at the same pH (F5). While acetate lowered the Tm only by 2-
3 °C to a value being comparable to the results of the unbuffered solution at pH 5.0 
(F9), citrate showed a Tm decreased of ~ 6 °C and ranks as the most instable 
formulation in the screening. Overall, the evaluation of t-jump alone did result in 
smaller amplitudes for the unfolding transition compared to the thermophoresis and the 
combined evaluations. Consequently, this led to a lower signal-to-noise ratio and a 
reduced precision for the fitting of the peak maxima. 
A clear effect on aggregation stability in terms of an individual aggregation signal could 
not be derived from the raw unfolding curves, although it is noticeable that the curve 
shape after the unfolding transition is identical for all formulations in the t-jump melting 
curves (Figure 36 – right), but differs for the different pH values in the thermophoresis 
evaluation (Figure 36 – left). Thereby, the formulations at low pH values (F1-F4, green 
lines) show polymorphous, scattering and overall decreasing progressions, which 
changes at higher pH values and under the usage of buffering agents (F5-F12, grey & 
red lines) to rather uniform, straight and ascending trending. 
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Figure 36: Melting curves by thermophoresis (left) and t-jump (right) within the rh-GCSF 
formulation screening (n=1). 
 
Figure 37: Melting temperatures determined for T-Jump (green squares), Thermophoresis (red 
squares) and Thermophoresis including T-Jump (grey squares) within the rh-GCSF study (n=4). 
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These results are put into context with the literature, where manifold studies targeting 
the conformational and aggregation stability of rh-GCSF can be found.8-16 These 
precisely confirm the high relevance of the pH value and the buffer system, which was 
derived from the MST results, accordingly describing an increased conformational 
stability and aggregation resistance at acidic pH values of pH 4.0 or less. Moreover, 
the stability of rh-GCSF was in all cases highest for the formulations without any added 
buffer salt. In buffered formulations, acetate, phosphate, and glutamate provided 
improved stabilities compared to citrate and succinate. Additionally, a stabilizing effect 
is reported for sugars13,17 and polysorbate4,18, while high salt concentration 
destabilize7,16,19. By analogy, the marketed originator products are formulated in 
sodium acetate buffer containing sorbitol and polysorbate20,21. 
Furthermore, mechanistic studies on the irreversible aggregation of rh-GCSF are 
available, elucidating this process in greater detail.7,10,17,19,22,23 Summarizing these 
investigations, the aggregation cascade can be divided in two major, equally relevant 
steps. Initially, aggregation is induced by slight conformational expansion within the 
native state ensemble, which in the following leads to colloidal interactions and 
irreversible aggregation. Depending on the solution conditions, the rate-limiting step 
can be either the conformational change (depending on the free energy of unfolding 
(ΔGunf)) or the colloidal interaction (depending on the osmotic second virial coefficient 
(B22)). This widely explains the importance of colloidal factors like pH and ionic 
strength, preventing or favoring attractive interactions, as well as conformational 
stabilizers like sugar or sugar alcohols, which promote structurally compact 
conformations by direct interaction or preferential exclusion. 
In our case, the colloidal stability seems to be rate‐limiting, as increasing the pH and/or 
the ionic strength has a much higher stability effect than the addition of HP-β-CD. 
Moreover, the addition of polysorbate did not have a pronounced effect on the thermal 
stability. This is in alignment with the results of the studies by Bam et al.24 and Youssef 
et al.14, who both refer to interfacial stabilization potentially playing an inferior role in 
thermal denaturation. 
VII.2.1.2. Fluorescence Emission Spectroscopy (FES) 
Comparative measurements benchmarking the results of the thermophoretic melting 
curves were carried out by using intrinsic and extrinsic fluorescence emission 
spectroscopy.  
  
CHAPTER VII   RECOMBINANT HUMAN GRANULOCYTE COLONY 
STIMULATING FACTOR (RH-GCSF) 
99 
While two independent measurement setups evaluating intrinsic fluorescence 
(NanoTemper Prometheus NT.48 and Avacta Optim 1000) showed distinct unfolding 
transitions, independent of the type and concentration of excipients used for the 
formulations, extrinsic fluorescence performed worse (Figure 39). 
The interaction of the hydrophobic excipient Tween and the reporter dye Sypro Orange 
is well described in literature and leads to a concentration dependent increased 
background fluorescence emission, reducing the extent of fluorescence increase 
during protein unfolding.25-27 In our thermal unfolding experiments (Figure 38 – left), 
this interference was negligible for the formulations containing 0.005% Tween 80 (F1, 
5, 9, 11 and 12) but very pronounced at an 10-fold increased surfactant concentration 
of 0.05% (F2, 6, 10). There, the unfolding transition was completely superimposed, 
making a Tm determination impossible. Moreover, a concentration independent 
interference was found for formulations containing HP-β-CD in the range of 1% to 5%, 
where overall fluorescence levels were comparable to the other formulations, but still 
no unfolding induced fluorescence increase was detected. This observance might as 
well be caused by hydrophobic interactions between the SO and the hydrophobic 
cavity of β-cyclodextrin28, which prevent the dye molecules from binding to the 
exposed hydrophobic sites (AA residues) upon unfolding of rh-GCSF. 
The molecular rotor DCVJ is used to measure melting curves in the presence of 
polysorbates as the quantum yield/fluorescence increase following the decrease of 
rotational freedom during protein unfolding is not impacted by surfactants.25,29,30 
However, our data indicate that higher protein concentrations are required, so that 
none of the used dye concentrations showed an unfolding transition (Figure 38 – right). 
 
Figure 38: Melting curves for DSF by using extrinsic fluorescence emission of sypro orange (left) 
and DCVJ (right). Both data sets are displayed as raw data before background subtraction. (n=1) 
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In the Tm data evaluation (Figure 39), the trending towards lower conformational 
stability at increased pH values was confirmed by both intrinsic fluorescence assays, 
as well as DSF using SO as extrinsic fluorescence probe. Furthermore, for the 
comparison of the buffer-free (F5), citrate-buffered (F11) and acetate-buffered (F12) 
formulation, a consistent and pronounced destabilization by citrate was found, 
whereas the absence of buffer salt was beneficial over acetate in Prometheus FES 
and qTower DSF, while the Tm values of the two formulations were comparable in 
Optim FES. Results on the influence of different excipient concentrations (polysorbate 
and HP-β-CD) on the conformational stability could only be achieved by intrinsic 
fluorescence, as the above described dye interactions in DSF make an evaluation 
impossible. However, the impact was not fully identical among the intrinsic methods 
and the different pH values studied, showing individual trends towards stabilization as 
well as destabilization at higher concentrations. Moreover, both excipients contributed 
equally to the overall formulation stability, not indicating a definite benefit from 
polysorbate over cyclodextrin or vice versa. Remarkably, the increased resolution of 
the Prometheus data compared to the benchmark methods (> 11 data points/°C 
compared to ≤ 1 data point/°C) resulted in a minimal replicate deviation and an 
additional pre-melting transition for F2, explaining the large inter-assay variance for 
this formulation. Additionally, it is to mention that the spectral shift in intrinsic 
fluorescence from 330 nm to 350 nm was found to be much weaker compared to the 
changes in single wavelength fluorescence emission. For this reason, the evaluation 
was performed at 330 nm (Prometheus) and for fluorescence intensity (Optim), 
respectively. 
 
Figure 39: Comparison of absolute (left) and relative (right) melting temperatures (Tm) by using 
intrinsic (green and grey squares) as well as extrinsic (red squares) fluorescence emission 
spectroscopy. The dashed lines indicate the steps between pH 4.0 (F1-F4), pH 4.5 (F5-F8), pH 5.0 
(F9-F10), and pH 4.5 with buffering agent (F11-F12). 
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Figure 40 shows the correlation of intrinsic fluorescence with extrinsic fluorescence as 
well as both intrinsic fluorescence methods among each other. The clear pH effect on 
the conformational stability is producing strongly correlating data for the comparison of 
intrinsic fluorescence by Prometheus and evaluable formulations for extrinsic 
fluorescence by Sypro Orange measured in the qTower rt-PCR system. However, the 
discussed variations for the influence of the excipients and their different 
concentrations led to a slightly lowered correlation between the two intrinsic 
fluorescence methods. 
 
Figure 40: Correlation of intrinsic fluorescence emission at 330 nm by using Prometheus NT.48 
with intrinsic fluorescence intensity by Optim 1000 (black squares and line) and extrinsic 
fluorescence by Sypro Orange measured in a qTower rt-PCR device (red squares and line). 
VII.2.1.3. Differential Scanning Micro-Calorimetry (µDSC) 
The obtained µDSC data do not show the pronounced influence of pH on the thermal 
stability of rh-GCSF, which was previously described for the other methods 
investigated and in the literature. In our experiments, a minor tendency towards 
conformational destabilization by increasing the pH value was only visible between 
pH 4.0 (F1 – F4) and pH 4.5 (F5 - F8). Further neutralization of the pH to 5.0 did not 
have a remarkable effect. The most pronounced destabilization determined by using 
µDSC was caused by the change from an unbuffered (F5) to a citrate (F11) or acetate 
(F12) buffered formulation, which led to an immense decrease of the Tm by ~ 10 °C. 
This is in agreement with earlier investigations by Youssef31, who evaluated the 
predictive power of µDSC measurements of rh-GCSF and received a comparably 
weak influence of pH on the unfolding temperature evaluated by µDSC. Moreover, 
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high standard deviations were found for most of the performed replicate 
measurements, what makes a clear differentiation of conformational stabilities among 
the different formulations difficult. These large variances might be caused by the low 
protein concentration used and the associated low self-buffering capacity, potentially 
leading to pH changes upon storage. Furthermore, the substantially higher sample 
consumption, compared to all other methods investigated, made the analysis of 
different aliquots necessary. 
 
Figure 41: Melting temperatures for differential scanning calorimetry within the rh-GCSF 
formulation screening (n≥3). 
VII.2.1.4. Static Light Scattering (SLS) 
Aggregation stability investigated by static light scattering distinguished most clearly 
between stabilizing and destabilizing formulation conditions, which yielded in a very 
distinct stability trending over pH values. The raw data evaluation at 266 nm (Figure 42 
– left) not only differentiates between aggregation propensities by the scattering onset 
temperature (Figure 42 – right), but moreover between the underlying aggregation 
rates by the progression of the overall scattering intensity. Both aggregation markers 
indicate a higher stability at pH 4.0 (F1-F4), showing (i) highest Tagg onset values and (ii) 
comparably moderate slopes leading to low scattering plateaus below 200000 A.U.. 
Interestingly, F2 and less pronounced F1 (dark grey and black lines) seem to establish 
only intermediate plateaus followed by a second aggregation onset at temperatures 
> 75 °C (F2) and > 85 °C (F1). However, a second aggregation onset did not occur 
when Tween 80 was replaced by HP-β-CD (F3+4), independent of the cyclodextrin 
concentration. 
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On the contrary, formulations at pH 4.5 and 5.0 aggregate at lower temperatures and 
exhibit steep increases as well as high scattering intensities. Whereas the Tagg onset is 
strongly dependent on the formulation pH (except of F11 – 20 mM citrate, pH 4.5), the 
slope and the overall scattering intensities are found to be comparable between the 
two pH levels. Regarding the different buffer systems at pH 4.5, the unbuffered 
formulation (F5) and acetate buffer (F12) perform comparable, while citrate buffer 
(F11) is considerable less stable and ranks among the unbuffered formulations at pH 
5.0 (F9+F10). 
The influence of Tween 80 and HP-β-CD as formulation excipients was comparable, 
showing a slight trend towards higher Tagg onset values for increased concentrations and 
for the cyclodextrin over the polysorbate. 
 
Figure 42: Static light scattering for rh-GCSF formulation screening (n=4). Left: Raw data for SLS 
at 266 nm over temperature. Right: Comparison of the determined Tagg onset values at 266 nm and 
473 nm. 
VII.2.1.5. Comparison and Evaluation of MST as a Tool for Unfolding and 
Aggregation Investigations 
Within the rh-GCSF formulation screening, MST was able to achieve a matching and 
well correlating conformational stability ranking compared to intrinsic fluorescence 
based benchmark methods (Figure 43) and indicated several advantages over 
microcalorimetry and extrinsic fluorescence. Furthermore, a very high coincidence was 
found for the comparison with literature data regarding the stability dependencies on 
the formulation pH, the presence or absence of buffering agents as well as stabilizers. 
On the contrary, microcalorimetry performed imperfect in the low concentration range 
used, what resulted in a low signal-to-noise ratio for the single thermograms and large 
standard deviations for the respective Tm values obtained. 
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Extrinsic fluorescence was investigated by using two different dyes, Sypro Orange and 
DCVJ, both exposing drawbacks compared to intrinsic fluorescence and 
thermophoresis. On the one hand side, DSF under the use of SO was able to identify 
congruent unfolding events for the formulations containing 0.05% Tween 80, but did 
not expose any unfolding transition at higher polysorbate concentrations as well as for 
cyclodextrin containing formulations. On the other hand side, DCVJ that is described to 
facilitate measurements in the presence of polysorbates was found to require 
increased protein concentrations as no unfolding event was detected for any of the 
formulations and different dye concentrations investigated. 
However, in retrospect it must be stated that the selection of formulations was non-
optimal. A lot of unbuffered formulations in a rather low protein concentration were 
used. This has not only the disadvantage that the measurements are in all methods 
close to the detection limit but moreover that the self-buffering capacity of the protein is 
very weak. This leads to a rather instable system that shows large aliquot to aliquot 
variations (µDSC) and potential pH shifts upon pulling up or pipetting the solution into 
acid capillary glass (MST, Optim and Prometheus). 
Aggregation stability, determined as the onset temperature of light-scattering increase, 
showed the most differentiated results between stable and unstable formulations and 
was found to be highly impacted by the unfolded state of the protein, as both stability 
readouts show a similar trending and explicit as well a high overall correlation between 
the calculated Tm and Tagg onset values. 
 
Figure 43: Benchmarking of thermophoresis with t-jump (Tm) with fluorescence emission 
spectroscopy (Tm) and static light scattering (Tagg onset). Left: Comparison of relative melting as well 
as aggregation onset temperatures. Right: Correlation of conformational stability and aggregation 
parameters. 
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VII.2.2. Forced Degradation Studies 
VII.2.2.1. Thermo-Optical Protein Characterization (TOPC) 
In addition to the unfolding and aggregation studies using MST (VII.2.1), TOPC was 
investigated for the twelve different rh-GCSF formulations (see page 85) in order to 
further investigate the dependencies of the aggregation stability with the orthogonal 
approach of forced degradation. The results are displayed in Figure 44 as raw (left) 
and normalized (right) intrinsic fluorescence signal over time. As visible from the raw 
signal, the initial fluorescence values of the different formulations vary widely, with 
F10, F2, and F6 showing the highest, while F3 is showing the lowest fluorescence 
values. This fluorescence difference is attributable to the addition of excipients, which 
either show a concentration dependent auto-fluorescence or increase the fluorescence 
of the protein. In our case, mainly Tween 80 at the high concentration level of 0.05% 
leads to a fluorescence increase. This excipient related fluorescence change seems 
not to be stability indicative, as e.g. the pH value had a much larger influence in the 
unfolding and aggregation studies. Moreover, it impedes the data evaluation of the 
mean fluorescence levels from the normalized fluorescence values, which is normally 
performed in order to compensate for differences in protein concentration. However, 
by evaluating the raw fluorescence curves, after 100 s of laser input, the fluorescence 
difference of F2 and F3 – two of the initially most distant formulations – was reduced 
from ~ 12.000 to ~925 A.U.. Moreover, for the majority of formulations, a stability 
profiling comparable to the unfolding and aggregation assay is obtained that 
underlines the strong pH dependence of rh-GCSF aggregation stability. 
 
Figure 44: TOPC raw (left) and normalized (right) intrinsic fluorescence over time within the rh-
GCSF formulation screening. The area between the horizontal bars (grey background) indicates 
the timeframe of the measurement that was used for further evaluation. (n=1) 
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The results of the mean fluorescence and standard deviation evaluation from the raw 
intrinsic fluorescence values in the timeframe between 100 and 125 s are displayed in 
Figure 45. In comparison of the formulations, a clear stepwise progressing trend was 
detectable with increasing mean fluorescence and standard deviations from pH 4.0 
(F1-F4) to pH 4.5 (F5-F8). However, for the next step to pH 5.0 (F9 and F10) this trend 
was less clear, with F9 showing a comparable stability to the formulations at pH 4.5 
and only F10 exposing increased fluorescence and scattering levels.  
Another strong influence was detected for concentration changes of the excipients. 
While increasing concentrations of Tween 80 (F1 to F2, F5 to F6, F9 to F10) led to a 
higher aggregation and precipitation propensity, increasing concentrations of HP-β-CD 
(F3 to F4 and F7 to F8) tended to stabilize the system. 
The buffered formulation compositions F12 (20 mM acetate) and especially F11 
(20 mM citrate) showed increased baseline scattering, which is transferrable to 
enhanced aggregation and precipitation, when compared to the other formulations at 
pH 4.5 (F5-F8). The strong precipitation for F11 led to enormous scattering 
amplitudes, caused by the generation of very large particle sizes or concentrations. In 
comparison to the next lower scattering sample (F10), the standard deviation of F11 
was more than 30-fold higher. 
 
Figure 45: Mean fluorescence and standard deviation analysis from the raw intrinsic fluorescence 
values of the TOPC experiment in the timeframe between 100 and 125 s. (n=1) 
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VII.2.2.2. Conventional Stress Testing 
VII.2.2.2.1. Turbidimetry 
As an orthogonal conventional approach to elucidate the processes during TOPC and 
to test the rh-GCSF stability upon forced degradation, turbidity measurements were 
conducted after horizontal shaking or intensive heat exposure (Figure 46). 
The turbidity after heat stressing confirms the previously derived stability ranking with a 
distinct stability dependency on the formulation pH and the presence or absence of 
buffering agents. Consequently, the formulations with a pH value of 4.0 (F1-F4) 
showed a very high aggregation resistance with only a minor change of the sample 
turbidity by a factor of two, when compared to a reference sample stored at 4 °C. This 
factor grows to around 25-fold at pH 4.5 and to around 60-fold at pH 5.0. The addition 
of buffer salts (F11 and F12) furthermore increased the aggregation and precipitation 
in comparison to the unbuffered formulation of the same pH (F5-F8). This effect was 
most pronounced for the citrate buffered formulation (F11), where the highest visible 
turbidity, but also severe precipitation with high sedimentation velocities was observed. 
Due to the colloidal instability of this sample, it was excluded from the turbidity analysis 
and was plotted only for illustrative reasons. 
 
Figure 46: Turbidity measurements of the heat (light grey) and shake (dark grey) stressed rh-GCSF 
formulations in comparison to unstressed reference formulations (black). F11 showed severe 
precipitation after heat stress and was excluded from the measurements. The respective bar was 
marked with precipitation and was included to the plot for illustrative reasons only. (n=1) 
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Strong shaking of the formulations with consecutive turbidity analysis of the samples 
however resulted in a different turbidity ranking. Here, besides F9 and F11, the 
formulations containing HP-β-CD (F3, F4, F7, and F8) showed the highest turbidity 
values. Whereas the increased turbidity of F9 and F11 after shaking is likely to be a 
valid indicator of the agitation stability, the influence of HP-β-CD on the turbidity after 
shaking, but not after heating is not expected. It might in parts be a true effect, 
especially due to the larger increase at higher pH, but could also be caused by the 
stabilization of air bubbles in solution during this specific stressing procedure, which 
can lead to an increased turbidity. 
VII.2.2.2.2. Light Obscuration 
Light obscuration analysis was performed in order to determine the concentration 
increase of sub-visible particles in solution after forced degradation. 
The majority of control samples stored at 4 °C showed very low particle concentrations 
 5,000 particles/ml (1-200 µm), while the particle counts for some of the HP-β-CD 
containing formulations were arbitrarily higher and reached values up to 20,000 
particles/ml (1-200 µm) for F3 (pH 4.0, 1% HP-β-CD) and F4 (pH 4.0, 5% HP-β-CD). In 
contrast to the shaking stress samples, this deviation was not fully consistent after 
heat stressing, which could be caused by the elimination of air bubbles during the 
heating cycle and would further support the abovementioned air bubble-hypothesis. 
The detection of air bubbles is expected for the light obscuration setup as well, as the 
system is not able to distinguish between proteinaceous particles and air bubbles 
blocking the light before reaching the detector. 
The particle analysis after shaking stress precisely confirms the picture gathered from 
the turbidity measurements that however differs widely from the TOPC results. Again, 
F9, F11 and the CD containing formulations (F3, F4, F7, and F8) show the largest 
increase of particles in the µm-range. The fact that the particle content of F9 shows a 
substantial increase that is not observed for F10, while both formulations differ only in 
the concentration of the included polysorbate, indicates the stabilizing effect of the 
surfactant at a concentration of 0.05% but not at 0.005%. By contrast, the protein did 
not show any instability at lower pH levels (pH 4.0 and pH 4.5), independent of the 
surfactant concentration.  
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Figure 47: Light obscuration measurements of the heat (light grey) and shake (dark grey) stressed 
rh-GCSF formulations in comparison to unstressed reference formulations (black). F11 showed 
severe precipitation after heat stress and was excluded from the measurements. The respective 
bar was marked with precipitation and was included to the plot for illustrative reasons only. (n=3) 
For the heating stress samples, only F9 and F10 (both pH 5.0) showed increased 
particle concentrations. These results are so far congruent with the TOPC assay and 
the turbidity determination that these formulations showed a considerably reduced 
aggregation stability when compared to the formulations at lower pH values. However, 
a differentiation between the lower pH values pH 4.0 (F1-F4) and pH 4.5 (F5-F8) could 
not be resolved in the particle measurement, whereas TOPC and turbidity analysis 
detected a clear difference between the two groups. Surprisingly, also the particle 
concentration of F12 (20 mM acetate pH 4.5) was not substantially increased after 
heat exposure. Yet, the turbidity measurements after forced degradation and the 
TOPC showed considerably increased values and pointed towards an increase in 
particulate matter. For F11 (20 mM citrate pH 4.5) that showed severe precipitation, 
potentially very high particle counts would have been observed. Though, the sample 
was excluded from the light obscuration analysis in order to not block the fluidics of the 
system and was plotted only for illustrative reasons. 
However, it is to mention that the chosen heat stress conditions (storage at 75 °C) 
deviate from standard forced degradation approaches, where incubation usually is 
executed below the melting temperature of the protein. In our case, we wanted to 
mimic the condition during TOPC, where full denaturation of the protein is reached 
before aggregation is induced. 
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VII.2.2.3. Comparison and Evaluation of TOPC as a Tool for Predictive 
Forced Degradation Studies 
The aim of the study presented was to promote two different aspects of the 
establishment and evaluation of TOPC as a tool for predictive aggregation studies. On 
the one hand side, more detailed information about the stress characteristics during 
the TOPC analysis should be achieved. On the other hand side, the TOPC results 
should be benchmarked against conventional forced degradation approaches and 
thermal unfolding and aggregation screenings in order to strengthen the validity of the 
assay. In principle, continuous IR-laser input mainly applies heat stress, but also shear 
stress could be induced. In our assay, heating is achieved due to IR-laser absorption 
by water, while shear stress occurs due to particle migration and mixing by convective 
molecular flow within the temperature gradient. Consequently, we covered both parts 
of the study by comparing the TOPC results to two different forced degradation 
strategies, (i) heat exposure and (ii) shaking stress. 
In conclusion, with TOPC we were able to distinguish between formulations in terms of 
different aggregation and precipitation propensities. The TOPC results were closely 
reflected by heat stressing, almost perfectly matching the turbidity increase after 
external forced degradation and widely confirmed by the stability ranking gathered 
from sub-visible particle determination. On the contrary, shaking stress was found to 
play a tangential role for the conditions during IR-laser exposure (Table 14). 
Table 14: Comparison of the TOPC results with conventional stress testing. Results for each 
evaluation were normalized between 0 (low) and 100 (high). The not determined results for the heat 
stressed and precipitating F11* are displayed for illustrative reasons only and were arbitrarily set 
to 125% of the maximum value observed. 
ID 
TOPC 
(mean) 
TOPC 
(SD) 
Turbidity 
(heat) 
LO 
(heat) 
Turbidity 
(shake) 
LO 
(shake) 
F1 5.0 1.0 1.5 0.0 0.1 0.2 
F2 6.6 0 1.1 0.1 0 0 
F3 0 3.0 0.2 0.0 16.5 24.8 
F4 6.5 0.6 0 0.3 13.6 13.1 
F5 33.4 4.0 32.0 0.0 1.5 0.2 
F6 71.3 5.3 26.2 0.2 0.8 0.1 
F7 45.2 7.5 33.9 0.0 29.3 50.1 
F8 49.6 9.6 29.2 0.5 27.1 40.2 
F9 70.8 9.9 61.5 36.9 8.0 10.6 
F10 100 24.1 83.0 83.3 0.2 0.3 
F11 96.4 100 100* 100* 100 100 
F12 93.6 16.8 46.7 0.3 0.2 0.1 
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VII.2.3. Protein-Excipient Interaction Analysis 
VII.2.3.1. Binding Studies with Cyclodextrins 
VII.2.3.1.1. MicroScale Thermophoresis (MST) 
The binding curves obtained for the MST measurement of rh-GCSF with three different 
cyclodextrins (α-CD, β-CD, and γ-CD), three β-CD derivatives (HP-β-CD, SBE-β-CD, 
and M-β-CD), and a negative control (maltoheptaose) in 20 mM acetate buffer pH 4.0 
are shown in Figure 48 (thermophoresis) and Figure 49 (intrinsic fluorescence). For 
both evaluations, an interaction with rh-GCSF is only apparent for SBE-β-CD, while all 
other cyclodextrins including the different modifications of β-CD and maltoheptaose did 
not show any concentration dependent change neither in thermophoresis, nor in 
intrinsic fluorescence evaluation. Interestingly, the interaction between SBE-β-CD and 
rh-GCSF evaluated by thermophoresis revealed a non-expected curve shape, that 
deviates from the ideal sigmoidal progression and indicates a superposition by a 
second effect at cyclodextrin concentrations between 58.59 and 937.5 µM. This 
interference is reflected by a spontaneous decrease in thermophoretic depletion (i.e. 
increase in Fnorm [‰]). However, the intrinsic fluorescence analysis did not show 
pronounced alterations in the binding curves, but only a broader deviation of the single 
titration points from the ideal curve progression in the same concentration range. 
Removing the thermophoresis evaluation data points in the area of the adverse effect 
(Figure 48 – right), the interaction between SBE-β-CD and rh-GCSF was fitted with a 
Kd of 6.68 µM as mean value of triplicate measurements (Table 15). On the other hand 
side, intrinsic fluorescence yields a highly comparable value of 7.30 µM without the 
necessity of removing data points (Figure 49 – right and Table 16). Due to the 
sulfobutylether residues, SBE-β-CD that was used as sodium salt with a strong 
negative net charge is the only ionic excipient investigated. rh-GCSF is positively 
charged at the assay pH of 4.0, having an isoelectric point of 6.1.19 This suggests the 
presence of an ionic interaction beyond the theory of cyclodextrins’ hydrophobic cavity 
interacting with solvent exposed hydrophobic amino acid residues of the protein32-34. 
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Figure 48: Thermophoresis binding studies of rh-GCSF to cyclodextrins in 20 mM acetate buffer 
pH 4.0. Left: Interaction screening of rh-GCSF to various cyclodextrins and maltoheptaose as a 
reference. Right: Kd fit of the interaction between rh-GCSF and SBE-β-CD. Before fitting the 
protein-excipient binding, the titration points showing the additional phase between 58.59 and 
937.5 µM SBE-β-CD have been removed. 
 
Figure 49: Intrinsic fluorescence binding studies of rh-GCSF to cyclodextrins in 20 mM acetate 
buffer pH 4.0. Left: Interaction screening of rh-GCSF to various cyclodextrins and maltoheptaose 
as a reference. Right: Kd fit of the interaction between rh-GCSF and SBE-β-CD. 
In order to characterize the interaction of SBE-β-CD and rh-GCSF in more detail and 
to elucidate the interaction mechanism, additional measurements were performed 
while adding 7.5 mM NaCl (1:1 ratio with SBE-β-CD) and 75 mM NaCl (10:1 ratio with 
SBE-β-CD) to the assay buffer. This alteration interferes with potential ionic 
interactions by shielding of the charged residues, what in consequence would lead to a 
weakening or complete suppression of the interaction. The thermophoresis results of 
this study can be found in Figure 50 and Table 15, while the intrinsic fluorescence 
evaluation is shown in Figure 51 and Table 16. Salt addition changed the binding 
characteristics as anticipated and shifts the Kd towards higher SBE-β-CD 
concentrations. For the thermophoresis data evaluation, the initial Kd of 6.68 µM 
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increased in the first step to 10.5 µM (7.5 mM NaCl) and in the second step to 602 µM 
(75 mM NaCl). At the same time, the adverse binding effect, being apparent under 
NaCl free conditions, vanished and the overall binding amplitude between unbound 
and bound declined. These findings substantiate the existence of a protein-excipient 
binding and serve as another evidence of an interaction quenching by NaCl. The 
respective Kd values for intrinsic fluorescence raised from 7.30 µM, over 31.4 µM 
(7.5 mM NaCl), to 651 µM (75 mM NaCl). However, an amplitude change was not 
observed for fluorescence. In total, these finding strengthen our hypothesis of ionic 
attraction driving the interaction between SBE-β-CD and rh-GCSF. 
 
Figure 50: Thermophoresis binding studies of rh-GCSF to SBE-β-CD in 20 mM acetate buffer 
pH 4.0 in the presence and absence of sodium chloride. Left: interaction screening of rh-GCSF to 
SBE-β-CD under the presence of 7.5 mM and 75 mM NaCl. Right: Kd fit of the interaction between 
rh-GCSF and SBE-β-CD. Before fitting the protein-excipient binding in the absence of NaCl, the 
titration points showing the additional phase between 58.59 and 937.5 µM SBE-β-CD have been 
removed. 
 
Figure 51: Intrinsic fluorescence binding studies of rh-GCSF to SBE-β-CD in 20 mM acetate buffer 
pH 4.0 in the presence and absence of sodium chloride. Left: interaction screening of rh-GCSF to 
SBE-β-CD under the presence of 7.5 mM and 75 mM NaCl. Right: Kd fit of the interaction between 
rh-GCSF and SBE-β-CD. 
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Table 15: Kd comparison for the interaction between SBE-β-CD and rh-GCSF in 20 mM acetate 
buffer pH 4.0 measured by thermophoresis in the presence and absence of sodium chloride. 
Computed Kd values for single experiments are given including the fitting error, while for mean Kd 
values, the standard deviation of the included experiments is presented. 
Experiment 
name 
Computed Kd  
[µM] 
Unbound 
[‰] 
Bound 
[‰] 
Amplitude 
[‰] 
SBE-β-CD 
+ 0.0 mM NaCl (1) 
9.61  0.828 965.76 921.80 -43.96 
SBE-β-CD 
+ 0.0 mM NaCl (2) 
4.98  0.359 962.25 912.99 -49.26 
SBE-β-CD 
+ 0.0 mM NaCl (3) 
5.45  0.258 961.34 911.16 -50.18 
Mean 
+ 0.0 mM NaCl 
6.68  2.55 963.12 915.32 -47.80 
SBE-β-CD 
+ 7.5 mM NaCl (1) 
10.4  0.5 961.06 918.43 -42.63 
SBE-β-CD 
+ 7.5 mM NaCl (2) 
10.6  0.5 957.00 917.73 -39.27 
Mean 
+ 7.5 mM NaCl 
10.5  0.1 959.03 918.08 -40.95 
SBE-β-CD 
+ 75 mM NaCl (1) 
770  38 950.68 921.18 -29.50 
SBE-β-CD 
+ 75 mM NaCl (2) 
233  42 949.91 927.25 -22.66 
Mean 
+ 75 mM NaCl 
502  380 950.30 924.22 -26.08 
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Table 16: Kd comparison for the interaction between SBE-β-CD and rh-GCSF in 20 mM acetate 
buffer pH 4.0 measured by intrinsic fluorescence. Computed Kd values for single experiments are 
given including the fitting error, while for mean Kd values, the standard deviation of the included 
experiments is presented. 
Experiment 
name 
Computed Kd 
[µM] 
Unbound 
[A.U.] 
Bound 
[A.U.] 
Amplitude 
[A.U.] 
SBE-β-CD 
+ 0.0 mM NaCl (1) 
9.27  2.30 10083.29 13299.92 3216.63 
SBE-β-CD 
+ 0.0 mM NaCl (2) 
5.19  0.61 10786.59 14233.27 3446.68 
SBE-β-CD 
+ 0.0 mM NaCl (3) 
7.44  0.86 10128.45 13519.41 3390.96 
Mean 
+ 0.0 mM NaCl 
7.30  2.04 10332.78 13684.20 3351.42 
SBE-β-CD 
+ 7.5 mM NaCl (1) 
16.0  0.9 9726.46 13149.68 3423.22 
SBE-β-CD 
+ 7.5 mM NaCl (2) 
46.7  8.6 10269.40 13545.14 3275.74 
Mean 
+ 7.5 mM NaCl 
31.4  21.7 9997.93 13347.41 3349.48 
SBE-β-CD 
+ 75 mM NaCl (1) 
948  38 8633.09 12329.17 3696.08 
SBE-β-CD 
+ 75 mM NaCl (2) 
354  56 8802.26 12654.94 3852.68 
Mean 
+ 75 mM NaCl 
651  420 8717.68 12492.06 3774.38 
 
Additionally, the rh-GCSF-excipient binding studies in 20 mM acetate buffer pH 4.0 
were extended to a different buffer system (20 mM phosphate buffer pH 4.0) and an 
altered buffer pH value (20 mM phosphate buffer pH 7.0).  
In accordance to our previous findings, SBE-β-CD also showed a thermophoresis 
(Figure 52) as well as an intrinsic fluorescence (Figure 53) binding signal in the 
phosphate buffer with identical pH. Furthermore, neither fluorescence, nor 
thermophoresis changes were observed when varying the concentration for any of the 
other cyclodextrins (α-CD, β-CD, and γ-CD), β-CD derivatives (HP-β-CD and M-β-CD), 
and the negative control (maltoheptaose) in the range of 0.23 to 7500 µM. In detailed 
consideration of the binding affinities of SBE-β-CD to rh-GCSF in 20 mM phosphate 
buffer pH 4.0 (Table 17), differences between the thermophoresis and the 
fluorescence evaluation as well as the parameters determined for 20 mM acetate 
buffer pH 4.0 become apparent. The Kd values determined in the phosphate buffer are 
generally higher as in the acetate buffer. In the case of intrinsic fluorescence, the 
affinity in phosphate buffer is around 300 µM higher than for acetate. As we recently 
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learned, this could be caused by an increased salt concentration due to the titration of 
the sodium dihydrogen phosphate buffer to a pH value as low as 4.0. However, the 
NaCl content needed for the actual Kd-shift would be substantial and is not expected 
for this pH adjustment. Moreover, the differences between the two MST evaluations 
(thermophoresis and intrinsic fluorescence) are increased. One possible explanation 
for the high fluorescence Kd of 307 µM could be the non-optimal curve fitting. 
Nevertheless, when the data points for the five lowest SBE-β-CD concentrations are 
removed, the fitted binding curve experiences the most extreme shift to lower affinities, 
but the computed Kd would only be decreased to 181 µM (data not shown). Moreover, 
in the literature, a very similar binding affinity of 365 µM was reported for the binding of 
SBE-β-CD to rh-GCSF in exactly the same assay buffer.35 This information increases 
the confidence in the values generated by intrinsic fluorescence despite the 
problematic curve fitting and rather disputes the conclusions for thermophoresis, which 
resulted in an almost perfect fit but should in general be evaluated with care when the 
underlying fluorescence values are changing over the concentration range 
investigated. 
As a final point, the results received for the interaction assay in 20 mM phosphate 
buffer pH 7.0 reinforce the assumptions of an ion-ion binding mechanism between 
SBE-β-CD and rh-GCSF, which were based on the opposing charges of the binding 
partners at pH 4.0 and the influence of increased salt concentrations. As shown in 
Figure 54, the interaction is completely inhibited when increasing the assay pH from 
4.0 to 7.0. This drastic change is effected by charge inversion of the former positively 
charged rh-GCSF to an overall negatively charged molecule.19 Thus, an ionic binding 
to the highly negatively charged sulfobutylether-β-cyclodextrin is hindered. 
 
Figure 52: Thermophoresis binding studies of rh-GCSF to cyclodextrins in 20 mM phosphate 
buffer pH 4.0. Left: interaction screening of rh-GCSF to various cyclodextrins and maltoheptaose 
as a reference. Right: Kd fit of the interaction between rh-GCSF and SBE-β-CD. 
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Figure 53: Intrinsic fluorescence binding studies of rh-GCSF to cyclodextrins in 20 mM phosphate 
buffer pH 4.0. Left: interaction screening of rh-GCSF to various cyclodextrins and maltoheptaose 
as a reference. Right: Kd fit of the interaction between rh-GCSF and SBE-β-CD. 
 
Table 17: Kd comparison for the interaction between SBE-β-CD and rh-GCSF in 20 mM phosphate 
buffer pH 4.0 measured by thermophoresis and intrinsic fluorescence. Computed Kd values are 
given including the fitting error. 
Experiment 
name 
Computed Kd  
[µM] 
Unbound 
[‰ / A.U.] 
Bound 
[‰ / A.U.] 
Amplitude 
[‰ / A.U.] 
SBE-β-CD 
(Thermophoresis) 
61.9  2.9 970.79 929.43 -41.36 
SBE-β-CD 
(Intr. Fluorescence) 
307  20 9239.94 12166.80 2926.86 
 
 
Figure 54: Binding studies of rh-GCSF to SBE-β-CD and HP-β-CD in 20 mM phosphate buffer pH 7. 
Head-to-head comparison of the thermophoresis (left) and intrinsic fluorescence (right) data 
evaluation. 
 
0.1 1 10 100 1000 10000
8000
8500
9000
9500
10000
10500
11000
11500
12000
 
 
In
tr
in
s
ic
 F
lu
o
re
s
c
e
n
c
e
 [
A
.U
.]
Excipient Concentration [µM]
 SBE-b-CD
 a-CD
 b-CD
 y-CD
 HP-b-CD
 M-b-CD
 Maltoheptaose
0.1 1 10 100 1000 10000
8500
9000
9500
10000
10500
11000
11500
12000
12500
 
 SBE-b-CD
 Fit SBE-b-CD
Excipient Concentration [µM]
In
tr
in
s
ic
 F
lu
o
re
s
c
e
n
c
e
 [
A
.U
.]
0.1 1 10 100 1000 10000
875
880
885
890
895
900
905
910
915
920
T
h
e
rm
o
p
h
o
re
s
is
 [
F
n
o
rm
 (
‰
)  
]
Excipient Concentration [µM]
 SBE-b-CD (1)
 SBE-b-CD (2)
 HP-b-CD (1)
 HP-b-CD (2)
0.1 1 10 100 1000 10000
7500
7750
8000
8250
8500
8750
9000
9250
9500
 
 
In
tr
in
s
ic
 F
lu
o
re
s
c
e
n
c
e
 [
A
.U
.]
Excipient Concentration [µM]
 SBE-b-CD (1)
 SBE-b-CD (2)
 HP-b-CD (1)
 HP-b-CD (2)
MICROSCALE THERMOPHORESIS (MST) 
FOR PROTEIN FORMULATION DEVELOPMENT 
118 
VII.2.3.1.2. Nano Differential Scanning Fluorimetry (nanoDSF) 
Subsequent to the protein-excipient binding analysis by MST, the prepared titration 
series were reused for a thermal unfolding stability screening in dependence of the 
cyclodextrin concentration. Thus, for every titration step an unfolding scan was 
performed and changes in the unfolding curves, as well as the respective melting 
temperatures were evaluated from the intrinsic fluorescence emission at 350 nm in 
order to track binding induced changes in the conformational stability of rh-GCSF. 
Figure 55 shows the unfolding screening of rh-GCSF in 20 mM acetate buffer pH 4.0 
while changing the concentration of SBE-β-CD (top – left) and HP-β-CD (top – right) 
between 0.23 and 7500 µM. Additionally, the influence of 7.5 mM NaCl (bottom – left) 
and 75 mM NaCl (bottom – right) on the SBE-β-CD binding to rh-GCSF was tested. 
The evaluated melting temperatures of this study are plotted and compared in Table 
18 and Figure 56. While the first derivative melting curves of rh-GCSF and the 
corresponding melting temperatures remained unchanged for increasing 
concentrations of HP-β-CD, enormous differences were observed for µM to mM 
concentrations of SBE-β-CD. At nM concentrations of SBE-β-CD, the unfolding 
transitions are still congruent with the melting curves in the absence of an excipient 
(data not shown) and under addition of HP-β-CD. However, from the low µM range 
onwards, the transition shifts towards lower temperatures and additionally a second, 
less stable conformation occurs. At SBE-β-CD concentrations above 7.32 µM, the 
initial transition vanishes completely and is fully replaced by the alternative melting 
point. Hence, a drastic destabilization of rh-GCSF is present in the presence of SBE-β-
CD, shifting the Tm from ~ 67.5 °C to a minimum of 42.8 °C at a SBE-β-CD 
concentration of 117.2 µM. These results are in perfect agreement with unfolding 
studies reported by Serno35, where a destabilization by more than 10 °C was induced 
by the addition of 10 mM SBE-β-CD, while an identical concentration of HP-β-CD did 
not have any effect on the conformational stability when compared to a reference 
formulation. In conclusion, the destabilization under increasing cyclodextrin 
concentrations match the previously characterized binding event between the excipient 
and the protein where 50% of the molecules were bound at low µM concentrations. 
Moreover, the SBE-β-CD concentration at which the minimum melting temperature 
was observed coincides with the peak of the superimposed thermophoresis event. 
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Under addition of 7.5 mM sodium chloride to the assay buffer, the initial melting 
transition is shifted towards lower temperatures and the additional unfolding peak 
appears at higher temperatures, therefore the events converge. At an increased 
concentration of 75 mM NaCl, this trend is furthermore strengthened and the 
differences between the two states coalesce. In summary, NaCl destabilizes the initial 
native state but stabilizes the additional appearing conformation. Whereas the colloidal 
destabilization of rh-GCSF under increased salt concentration is a well described 
effect7,16,19, the latter mentioned stabilization of the transition with lower conformational 
stability can be explained by a weakening of the detrimental SBE-β-CD interaction to 
rh-GCSF at excess concentrations of salt, as it was already described in section 
VII.2.3.1.1. 
 
Figure 55: Thermal unfolding studies of the dilution series of SBE-β-CD (top – left) and HP-β-CD 
(top – right) to rh-GCSF in 20 mM acetate buffer pH 4.0. Additionally, the unfolding curves for the 
titration of SBE-β-CD in the presence of 7.5 mM NaCl (bottom – left) and 75 mM NaCl (bottom – 
right) is shown. The color code corresponds to different cyclodextrin concentrations and changes 
from green over grey to red with progressing dilution. 
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Table 18: Melting temperature comparison of the rh-GCSF thermal unfolding studies in 20 mM 
acetate buffer pH 4.0 at different concentrations of HP-β-CD and SBE-β-CD (including 0.0, 7.5 and 
75 mM NaCl). 
Excipient 
concentration 
[µM] 
Melting temperature - nanoDSF – 350 nm [°C] 
HP-β-CD SBE-β-CD 
SBE-β-CD + 
7.5 mM NaCl 
SBE-β-CD + 
75 mM NaCl 
Tm Tm1 Tm2 Tm1 Tm2 Tm 
0.229 67.6 - 67.2 - 66.1 60.0 
0.458 67.3 - 67.5 - 66.0 60.1 
0.916 67.6 - 67.5 56.1 66.1 59.9 
1.831 67.5 - 67.7 55.7 66.1 59.8 
3.662 67.3 53.7 66.9 53.4 64.0 59.3 
7.324 67.6 51.9 62.8 52.6 62.1 58.3 
14.65 67.3 49.5 - 51.0 - 57.2 
29.30 67.6 47.2 - 48.8 - 55.9 
58.59 67.6 43.8 - 47.5 - 54.7 
117.2 67.6 42.8 - 46.4 - 53.1 
234.4 67.7 43.1 - 46.2 - 52.5 
468.8 67.4 43.5 - 46.3 - 51.5 
937.5 67.3 45.8 - 46.7 - 51.3 
1875 67.8 47.1 - 47.7 - 51.4 
3750 67.6 48.7 - 49.5 - 51.8 
7500 67.3 51.3 - 51.6 - 53.0 
 
 
Figure 56: Melting temperature evaluation of the rh-GCSF thermal unfolding studies in 20 mM 
acetate buffer pH 4.0 at different concentrations of HP-β-CD and SBE-β-CD (including 0.0, 7.5 and 
75 mM NaCl). For SBE-β-CD without NaCl and with 7.5 mM NaCl, two melting points were detected, 
which co-occurr for 2-4 SBE-β-CD concentrations between 0.916 and 7.32 µM SBE-β-CD. 
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The melting curve comparison was continued with the binding studies in 20 mM 
phosphate buffer pH 4.0 (Figure 57) and 20 mM phosphate buffer pH 7.0 (data not 
shown). When changing the buffer system from acetate to phosphate while 
maintaining the buffer pH at 4.0, a comparable destabilization becomes apparent with 
increasing concentrations of SBE-β-CD. Moreover, HP-β-CD addition did again not 
have any impact on the evaluated unfolding temperatures. Nevertheless, it is worth to 
mention that the Tm values in the phosphate buffer for all HP-β-CD and for the 
neglegibly low SBE-β-CD concentrations are around 4 °C lower when compared to the 
acetate buffer. Moreover, the Tm decrease is less pronounced under influence of SBE-
β-CD. Thus, the conformational stability rather compares to the acetate buffer with an 
increased ionic strength, which also would fit very good to the higher Kd values 
measured in the phosphate buffer system. Overall, the trends received for 20 mM 
phosphate buffer pH 4.0 are very comparable to 20 mM acetate buffer pH 4.0. 
For 20 mM phosphate buffer pH 7.0, no change in melting temperature was observed 
for both, the SBE- and HP-β-CD titration. That confirms the lack of any measurable 
interaction under these conditions. Furthermore, the apparent Tm values for both 
excipients range around 57.5 °C, what corresponds to another destabilization by 6 °C 
in comparison to 20 mM phosphate buffer pH 4.0 and an overall reduction by 10 °C 
compared to the initial 20 mM acetate buffer at pH 4.0. 
These results substantiate the presence of an ionic interaction between SBE-β-CD and 
rh-GCSF under acidic assay conditions, shifting the Tm values to lower temperatures 
and therefore destabilizing the protein conformation. Moreover, again no interaction of 
HP-β-CD to surface exposed aromatic amino acid residues was observed, which is 
described to preferentially occur for the unfolded state36,37 and thus expected to lower 
the apparent melting temperature. 
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Figure 57: Thermal unfolding studies of the dilution series of SBE-β-CD (left) and HP-β-CD (right) 
to rh-GCSF in 20 mM phosphate buffer pH 4.0. The color code corresponds to different 
cyclodextrin concentrations and changes from green over grey to red with progressing dilution. 
VII.2.3.1.3. Static Light Scattering (SLS) 
Aggregation propensity as the other half of thermal stability investigations was studied 
to complete the rh-GCSF-cyclodextrin binding analysis. Since unfolding stability was 
already drastically reduced by the addition of SBE-β-CD, there is reason to presume a 
negative effect on the tendency to aggregate. Aggregation stability was investigated 
for the excipient-buffer combinations from former measurements by using static light 
scattering in a linear thermal ramp assay. 
For the dilution series of HP-β-CD to rh-GCSF in 20 mM acetate buffer pH 4.0 (Figure 
58 – right) and 20 mM phosphate buffer pH 4.0 (Figure 59 – right) only minor 
aggregation was observed, starting in the temperature range of the respective 
unfolding events (see VII.2.3.1.2) and not showing any difference between changing 
concentration levels of the cyclodextrins. Nevertheless, the absolute amplitude of 
aggregation is larger for the phosphate buffer what indicates the generation of an 
increased number or size of particles. 
For SBE-β-CD (Figure 58 – left and Figure 59 – left), aggregation sets in immediately 
after initiating the temperature increase for both buffer systems. Moreover, earlier 
aggregation onsets and overall increased scattering levels are seen for higher 
cyclodextrin concentrations. At this immense instability, a difference between the two 
buffer salts was not identified. 
The aggregation propensities derived from the type of cyclodextrin used are in very 
good aggreement with previous investigations by Serno35, where the addition of HP-β-
CD effectively supressed rh-GCSF aggregation during agitation, freeze-thawing and 
storage stability studies, while SBE-β-CD even showed adverse stability effects. 
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Figure 58: Thermal aggregation studies of the dilution series of SBE-β-CD (left) and HP-β-CD 
(right) to rh-GCSF in 20 mM acetate buffer pH 4.0. The color code corresponds to different 
cyclodextrin concentrations and changes from green over grey to red with progressing dilution. 
 
Figure 59: Thermal aggregation studies of the dilution series of SBE-β-CD (left) and HP-β-CD 
(right) to rh-GCSF in 20 mM phosphate buffer pH 4.0. The color code corresponds to different 
cyclodextrin concentrations and changes from green over grey to red with progressing dilution. 
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VII.2.3.2. Binding Studies with Surfactants 
Additional binding studies were used to examine the interaction of rh-GCSF with 
monomeric surfactant molecules or incorporation into micellar structures. Elucidating 
the interaction mechanism between the protein of interest and surfactants can simplify 
the development of stable formulations that minimize interfacial degradation.38-40 For 
our investigations, Pluronic F-127, an amphiphilic triblock copolymer consisting of 
ethylene oxide and propylene oxide units, was chosen over other more commonly 
used non-ionic group members like polysorbate 20 or 80, as it does not show intrinsic 
auto-fluorescence in the concentration range used and is also FDA approved for 
parenteral administration.41-43 
VII.2.3.2.1. MicroScale Thermophoresis (MST) 
Figure 60 shows the intrinsic fluorescence (left) and thermophoresis (right) values for a 
broad range of pluronic F-127 concentrations titrated to rh-GCSF. The assay was 
performed in 20 mM acetate buffer pH 4.0 under variation of the temperature. 
At an assay temperature of 22 °C only a minor fluorescence increase at the highest 
surfactant concentrations was observed. However, when changing the assay 
temperature to 27 °C, the quantum yield increases drastically from pluronic 
concentrations above 0.1%. Moreover, this immense increase was found to be also 
highly temperature dependent, as the onset of the increase in fluorescence is shifted 
to lower concentrations when the temperature is further increased. In our assay, the 
maximal temperature of 37 °C decreases the onset concentration to approximately 
0.01%. These findings indicate rather the formation of micelles and incorporation of rh-
GCSF than a simple 1:1 binding between monomeric pluronic and rh-GCSF. In this 
theory, the strong temperature dependence observed is explained by the 
characteristics of pluronic F-127 micellization, being highly temperature dependent in 
the range investigated44. Consequently, the spontaneous increase in fluorescence 
would be caused by the encapsulation of rh-GCSF into the hydrophobic core of the 
micelles. Intrinsic protein fluorescence by aromatic amino acids (mainly Trp and Tyr) is 
known to be very sensitive to changes in the local environment of the fluorophores and 
might increase upon transition from the aqueous, hydrophilic solution to the 
hydrophobic environment within the core of a micelle.45,46 
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For thermophoresis, the measurement data have to be interpreted with great care as 
variations in the underlying fluorescence signal can lead to evaluation artifacts. In 
detail, the thermophoresis evaluation would be biased by a high fluorescence increase 
in terms of enhanced thermophoretic depletion and consequent decrease in the 
thermophoresis values. Therefore, only data points at which the fluorescence was not 
increased were taken into account for analysis. At low concentrations of pluronic F-
127, the thermophoresis signal is constant for all temperatures investigated. With 
increasing surfactant concentrations a rise in the thermophoresis signal is observed. 
Comparing the increases in thermophoresis and fluorescence at 22 and 27 °C, 
thermophoresis already changes at lower surfactant concentrations. This deviation 
might be caused by the IR-laser induced heating of the sample, which potentially is 
enough to exceed the critical micelle temperature (CMT) and therefore allow the in-situ 
formation of micelles during the measurement. This would also explain the rapid 
thermophoresis increase, as a micelle formation induced fluorescence increase during 
the measurement would lead to a pseudo decrease in thermophoretic depletion or 
even negative thermophoresis and a consequential increase in thermophoresis values. 
In conclusion, incorporation into pluronic F-127 micelles is assumed, while for this 
application the fluorescence readout is less ambiguous than thermophoresis, which 
inevitably induces an IR-laser temperature increase. 
 
Figure 60: rh-GCSF binding studies with pluronic F-127 in 20 mM acetate buffer pH 4.0 at different 
temperatures evaluated by intrinsic fluorescence (left) and thermophoresis (right). 
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VII.2.3.2.2. Nano Differential Scanning Fluorimetry (nanoDSF) 
Thermal protein unfolding analysis by intrinsic fluorescence analysis (nanoDSF) was 
used to get a broader picture of the fluorescence changes over temperature for every 
single titration step. In Figure 61 the fluorescence emission (left) as well as the first 
derivative curves (right) of rh-GCSF with varying concentrations of pluronic F-127 are 
shown as a function of the temperature. For very low concentrations of Pluronic F-127 
(red lines) there is an increase in the fluorescence observed only when the protein 
unfolds at around 67 °C. When the surfactant concentration exceeds 0.002%, a 
fluorescence increase at above 40 °C prior to the melting temperature appears and the 
fluorescence traces split from the uniform unfolding curves. Further, the size of the 
unfolding peak in the first derivative curve decreases and another event at lower 
temperatures emerges. From concentrations of 0.125% onwards, the fluorescence at 
lower temperatures is drastically increased and the melting event is not visible any 
longer. Overall, a combination of temperature and concentration dependence is 
observed in this measurement, as at high concentrations the large fluorescence 
increase occurs at lower temperatures compared to lower concentrations of pluronic F-
127. A formation of micelles at pluronic concentrations above 0.125% is likely, as the 
reported critical micelle concentration (CMC) values of pluronic F-127 at ambient 
temperatures are in a broad range of 0.1 to 2%, with generally decreasing 
concentrations being reported at increasing temperatures.44,47-49 Moreover, the 
fluorescence intensity increase is purely related to the intrinsic fluorescence of rh-
GCSF as comparable temperature ramp studies performed with pure pluronic dilution 
series in the absence of rh-GCSF did result in very low fluorescence values (below 
250 A.U.), without any fluorescence peaks/increases over the whole temperature 
range (data not shown). 
In conclusion, a formation of micelles and incorporation of rh-GCSF molecules under 
the present measurement conditions is hypothesized and additional studies 
investigating CMC values in the presence of the protein with orthogonal techniques 
would give further insight in the underlying mechanisms. 
CHAPTER VII   RECOMBINANT HUMAN GRANULOCYTE COLONY 
STIMULATING FACTOR (RH-GCSF) 
127 
 
Figure 61: Thermal unfolding studies of the dilution series of pluronic F-127 to rh-GCSF in 20 mM 
acetate buffer pH 4.0 by nanoDSF evaluated at 350 nm (left) and the first derivative plot (right). The 
color code corresponds to different pluronic F-127 concentrations and changes from green over 
grey to red with progressing dilution of the surfactant. 
VII.2.3.3. Comparison and Evaluation of MST as a Tool for Protein-
Excipient Interaction Analysis 
Protein-excipient interaction analyses by MST, as exemplarily studied for the binding 
of cyclodextrins and pluronic F-127 to rh-GCSF, were found to provide valuable 
insights into the molecular stabilization and destabilization mechanisms in protein 
formulations. 
Within the interaction screening of various cyclodextrins, MST measurements 
conclusively distinguished between binding and non-binding variants. Moreover, 
influences of the formulation pH, the buffering agent and added salt on the protein-
excipient interaction between SBE-β-CD and rh-GCSF were revealed. In the following, 
the determined interactions were confirmed by analyzing the stability consequences 
via thermal unfolding and aggregation studies, which led to a pronounced 
destabilization of rh-GCSF for increasing concentrations of SBE-β-CD. 
Furthermore, incorporation of rh-GCSF into the hydrophobic core of micelles upon 
reaching the CMC or the CMT was indicated via MST and nanoDSF studies. All 
gathered results and derived trends were found to correlate well with literature data, 
making MST a valid and with great justice accepted tool for the screening of all kinds 
of biomolecular interactions. 
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VII.3. Summary and Conclusions 
In the case study presented, the stability of twelve rh-GCSF formulations was 
assessed as resistance towards unfolding and aggregation in a stepped thermal ramp 
assay by using MST and an innovative forced degradation approach by using TOPC. 
Stability trends were derived for the formulation pH, as well as the addition of 
polysorbate, HP-β-CD, and buffering agents. The derived trends for protein unfolding 
as well as aggregation propensity were benchmarked with orthogonal approaches for 
the determination of physical stabilities. 
In summary, the unfolding and aggregation propensity of rh-GCSF was found to 
consistently increase with increasing pH values and in the presence of buffer salts, 
which is in very good alignment with the comprehensive literature and patent database 
available. Thermal unfolding and aggregation evaluated by MST, as well as forced 
degradation by using TOPC showed several advantages over conventional 
approaches, being unaffected by the excipients tested and very low in material and 
time consumption. This could be beneficial for cost-efficient early formulation 
selections by screening of a large number of solution conditions under high material 
scarcity and time pressure. 
Furthermore, rh-GCSF-excipient interactions were investigated for cyclodextrins and 
pluronic F-127 via MST binding titrations. Interactions between rh-GCSF and 
cyclodextrins were detected and quantified under variation of the buffer salt, ionic 
strength and the solution pH. Moreover, the stability consequences of protein-excipient 
binding were investigated. For pluronic F-127, the presence and mode of interaction 
between rh-GCSF and the surfactant were assessed. 
Among the list of cyclodextrins investigated, protein-excipient binding was merely 
detected for rh-GCSF and SBE-β-CD. The binding mechanism was characterized as 
ionic interaction between the negatively charged excipient and the positively charged 
protein. Consequently, salt addition weakened and changing the formulation pH to 
neutral inhibited the interaction. Stability investigations by using nanoDSF and SLS 
confirmed the interaction and rendered the ion-pairing detrimental for unfolding and 
aggregation stability. Investigation of the interaction between rh-GCSF and pluronic F-
127 resulted in prominent and strongly temperature and concentration dependent 
fluorescence effects, which indicate interaction and protein incorporation into micelles. 
Taken all aspects together, MST and TOPC are suggested for greater applicability in 
straightforward, material and time saving stability investigations as well as rational 
excipient selections in the early phases of protein formulation development.  
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Chapter VIII  
Monoclonal Antibody (mAb) 
Antibodies and antibody derivatives have already been introduced in Chapter V as 
they make up the most prominent group of marketed biopharmaceutical drug products, 
showing a very high efficacy and low adverse effects.1 
Due to this high relevance, an extended formulation screening investigating the 
stability of another monoclonal antibody (mAb) is presented in this chapter. In a pH 
pre-screening, the influence of different pH values on protein unfolding and 
aggregation parameters is targeted. The second step consists of a set of eleven 
formulations that is used to additionally determine the stability dependence on different 
buffer salts and various formulation excipients such as sugars, polyols, salt and 
polysorbate. For both steps, the lead formulation (10 mM phosphate, pH 6.0), as well 
as the overall pH range and excipient selection were adapted from previous 
investigations on the same antibody2. Using these screening sets, the capability of 
MST and TOPC as valuable tools in drug product development is investigated. Our 
results for thermal unfolding and aggregation stability are compared to a variety of 
benchmark methods as intrinsic and extrinsic fluorescence emission spectroscopy, 
static and dynamic light scattering, as well as differential scanning calorimetry. 
Furthermore, chemical unfolding is investigated as an emerging technology in the field 
of protein formulation development.3,4 The TOPC results are benchmarked with a 
conventional forced degradation approach, followed by visual inspection, dynamic light 
scattering and turbidity readout. 
Additionally to the formulation screening, the mAb is undertaken interaction analyses 
by using MST. Three different cyclodextrins as well as two β-CD derivatives are used 
to investigate the interaction mechanism and to derive stability consequences of 
protein-excipient binding in dependence of the formulation pH. 
 
Parts of this chapter have been published under: Wanner R, Breitsprecher D, Duhr S, 
Baaske P, Winter G 2017. Thermo-Optical Protein Characterization for Straightforward 
Preformulation Development. Journal of Pharmaceutical Sciences  106(10):2955-
2958. 
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VIII.1. Materials and Methods 
VIII.1.1. mAb 
The monoclonal antibody (mAb) used in this study was kindly donated by Roche 
Diagnostics GmbH (Penzberg, Germany). The IgG subtype protein stock solution was 
formulated at a concentration of 18.65 mg/ml in 10 mM phosphate buffer, pH 6.4. 
VIII.1.2. Excipients and Reagents 
An overview of excipients and buffer salts used in the formulation screening can be 
found in Table 19. During formulation preparation, stock solutions of all listed 
substances were prepared in HPW and used for the formulation compounding. In 
Table 20 all materials used for the further preparation during chemical unfolding and 
protein-excipient interaction investigations are summarized. The sodium hydroxide and 
hydrochloric acid standard solutions used for pH adjustment were of analytical grade. 
All given pH values were adjusted by titration to a precision of ± 0.02. Highly purified 
water (ELGA Purelab, ELGA LabWater, Celle, Germany, now Veolia Water 
Technologies GmbH) was used exclusively for all preparation steps. 
Table 19: Overview of excipients and buffer salts used for the mAb formulation screenings. 
Material Supplier Art.-number Lot-number 
Tween 80 (Polysorbate) 
Merck KGaA, Darmstadt, 
Germany 
8.17061.1000 
K38539861 
827 
D(-)-Sorbitol 
Merck KGaA, Darmstadt, 
Germany 
1.07759.0100 
L58065059 
829 
Sucrose 
Südzucker AG, Plattling, 
Germany 
Raw material 
sample 
L 115210300 
Glycerol 
AppliChem GmbH, 
Darmstadt, Germany 
A4443,1000 3J008408 
Sodium chloride 
VWR International BVBA, 
Leuven, Belgium 
27810.295 12J150047 
Hydroxy-Propyl-beta-
Cyclodextrin (HP-β-CD, 
Cavasol W7 HP Pharma) 
Wacker Chemie AG, 
Burghausen, Germany 
60012210 73B012 
Sodium dihydrogen 
phosphate dihydrate 
Applichem GmbH, Darmstadt, 
Germany 
A1939,1000 0A006917 
L-Histidine 
monohydrochloride 
monohydrate 
Sigma Aldrich, St. Louis, MO, 
USA 
H4036-1KG 068K8310 
Succinic acid 
Merck KGaA, Darmstadt, 
Germany 
1.00682.0250 
K33027682 
434 
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Table 20: Overview of excipients and reagents used for chemical denaturation and the mAb-
excipient interaction study. 
Material Supplier Art.-number Lot-number 
Guanidine hydrochloride 
(GuHCl) 
Sigma Aldrich, St. Louis, MO, 
USA 
G4505-100G 071M5429V 
Sodium dihydrogen 
phosphate dihydrate 
Applichem GmbH, Darmstadt, 
Germany 
A1939,1000 0A006917 
Alpha-Cyclodextrin (α-CD) 
CycloLab R&D Ltd, Budapest, 
Hungary 
CY-1001 CYL-2322 
Beta-Cyclodextrin (β-CD, 
Cavamax W7 Pharma) 
Wacker Chemie AG, 
Burghausen, Germany 
60006994 70P255 
Hydroxy-Propyl-beta-
Cyclodextrin (HP-β-CD, 
Cavasol W7 HP Pharma) 
Wacker Chemie AG, 
Burghausen, Germany 
60012210 73B012 
Sulfobutyl-Ether-beta-
Cyclodextrin (Captisol  
SBE-β-CD Sodium Salt) 
CyDex Inc, Lenexa, KS, USA - 
NC-04A-
05009 
Gamma-Cyclodextrin (γ-
CD) 
CycloLab R&D Ltd, Budapest, 
Hungary 
CY-3001 CYL-1815 
 
VIII.1.3. Formulations 
For the preparation of the pH pre-screening, the protein stock solution was prediluted 
to 15.0 mg/ml with 10 mM phosphate buffer, pH 5.0, before it was further diluted to the 
final concentration of 0.5 mg/ml with the respective 10 mM phosphate reference 
buffers, ranging from pH 4.0 to 6.2 in steps of 0.2. Afterwards, the samples were 
adjusted to the desired pH values by titration using HCl/NaOH to an accuracy of ± 0.01 
and sterile filtrated using 0.22 µm Millex GV PVDF syringe filter units (Merck Millipore 
Ltd., Tullagreen, Ireland). The buffer references were filtrated using sterile syringe 
filters with a 0.2 µm cellulose acetate membrane (VWR International LLC, Radnor, PA, 
USA). 
Table 21: Overview of the formulations prepared for the mAb pH pre-screening. 
ID 
mAb 
[mg/mL] 
Buffer system pH 
pH 4.0, ..., pH 6.2 0.5 10 mM phosphate 4.0, 4.2, 4.4, ..., 6.0, 6.2 
 
For the subsequent formulation excipient screening, the protein stock solution was 
dialyzed in three batches to phosphate, histidine, and succinate buffer, each in a 
concentration of 10 mM at pH 6.0. All dialyses were performed at 2-8 °C in three steps 
of 4 liter dialysis buffer each by using Slide-A-Lyzer dialysis cassettes (10000 MWCO, 
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0.5-3 ml (His & Suc) and 3-12 ml (Pho) capacity, Thermo Scientific, Rockford, IL, 
USA). The extensive dialysis protocol consisted of two hours dialysis, 1st buffer 
exchange, two hours dialysis, 2nd buffer exchange and overnight dialysis, which 
ensured a dialysis time of 20 hours in total. Afterwards, the pH values were checked 
and, if necessary, adjusted to pH 6.0 by titration, using HCl or NaOH respectively. 
After measuring the resulting protein content and pre-adjustment of the concentration 
to 15.0 mg/ml in the respective dialysis buffer, the protein batches were diluted to 11 
different formulations (see Table 22) by using highly purified water, as well as the 
respective excipient and buffer stock solutions. After preparation, the pH value of every 
formulation was checked again and adjusted when needed. The protein formulations 
were filtrated using 0.22 µm Millex® GV PVDF syringe filter units (Merck Millipore Ltd., 
Tullagreen, Ireland). For each formulation a reference solution missing the protein was 
prepared accordingly, which was filtrated using 0.2 µm cellulose acetate sterile syringe 
filters (VWR International LLC, Radnor, PA, USA). The pH adjustments were 
performed by using an MP220 pH meter, equipped with an InLab Expert pH electrode 
(Mettler-Toledo, Greifensee, Switzerland). The given protein concentrations were 
determined by using UV spectroscopy measured with a NanoDrop2000 instrument 
(Thermo Scientific, Wilmington, USA) and using an extinction coefficient of 
ε280 nm=1.499 mL*mg-1*cm-1. After compounding, all formulations were stored at 2-8 °C. 
Table 22: Overview of the formulations prepared for the mAb excipient screening. 
ID 
mAb 
[mg/mL] 
Buffer system pH 
Excipient 
(% in m/V) 
F1 0.5 10 mM phosphate 4.2 - 
F2 0.5 10 mM phosphate 5.0 - 
F3 0.5 10 mM phosphate 6.0 - 
F4 0.5 10 mM histidine 6.0 - 
F5 0.5 10 mM succinate 6.0 - 
F6 0.5 10 mM phosphate 6.0 0.05% Tween 80 
F7 0.5 10 mM phosphate 6.0 5% sorbitol 
F8 0.5 10 mM phosphate 6.0 5% sucrose 
F9 0.5 10 mM phosphate 6.0 2.5% glycerol 
F10 0.5 10 mM phosphate 6.0 150 mM NaCl 
F11 0.5 10 mM phosphate 6.0 1% HP-β-CD 
An identical, randomized formulation order was used for all analyses, in order to 
exclude potential storage and measurement time effects on the determined stability 
parameters. 
 
CHAPTER VIII   MONOCLONAL ANTIBODY (MAB) 
137 
VIII.1.4. Further Preparations 
For the examination of isothermal chemical protein denaturation (ICD) in the course of 
the mAb formulation screening, all formulations were prepared in a dilution series of 
guanidine hydrochloride (GuHCl). Therefore, GuHCl was dissolved in the respective 
placebo buffers to a concentration of 6.25 mol/l and the pH values of the resulting 
stock solutions were readjusted to the formulation pH with a precision of ± 0.01. The 
pH adjustments were performed by using an MP220 pH meter, equipped with an InLab 
Expert pH electrode (Mettler-Toledo, Greifensee, Switzerland). At the same time, the 
residual mAb stock solutions (SS) from dialysis performed within the formulation 
screening were pre-diluted in dialysis buffer to working solutions (WS) of 10 mg/ml. For 
the preparation of the dilution series, different amounts of GuHCl-containing and 
GuHCl-free placebo buffers were mixed and the resulting solution was thoroughly 
homogenized by vortexing. Afterwards, an appropriate amount of the respective mAb 
WS was spiked in to reach a final protein of 0.5 mg/ml, before all compounded 
solutions were mixed by gentle pipetting. The final protein and excipient concentrations 
match the formulation conditions used for the thermal denaturation assays and allow 
for direct head-to-head comparison of the results. Finally, all samples were 
equilibrated for 14 hours at room temperature to reach full equilibration of the unfolding 
reactions. An overview of the pipetting scheme and the resulting GuHCl concentration 
steps is given in Table 23. 
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Table 23: GuHCl concentration steps and pipetting scheme for the chemical unfolding titrations. 
Sample 
ID 
GuHCl 
[M] 
10 mg/ml 
mAb WS 
[µl] 
Placebo [µl] Total 
volume 
[µl] 0 M GuHCl 
6.25 M 
GuHCl 
1 0.000 5.00 95.00 0.00 100.00 
2 0.250 5.00 91.00 4.00 100.00 
3 0.500 5.00 87.00 8.00 100.00 
4 0.750 5.00 83.00 12.00 100.00 
5 1.000 5.00 79.00 16.00 100.00 
6 1.125 5.00 77.00 18.00 100.00 
7 1.250 5.00 75.00 20.00 100.00 
8 1.375 5.00 73.00 22.00 100.00 
9 1.500 5.00 71.00 24.00 100.00 
10 1.625 5.00 69.00 26.00 100.00 
11 1.750 5.00 67.00 28.00 100.00 
12 1.875 5.00 65.00 30.00 100.00 
13 2.000 5.00 63.00 32.00 100.00 
14 2.125 5.00 61.00 34.00 100.00 
15 2.250 5.00 59.00 36.00 100.00 
16 2.375 5.00 57.00 38.00 100.00 
17 2.500 5.00 55.00 40.00 100.00 
18 2.625 5.00 53.00 42.00 100.00 
19 2.750 5.00 51.00 44.00 100.00 
20 2.875 5.00 49.00 46.00 100.00 
21 3.000 5.00 47.00 48.00 100.00 
22 3.125 5.00 45.00 50.00 100.00 
23 3.250 5.00 43.00 52.00 100.00 
24 3.375 5.00 41.00 54.00 100.00 
25 3.500 5.00 39.00 56.00 100.00 
26 3.625 5.00 37.00 58.00 100.00 
27 3.750 5.00 35.00 60.00 100.00 
28 3.875 5.00 33.00 62.00 100.00 
29 4.000 5.00 31.00 64.00 100.00 
30 4.250 5.00 27.00 68.00 100.00 
31 4.500 5.00 23.00 72.00 100.00 
32 4.750 5.00 19.00 76.00 100.00 
33 5.000 5.00 15.00 80.00 100.00 
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In the course of the protein-excipient interaction study, stock solutions of the different 
excipients were prepared as stated in Table 24. Thereby, all excipients were weighed 
into 10 ml volumetric flasks with an accuracy of ± 0.1 mg to the respective target 
weight. The excipients were then dissolved in the chosen buffer by vortexing and the 
volume was filled ad 10 ml with buffer after completely dissolving the substance. 
Table 24: Overview of the excipient stock solutions prepared for the mAb protein-excipient binding 
studies. 
Stock solution 
Target 
weight 
[g] 
Buffer system 
10 mM phosphate 
pH 4.2 
10 mM phosphate 
pH 6.0 
15 mM α-CD 0.1459 x x 
15 mM β-CD 0.1703 x x 
15 mM HP-β-CD 0.2100 x x 
120 mM HP-β-CD 1.6800 x - 
15 mM SBE-β-CD 0.2138 x x 
240 mM SBE-β-CD 3.4207 x - 
15 mM γ-CD 0.1946 x x 
x = solution prepared; - = solution not prepared  
 
Subsequently, the previously dialyzed mAb material in 10 mM phosphate buffer pH 6.0 
(VIII.1.3) was pre-diluted to working solutions (WS) of 1 mg/ml in the two buffer 
systems used. In the next step, a 1:1 serial dilution of the cyclodextrin stock solution 
was prepared in the respective assay buffer under thorough homogenization by 
pipetting up and down several times. Afterwards an equal amount of the mAb WS was 
added in order to reach a final protein concentration of 0.5 mg/ml for all dilution steps. 
All dilution steps were performed at 4 °C on ice. After final homogenization, the 
samples were centrifuged for 10 min (15000 g, 4 °C) in order to remove larger 
aggregates. 
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VIII.1.5. Unfolding and Aggregation Investigations 
VIII.1.5.1. MicroScale Thermophoresis (MST) 
The second and third generation prototype instruments (NanoTemper Technologies 
GmbH, Munich, Germany) have been used for predictive unfolding and aggregation 
studies within the mAb stability screenings. For both measurement setups a stepped 
thermal ramp assay was carried out by increasing the temperature from 30 °C to 90 °C 
in 1 °C steps and recording a thermophoresis timetrace at each step. Therefore, 
overall low, instrument specific UV-LED powers of 1% (2nd gen, PMT=780 V) and 2% 
(3rd gen, dual LED, medium sensitivity) were used respectively. NT.LabelFree Zero 
Background MST Premium Coated Capillaries (NanoTemper Technologies GmbH) 
were used exclusively in order to exclude measurement artifacts from protein binding 
to the capillary surface. Furthermore, liquid dip gum (Capillary Sealing Paste, 
NanoTemper Technologies) was applied at both capillary ends to effectively prevent 
sample evaporation during the temperature ramp. 
Preceding the thermophoretic analysis of the stability screenings, the measurement 
parameters were optimized to allow for a high signal to noise ratio and a clear 
detection of both unfolding transitions. Thereby, the 2nd generation prototype was used 
to examine the influence of differently strong thermophoretic driving forces on the 
resulting melting curves. This was achieved by a stepwise increase of the IR-laser 
power from 5% to 40%. NT Control software version 2.1.31 and NT Analysis software 
version 1.5.41 (both NanoTemper Technologies) were used for carrying out the MST 
measurements and calculating the thermophoresis values for each temperature step. 
Considering the results from this IR-laser experiment, the 3rd generation prototype was 
operated at an optimal intermediate laser power of 10%. Equipped with a dual-LED 
system, the system was used to measure initial intrinsic fluorescence and the three 
thermophoretic parameters (thermophoresis, t-jump, and thermophoresis with t-jump) 
at four different fluorescence readouts. These are the single fluorescence emission 
wavelengths at 330 nm and 350 nm, as well as the ratio of 350 nm/330 nm and the 
mean value of the two wavelengths. Eventually, thermophoresis with t-jump was 
determined as the most suitable thermophoretic parameter and the fluorescence 
readout wavelength at 350 nm was found beneficial. The above described settings 
were used for all following thermal unfolding and aggregation measurements in the 
course of the stability screenings. 
For both, the pH and the formulation screening, all samples were measured 
repetitively by using a customized measurement script and executing at least four 
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consecutive runs in a randomized order with fresh capillaries each. In this way, effects 
from a prolonged thermal history of capillaries at the end of the sample tray could be 
excluded. After the measurement, MO.AffinityAnalysis software version 0 
(NanoTemper Technologies) was used to calculate the values for thermophoresis with 
t-jump at 350 nm for each temperature step. The resulting melting curves exposed two 
unfolding transition peaks for each formulation which were assigned as apparent 
melting temperatures (Tm). Both values were calculated by smoothing (Savitzky-Golay, 
polynomial order 1, points of the window 5), interpolation (cubic spline, 6001 points 
between 30 °C and 90 °C) and local maximum analysis (Impulse Analyzer) of the 
melting curves by using Origin software version 8G (OriginLab Corp., Northampton, 
MA, USA). 
VIII.1.5.2. Fluorescence Emission Spectroscopy (FES) 
VIII.1.5.2.1. Nano Differential Scanning Fluorimetry (nanoDSF) 
A Prometheus NT.48 instrument (NanoTemper Technologies GmbH) was used to 
measure protein melting temperatures (Tm) and the reversibility of protein unfolding for 
both stability screenings. Therefore, two consecutive temperature up-scans from 30 °C 
to 90 °C in a linear ramp of 1 °C/min were performed each. Between the two up-scans, 
a controlled temperature down-scan from 90 °C to 30 °C at a scan rate of 1 °C/min 
was performed for the pH pre-screening, while for the formulation screening the 
samples were equilibrated at 30 °C after the first heating cycle as fast as possible. An 
initial delay of 15 min at 30 °C before the first and second measurement was set for 
both experiments to ensure temperature equilibration among the samples. In the 
formulation screening a fluorescence excitation power of 10% (medium sensitivity) was 
set for the 1st up-scan, which was decreased to 40% (low sensitivity) in the 2nd up-
scan. In the case of the pH screening a LED power of 75% (low sensitivity) was used 
for both measurements. Measurements were carried out in quadruplicates by using 
NT.LabelFree Zero Background MST Premium Coated Capillaries (NanoTemper 
Technologies) which were sealed with liquid gum (Capillary Sealing Paste, 
NanoTemper Technologies) on both capillary ends to prevent evaporation during the 
prolonged temperature cycle. 
For all temperature up-scans, Tm values were calculated by evaluating the inflection 
points in the shift of tryptophan fluorescence from 330 nm to 350 nm using 
NT.Prometheus Control software version 1.11 (NanoTemper Technologies). Unfolding 
reversibility was stated for the samples, again showing an unfolding transition in the 
second temperature up-scan. 
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In an orthogonal approach, isothermal chemical protein denaturation was measured 
and the unfolding denaturant concentration (Cm) at the inflection points of the obtained 
unfolding curves was determined. Therefore, one discovery scan was performed to for 
each formulation, measuring all 33 concentration steps in one run. For all 
measurements, the temperature of the capillary array was set to 25 °C and a 
fluorescence excitation power of 70% (low sensitivity) was used. Measurements were 
carried out in singlicates by using NT.LabelFree Zero Background Standard Treated 
Capillaries (NanoTemper Technologies GmbH). 
The shift in tryptophan fluorescence from 330 nm to 350 nm was evaluated by using 
NT.Prometheus Control software version 1.11 (NanoTemper Technologies GmbH) and 
calculating the ratio of 350 nm to 330 nm for each capillary. Afterwards, unfolding 
curves were plotted and the respective concentrations of GuHCl (Cm) at the inflection 
points were calculated by using Origin 8G software (OriginLab Corp., Northampton, 
MA, USA). For the determination of Cm values, the unfolding curves were differentiated 
(1st derivative), interpolated (cubic spline, 501 points between 0 M and 5 M GuHCl) 
and the local maxima were analyzed using the included Impulse Analyzer tool. 
VIII.1.5.2.2. Intrinsic Fluorescence Emission Spectroscopy (Intrinsic FES) 
An Optim 1000 instrument (Avacta Analytical Ltd, Wetherby, UK, now Unchained 
Labs, Pleasanton, CA, USA) was used for a comparative linear thermal unfolding and 
aggregation study. The samples were pipetted in the capillaries of a 9 µl micro-cuvette 
array (MCA), which were tightly closed with the provided silicone seals using a MCA 
frame. Using the Optim Client software V1.5.4 (Avacta Analytical), all formulations 
were measured at least 4 times by performing three consecutive runs with 1 MCA (=16 
capillaries) each. Before each measurement, the thermostat temperature was set to 
30 °C for a pre-scanning delay of 15 min. Following, the temperature was linearly 
increased from 30 °C to 90 °C in a rate of 1 °C per minute, while a hold time of 1 s was 
used at each well for recording of the fluorescence spectrum. An excitation laser 
wavelength of 266 nm was used to induce deep UV intrinsic fluorescence, setting a slit 
width of 100 µm and an exposure time of 1000 ms. Fluorescence emission was 
recorded from 249 to 504 nm using a center wavelength of approximately 380 nm. For 
data evaluation, the ratio of 350 nm/330 nm was chosen and unfolding temperatures 
(Tm) were automatically calculated by the Optim Analysis Software V2.0.4 (Avacta 
Analytical). If necessary, melting temperatures were re-adjusted according to the 
maxima of the 1st derivative fluorescence curves. 
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VIII.1.5.2.3. Differential Scanning Fluorimetry (DSF) 
In the formulation screening, differential scanning fluorimetry (DSF) was used for 
reference measurements of linear thermal unfolding by evaluating changes in the 
extrinsic fluorescence of SYPRO® orange (SO) and 9-(2,2-dicyanovinyl)julolidine 
(DCVJ). 
SYPRO® Orange Protein Gel Stain was purchased as a 5000x concentrated stock 
solution (SS) in DMSO (Sigma Aldrich, St. Louis, MO, USA). First, the SS was diluted 
with highly purified water (HPW) to a working solution (WS) of 21x. Subsequently, 
20 µl protein formulation or placebo reference respectively was provided in the wells of 
a skirted 96-well microplate (Biometra GmbH, Goettingen, Germany) and 1 µl WS was 
spiked in and thoroughly mixed. The resulting final volume per well was 21 µl with a 
SO concentration of 1x. For each formulation 8 wells were prepared, 6 with protein 
material and 2 with the respective placebo reference. To prevent evaporation and 
ensure proper filling of each without air bubbles, the well plate was covered with self-
adhesive optical sealing film (Biometra) and centrifuged at 2000 g for 2 minutes. 
The unfolding experiment was conducted using a qTower 2.2 UV instrument (Analytik 
Jena AG, Jena, Germany). After an initial equilibration time of 15 minutes at 30 °C, the 
temperature was stepwise increased to 90 °C following a scan rate of 1° C/min and a 
measurement interval of 1 per °C. An excitation wavelength of 490 nm was used, while 
the fluorescence emission of SO was collected at 580 nm by using the corresponding 
channel of the instrument at a gain of 5. At each temperature, three repetitive 
measurements were performed. 
Before melting temperatures (Tm) were evaluated, the placebo reference 
measurements were subtracted from the verum melting curves, in order to exclude 
effects from buffer background fluorescence. Subsequently, the background 
subtracted data were differentiated (1st derivative), smoothed (Savitzky-Golay, 
polynomial order 1, points of the window 5), interpolated (cubic spline, 6001 points 
between 30 °C and 90 °C) and the two local maxima were analyzed using the included 
Impulse Analyzer tool (Origin 8G, OriginLab Corp., Northampton, MA, USA). 
9-(2,2-dicyanovinyl)julolidine (DCVJ) was purchased as solid powder from Sigma 
Aldrich (St. Louis, MO, USA) and diluted in DMSO to a stock solution (SS) of 210 mM. 
This SS was further diluted to a 2.1 mM working solution (WS) with HPW. A dilution 
series of seven mAb concentrations ranging from 0.1 mg/ml to 15 mg/ml was prepared 
in 10 mM phosphate buffer at pH 5.0 by using protein stock solution material. 
Subsequently, 20 µl protein formulation or respective placebo reference was provided 
in the wells of a MicroAmp® optical 96-well reaction plate (Applied Biosystems, Foster 
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City, CA, USA) and 1 µl DCVJ WS was spiked in and thoroughly mixed. The resulting 
final volume per well was 21 µl with a DCVJ concentration of 100 µM. For each dilution 
and the placebo reference, four wells were prepared. The filled wells were sealed with 
optical adhesive film (Applied Biosystems, Foster City, CA, USA) and the plate was 
centrifuged for 2 minutes at 2000 g to ensure filling without air bubbles. 
A 7300 real-time PCR system (Applied Biosystems, Foster City, CA, USA) was used 
for the unfolding experiment. After an initial equilibration time of 15 minutes at the 
starting temperature of 30 °C, the temperature was stepwise increased to 90 °C 
following a scan rate of 1° C/min and a measurement interval of 1 per °C. A tungsten-
halogen lamp was used for fluorescence excitation, while the emission was recorded 
at ~ 520 nm using the detection filter A. For conducting the measurement, a 7300 
System SDS Software version 1.3.1 (Applied Biosystems, Foster City, CA, USA) was 
used. 
For data analysis, Origin 8G software (OriginLab Corp., Northampton, MA, USA) was 
used. For all verum formulation melting curves, the reference baseline of 10 mM 
phosphate buffer pH 5.0 was subtracted. Afterwards, the extrinsic fluorescence 
readout curves were differentiated (1st order), smoothed (polynomial order 1, points 5) 
and interpolated (cubic spline, 6001 data points between 30 °C and 90 °C). Tm values 
were determined by selecting the two local maxima by using the included Impulse 
Analyzer tool. 
VIII.1.5.3. Differential Scanning Micro-Calorimetry (µDSC) 
A VP-DSC microcalorimeter (MicroCal Inc., Northampton, MA, USA, now Malvern 
Instruments Ltd, Malvern, UK) was used for comparative thermal unfolding studies. 
The placebo and verum formulations were degassed for approx. 5 min by using a 
ThermoVac vacuum pump (MicroCal) in order to remove potential air bubbles from the 
samples. Subsequently, 550 µl of the placebo reference was injected using a 2.5 ml 
gastight Hamilton syringe (Hamilton Company, Reno, NV, USA) at 25 °C before the 
verum material was injected accordingly. A temperature up-scan was performed from 
30 °C to 90 °C by performing a slope of 60 °C/h. A pre-scan thermostat of 15 minutes 
was set at the starting temperature to ensure thermal equilibration. During the 
measurement, a filtering period of 1 second was set without a feedback mode/gain, 
while the chamber pressure was checked to be ≥ 22 psi. After each run, the cells were 
cooled down to 30 °C again. Sample analysis was performed at least in triplicates for 
each formulation. 
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Between two sample runs, a cleaning routine was performed by heating up a 50% 
(V/V) nitric acid solution under the same conditions as the samples, but using a scan 
rate of 90 °C/min and no pre-scan thermostat. Afterwards, a solution of 1% (w/V) 
sodium dodecyl sulfate (SDS) (Merck KGaA, Darmstadt, Germany) in HPW was used 
to flush each cell for 30 seconds, followed by a thorough rinse with 100 ml water per 
cell. 
The data evaluation was performed by the Origin DSC data analysis software (Origin 7 
SR2, OriginLab Corp., Northampton, MA, USA) and MicroCal VPViewer2000 version 
1.4.10 (MicroCal). The thermograms were normalized by subtracting a baseline 
measured by water vs. water scans to exclude device parameters and instrumental 
effects. Afterwards, the endothermic peaks indicating protein unfolding events (Tm) 
were determined using the included Peak Picking tool. 
VIII.1.5.4. Static Light Scattering (SLS) 
Additionally to intrinsic fluorescence (section VIII.2.1.2.2), static light scattering 
intensity over temperature was evaluated from the Optim 1000 measurement for the 
UV laser at 266 nm and the blue laser at 473 nm. Therefore, 90° light scattering values 
were plotted over temperature and aggregation onset temperatures (Tagg onset) were 
evaluated for 266 nm and 473 nm, given a bandwidth of 5 nm each, by using the 
Optim Analysis software V2.0.4 (Avacta Analytical). For calculation, the software 
applied a Heaviside step function to the 1st derivative curve of static light scattering 
and the temperature corresponding to the 10% value of the maximum was determined 
automatically. Formulations that showed no increase in light scattering over the 
complete temperature up-scan were assigned and displayed with a theoretical value 
above 90 °C. 
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VIII.1.6. Forced Degradation Studies 
VIII.1.6.1. Thermo-Optical Particle Characterization (TOPC) 
TOPC was used for predictive thermal aggregation studies by IR-laser induced stress 
testing for the pH pre-screening and the formulation screening. The fluorescence 
excitation LED power was set to 10% (PMT=825 V, pH screening) and 20% 
(PMT=780 V, formulation screening) and heat stress was applied by using an IR-laser 
power of 341%. Changes in intrinsic fluorescence were detected for 160 s in total. 
After recording the initial fluorescence for 5 s, the laser was turned on and the effects 
of the IR-laser input were tracked for 150 s, before the laser was turned off again and 
backdiffusion was measured for additional 5 s. 
In order to test the repeatability of the assay, the measurements of the pH screening 
were performed in triplicates by performing three independent consecutive runs, while 
for the formulation screening only singlicates were analyzed. All measurements were 
performed in a fixed random order of formulations at an ambient assay temperature of 
25°C by exclusively using NanoTemper LabelFree MST Premium Coated Zero 
Background Capillaries (NanoTemper Technologies GmbH) in order to avoid 
measurement artifacts from sample binding to the capillaries and capillary auto-
fluorescence. 
NT Control software version 2.1.31 was used to perform the measurements, while the 
intrinsic fluorescence timetraces were normalized and exported by using NT Analysis 
software version 1.5.41 (both NanoTemper Technologies). The TOPC experiments 
were analyzed by calculating mean values and standard deviations for all formulations 
in the timeframe between 125 and 150 s. All calculations and data plotting were 
performed with Origin 8G software (OriginLab Corp., Northampton, MA, USA). 
VIII.1.6.2. Conventional Stress Testing 
All formulations were heat-stressed in 2 ml conical micro-centrifuge tubes (VWR 
International LLC, Radnor, PA, USA) at 80 °C for 10 minutes (after 15 minutes for 
temperature equilibration) using a ThermoMixer Comfort (Eppendorf AG, Hamburg, 
Germany). As a reference, one aliquot of each sample was stored at 4 °C for the same 
time. 
VIII.1.6.2.1. Dynamic Light Scattering (DLS) 
Dynamic Light Scattering was measured using a Zetasizer Nano ZS (Malvern 
Instruments GmbH, Herrenberg, Germany). The Z-Average diameters of the native 
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and stressed protein formulations were evaluated to detect protein particle growth due 
to thermal aggregation and precipitation after the forced degradation. The 
measurements were carried out in triplicates using disposable semi-micro PMMA 
cuvettes (Brand GmbH & Co. KG, Wertheim, Germany). 
VIII.1.6.2.2. Turbidimetry 
A Dr. Lange Nephla Turbidimeter (Hach-Lange, Duesseldorf, Germany) was used for 
measuring the turbidity of the native and stressed protein formulations. 2 ml of each 
sample were filled in a glass cuvette and turbidity was determined as 90° scattered 
light (860 nm) in Formazin Nephelometric Units (FNU). The measurement was carried 
out in minimum triplicates by turning the cuvette and measuring turbidity again. 
VIII.1.6.2.3. Visual Inspection 
The heat stressed and native samples of the pH pre-screening were additionally 
visually inspected in the turbidimetry cuvettes using an inspection cabinet. Pictures 
were taken with a Nikon D5300 digital camera (Nikon Inc., Tokyo, Japan). 
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VIII.1.7. Protein-Excipient Interaction Analysis 
VIII.1.7.1. MicroScale Thermophoresis (MST) 
MST was used for protein-excipient binding studies of the mAb to cyclodextrins. All 
measurements were performed on a Monolith NT.LabelFree instrument (NanoTemper 
Technologies) by using a fluorescence excitation LED Power of 7% and a MST Power 
of 20%. These settings were selected in order to get a satisfactory high initial 
fluorescence signal and thermophoretic depletion. NT.LabelFree Zero Background 
MST Premium Coated Capillaries (NanoTemper Technologies GmbH) were used 
exclusively and the measurements were carried out at ambient room temperature. 
The measurements were performed by using NT Control software version 2.1.31, 
while NT Analysis software version 1.5.41 (NanoTemper Technologies) was used to 
calculate thermophoresis and intrinsic fluorescence values for each excipient 
concentration and compute equilibrium dissociation constants (Kd) by fitting a 
Boltzmann-function to the respective data. Plotting of the data was performed by using 
Origin 8G software (OriginLab Corp., Northampton, MA, USA). 
VIII.1.7.2. Nano Differential Scanning Fluorimetry (nanoDSF) 
A Prometheus NT.48 instrument (NanoTemper Technologies GmbH, Munich, 
Germany) was used for linear thermal unfolding measurements of the protein-excipient 
dilution series. A temperature ramp was executed from 15 °C to 95 °C in a slope of 
1 °C/min, while protein fluorescence was continuously collected at 330 nm and 
350 nm. The fluorescence excitation power was set to 30% (low sensitivity) in order to 
get a satisfactory high fluorescence signal. All titration steps have been analyzed in 
singlicate runs by using NT.LabelFree Zero Background MST Premium Coated 
Capillaries (NanoTemper Technologies). 
In order to obtain melting temperatures (Tm) from the intrinsic fluorescence emission, 
the intensities of the single wavelengths at 330 nm and 350 nm as well as the ratio of 
350/330 nm was calculated and evaluated over temperatures by using NT.Prometheus 
Control software version 1.11 (NanoTemper Technologies). 
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VIII.2. Results and Discussion 
VIII.2.1. Unfolding and Aggregation Investigations 
VIII.2.1.1. MicroScale Thermophoresis (MST) 
Prior to executing the pH pre-screening and the formulation excipient screening, a 
detailed investigation on two major influence factors of thermophoretic melting curves 
was performed and the measurement settings were optimized for clear detection and 
an improved signal to noise ratio of both unfolding events. In this pre-test, the 
dependency of the melting curves on (i) the MST/IR-laser power and (ii) the 
fluorescence readout was investigated. 
Figure 62 and Figure 63 display melting curves by thermophoresis for F1 (10 mM 
phosphate, pH 4.2) and F3 (10 mM phosphate, pH 6.0) measured at different MST 
powers. For both examples, the expected increase in thermophoretic depletion at 
higher laser intensities was apparent at the starting temperature of 30 °C. Increasing 
the laser intensity on the one hand side improves the signal to noise ratio for the 
individual timetraces, but on the other hand side, increases the temperature in the 
focal area and therefore the perturbation of the system in the same way. In order to 
focus on the laser power effects on the shape of the melting curves and to correct for 
the depletion amplitude, we normalized all melting curves for the further analysis. 
Formulation 1 (Figure 62 – right) displays a clear laser power effect on the formation of 
melting transitions. Whereas at a low MST power of 5% only one peak was detected 
(Tm1), an additional peak shoulder at higher temperatures (Tm2) emerges when using 
10% laser power that grows substantially during increasing laser intensities until its 
intensity outweighs the first peak for the highest laser powers of 30% and 40%. Taken 
this together, we observed a clear shift of the peak intensities in the MST melting 
curves from Tm1 to Tm2 with increasing laser intensities. For the lead formulation F3 
(Figure 63 – right), however, a similar effect could only be hypothesized when, 
increasing the laser power from 5% to 10%, a second transition appears. All other 
laser settings did not resolve both transitions, maybe due to the higher proximity and 
potential overlapping of the unfolding events at the increased pH value that is also 
apparent for the 10% MST power curve. Consequently, the MST/IR-laser power was 
fixed to an intensity of 10% for all following measurements. This setting will allow for 
full resolution of both unfolding transitions from pH 4.2 to pH 6.0, a moderate 
perturbation of the solution and a suitable signal to noise ratio for both, the single MST 
timetraces as well as the resulting melting curve. 
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With regard to our previously described mAb unfolding and aggregation studies by 
using MST (V.1.2.1) and many differential scanning microcalorimetry investigations of 
mAbs reported in the literature5-10, the first unfolding transition (Tm1) detected is 
presumably attributed to the unfolding of the CH2 domain localized within the Fc 
fragment. The second and most prominent melting event (Tm2) that is often associated 
with nascent protein aggregation and emerges in our case with increasing IR-laser 
intensities is caused by Fab unfolding. Heat denaturation of the CH3 domain is often 
found to be conformationally most stable, but due to the low intensity hard to separate 
from the Fab event. Therefore this transition either appears last, or is only detectable 
as a small shoulder and only evaluable by deconvolution of the unfolding signal. 
 
Figure 62: Dependence of the thermophoresis melting curves on the IR-laser (MST) power for 
Formulation 1 (10 mM phosphate, pH 4.2). Left: Absolute thermophoresis versus temperature. 
Right: Normalized thermophoresis versus temperature. 
 
Figure 63: Dependence of the thermophoresis melting curves on the IR-laser (MST) power for 
Formulation 3 (10 mM phosphate, pH 6.0). Left: Absolute thermophoresis versus temperature. 
Right: Normalized thermophoresis versus temperature. 
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Implemented with the dual-LED system in the 3rd prototype instrument, the detection of 
intrinsic fluorescence emission at two independent wavelengths (330 nm and 350 nm) 
was enabled. This development leads to the possibility of interpreting four different 
fluorescence modes in the evaluation of initial intrinsic fluorescence as well as 
thermophoresis and t-jump melting curves. The full melting curve comparison of all 
evaluations combined with all fluorescence readouts is given in Figure 64. In contrast 
to the HSA melting curves discussed in section VI.2.1.1, where the thermophoresis 
and t-jump melting curves both showed uniform negative unfolding peaks, the mAb 
behaved completely different. In the single wavelength inspection, the t-jump values 
(Figure 64 – top – left) showed a stepwise decrease over increasing temperatures that 
was hardly influenced by the evaluation wavelength. This minor wavelength 
dependence led to a very high noise level in the calculated fluorescence ratio 
(350 nm/330 nm) that though indicated the two transition steps which could be 
assigned to the separate unfolding events of individual antibody domains (Tm1 & Tm2). 
For the melting curves by thermophoresis (Figure 64 – top – right), the fluorescence 
emission at 330 nm showed only one small unfolding peak (Tm2), while the readout at 
350 nm exhibited both transitions additionally with a higher resolution (Tm1 & Tm2). 
Consequently, this clear difference in wavelengths induced a similar curve progression 
for the fluorescence ratio calculated by 350 nm/330 nm. The evaluation of 
thermophoresis with t-jump at 350 nm combines the stepwise signal decrease from the 
t-jump, the two peak-shaped unfolding transitions from the thermophoresis plots and 
moreover enhances the signal to noise ratio, especially for the smaller first transition 
(Tm1). Thus, we proceeded with these settings for the data analysis of the pH pre-
screening and the formulation excipient screening. 
As the evaluation of intrinsic fluorescence melting curves of mAbs is well described in 
literature11-14 and in our assay the fluorescence readout might be influenced by the 
repetitive UV-LED and IR-laser radiation, we will not go into any greater detail at this 
point and refer to the standalone fluorescence evaluations of the two mAb screenings 
discussed in section VIII.2.1.2. 
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Figure 64: Comparison of the four different fluorescence readouts (330 nm, 350 nm, mean 330 nm 
+ 350 nm, and ratio 350 nm/330 nm) measurable with the 3rd generation prototype instrument for 
the t-jump (top – left), thermophoresis (top – right), thermophoresis with t-jump (bottom – left), and 
initial fluorescence (bottom – right) melting curves. The exemplary curves are given for 
Formulation 2 (10 mM phosphate, pH 5.0). 
Figure 65 shows exemplary melting curves for the method selected above within the 
pH pre-screening of the mAb formulated in 10 mM phosphate buffer. For all pH values, 
two distinct melting peaks were obtained that shift to higher temperatures with 
increasing pH values. This observation was confirmed by the Tm evaluation (Figure 66 
– left) and results in an enhanced conformational stability with increasing pH that was 
found to be stronger for the first unfolding transition (Tm1). In the raw data, an 
additional very sharp aggregation peak was visible from pH 5.4 on that shifted towards 
lower temperatures with increasing pH values and disturbed the Tm2 determination 
above pH 5.6 and also the Tm1 value at pH 6.2. For further development steps, this 
emerging aggregation would require a compromise between minimum aggregation 
propensity and a high unfolding stability. As the aggregation peak appears first at a pH 
value of 5.4 and the increase in conformational stability is strongest between pH 4.0 
and pH 5.0, an intermediate pH value of 5.0 or 5.2 is proposed as an optimized lead 
formulation from this study. 
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Figure 65: Exemplary melting curves for thermophoresis with t-jump at 350 nm for the pH pre-
screening (Run 2 of 4). 
 
Figure 66: Melting temperatures for the pH pre-screening (left, n≥3) and the excipient screening 
(right, n=5) determined by thermophoresis with t-jump at 350 nm. Within the pH pre-screening, the 
Tm1 value at pH 6.2 as well as the Tm2 values at pH 5.8-6.2 were (partially) superimposed by an 
additional aggregation peak and were consequently excluded from the illustration. 
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The excipient screening, additionally targeting the mAb thermal stability dependent on 
different buffer salts as well as formulation excipients is based on the 10 mM 
phosphate buffered solution at pH 6.0 as a lead formulation (F3), which was selected 
only by maximum conformational stability. The corresponding Tm evaluation (Figure 66 
– right) re-iterates the strong pH dependency of the conformational stability that was 
already discussed for the pH pre-screening and stabilizes the antibody with increasing 
pH values from pH 4.2 (F1) over pH 5.0 (F2) to pH 6.0 (F3). Comparing the buffer salts 
phosphate (F3), histidine (F4) and succinate (F5), a destabilizing effect of histidine is 
apparent. However, this fact has to be interpreted with care, as especially histidine 
shows a by approximately one decade more pronounced temperature effect on its pKa 
value compared to the other buffer systems used3,15,16. This distinct property leads to a 
negative pH shift of ~0.9 pH units at 63 °C and ~1.1 pH units at 71 °C that lowers the 
actual pH value of the solution at Tm1 to pH 5.1, and at Tm2 to pH 4.9. Consistent with 
this argument is the observation that the apparent Tm1 value for Formulation 4 is 
between F3 (pH 6.0) and F2 (pH 5.0), while the Tm2 approaches the value for F2 even 
more. Excipients had a substantially less pronounced effect on the conformational 
stability compared to changes in the pH value. However, sorbitol (F7) and sucrose (F8) 
slightly stabilized the antibody while high salt concentrations (F10) destabilized. In 
order to put these results in context, the conformational stabilization by polyols and 
sugars is well described in literature and attributed to preferential hydration17. 
Additionally, a reduction of electrostatic repulsion in the native state is observed at 
increased salt contents for many mAbs and consequently leads to colloidal 
destabilization.1 
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VIII.2.1.2. Fluorescence Emission Spectroscopy (FES) 
VIII.2.1.2.1. Nano Differential Scanning Fluorimetry (nanoDSF) 
In the pH pre-screening, thermal unfolding detected by nanoDSF showed a strong pH 
dependence of unfolding and aggregation events. With increasing pH values, the 
thermal unfolding curves, detected by the ratio in intrinsic fluorescence emission at 
350 nm/330 nm, were shifted to higher temperatures and hence overall conformational 
stability increased (Figure 67). In the melting temperature evaluation, this stability 
improvement holds true for the first as well as for the second unfolding transition. 
However, the increasing effect is considerably stronger for Tm1 and persists up to 
pH 6.2, whereas the Tm2 values reach a plateau at ~ 76 °C above pH 5.0. 
 
Figure 67: Benchmarking of the pH pre-screening results by using nanoDSF (1st up-scan). Left: 
Thermal unfolding monitored by the intrinsic fluorescence ratio of 350 nm/330 nm over 
temperature. Right: Conformational stability was calculated by determining the inflection points of 
the unfolding curves. All samples were measured in quadruplicates (n=4). 
Furthermore, the propensity of non-native aggregation was tracked by measuring the 
reversibility of unfolding when performing a second consecutive temperature up-scan 
und re-evaluating the melting transitions, if present (Figure 68). Thereby, the inversely 
proportional trend of conformational and aggregation stability was reconfirmed, as the 
reversibility of unfolding and, therefore, the aggregation resistance decreased with 
increasing pH values. For the formulations from pH 4.0 to 5.4, protein unfolding was 
partially reversible, while with increasing pH values, the amplitude of the unfolding 
transition steadily decreased. This suggests the rise of an altered conformation on 
reheating, which is substantially influenced by pH. Nevertheless, consistent Tm2 values 
were obtained for all formulations in this range, while the first unfolding transition was 
only recurrent at pH 4.0. With the formulations at pH values higher than 5.4 showing 
no reversibility at all, these findings are in very good agreement with the MST results 
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where those pH values displayed an additional aggregation peak approaching lower 
temperatures with increasing pH values. Additionally, a µDSC study by Youssef2 
yielded highly comparable stability and reversibility data on the same mAb. 
In summary, identical conclusions as for MST can be drawn, rendering intermediate 
pH values around 5.0 as lead conditions for further development, providing a suitable 
compromise between conformational stability and aggregation resistance. 
 
Figure 68: Benchmarking of the pH pre-screening results by using nanoDSF (2nd up-scan). Left: 
Colloidal stability was investigated by performing a second up-scan and checking for reversibility 
of unfolding. Right: Conformational stability was calculated by determining the inflection points of 
the unfolding curves. Evaluable Tm2 values were obtained for pH values in the range of 4.0 to 5.4, 
while a Tm1 value was observed for pH 4.0 only. All samples were measure in quadruplicates (n=4). 
For the formulation excipient screening, the same assay was executed by performing 
two consecutive temperature up-scans from 30 °C to 90 °C and evaluating the 
conformational stability profile by melting temperature determination from the 1st and 
the aggregation propensity by unfolding reversibility from the 2nd ramp. 
The first unfolding scan (Figure 69) very well validates the stability principles derived 
from the MST study. Once more, the strong pH influence on the unfolding stability of 
the mAb is highlighted, leading to the highest Tm value among the three phosphate 
buffers investigated (F1-F3, pH 4.2-pH 6.0) for pH 6.0 (F3). Furthermore, the buffer 
comparison of phosphate (F3), histidine (F4) and succinate (F3) shows identical trends 
for Tm1, revealing the reduced conformational stability for histidine which bears the risk 
of a negative pH shift upon heating, as described in the MST section (VIII.2.1). 
Surprisingly, the corresponding Tm2 does not show a destabilization for histidine and 
thus all buffer systems rank with comparable values. However, in general it is to 
mention that the stability trends for Tm2 in the nanoDSF results are considerably less 
pronounced compared to Tm1.The addition of polysorbate 80 (F6), glycerol (F9) or 
hydroxypropyl-beta-cyclodextrin (F11) had no effect on the melting temperatures of the 
10 mM phosphate, pH 6.0 lead formulation, albeit we again revealed a slight 
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destabilization by sodium chloride (F10) and higher Tm values for sorbitol (F7) and 
sucrose (F8). 
 
Figure 69: Benchmarking of the formulation screening results by using nanoDSF (1st up-scan). 
Left: Thermal unfolding monitored by the intrinsic fluorescence ratio of 350 nm/330 nm over 
temperature. Right: Conformational stability was calculated by determining the inflection points of 
the unfolding curves. All samples were measured in quadruplicates (n=4). 
The second, consecutive unfolding scan of the formulation screening was performed 
by analogy to the first thermal ramp and elucidates the potential of intermediate protein 
refolding and formation of repetitive unfolding transitions with comparable melting 
temperatures (Figure 70). As already shown for the pH pre-screening, the mAb shows 
partial reversibility of unfolding when formulated in 10 mM phosphate buffer in the pH 
range between 4.0 and 5.4, which vanishes at higher pH values. Consequently, 
Formulation 1 (pH 4.2) and Formulation 2 (pH 5.0) were reversible to a certain degree, 
while Formulation 3 (pH 6.0) was not. Moreover, reversibility was confirmed to be 
mostly pH driven, as the addition of formulation excipients (F6-F11) had no effect on 
the second melting curve and were therefore not able to retrieve measurable changes 
in secondary or tertiary structure. In contrast to phosphate (F3) and succinate (F5), 
reversibility and repeatability was interestingly established for histidine buffer (F4) at 
pH 6.0. Taken the general thoughts about histidine as a buffer system (VIII.2.1) and 
the apparent Tm value into consideration, this finding may also be related to the 
expected negative pH shift occurring at elevated temperatures. Thus, Formulation 4 
(histidine, pH 6.0) is expected to lower its pH value by up to one pH unit in the relevant 
temperature range and indeed reveals melting temperatures of the second unfolding 
transition (Tm2) comparable to Formulation 2 (phosphate, pH 5.0). Moreover, the 
fluorescence ratios (350 nm/330 nm) at 30 °C overlay almost perfect for Formulation 2 
and 4 after performing the first temperature cycle. That implies the absence of 
irreversible aggregation and the formation of similar structures in a coherent refolding 
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mechanism that does not develop at elevated pH values. It is therefore assumed that 
aggregation and precipitation are closely associated with the pH and the resulting net 
charge of the antibody that is the main driving factor for colloidal interactions. This 
hypothesis is consistent with the pH dependence of unfolding and aggregation for 
different IgG1 type antibodies as reported by Sahin et al.18 and Brummitt et al.19. 
 
Figure 70: Benchmarking of the formulation screening results by using nanoDSF (2nd up-scan). 
Left: Colloidal stability was investigated by performing a second up-scan and checking for 
reversibility of unfolding. Right: Conformational stability was calculated by determining the 
inflection points of the unfolding curves. Evaluable Tm2 values were obtained for F1, F2 and F4 
only. Tm1 values were not observed upon rescan. All samples were measure in quadruplicates 
(n=4). 
VIII.2.1.2.2. Intrinsic Fluorescence Emission Spectroscopy (Intrinsic FES) 
An alternative approach for benchmarking the MST results while measuring intrinsic 
fluorescence by the ratio of 350 nm/330 nm was investigated for the mAb formulation 
screening by using an Optim 1000 instrument. Comparably to the nanoDSF results, 
the melting curves (Figure 71 – left) resulted in a double sigmoidal curve showing two 
inflection points. However, the raw data quality is substantially lower for the Optim 
instrument when compared to the Prometheus, as the full spectrum fluorescence 
acquisition at every temperature step only allows for recording ~ 0.75 data points per 
°C and sample well when measuring 16 capillaries in a ramp of 1°C/min. For our 
measurement, this corresponds to ~ 45 data points per melting curve, which rather 
compares to the 60 data points measured in the MST setup. In comparison, the 
Prometheus instrument, operating with a dual wavelength detection emission filter 
setup, collected exactly 1009 data points per capillary, measuring the full formulation 
screening set in quadruplicates within one single run (44 capillaries in total). Given a 
temperature range of 30 °C to 90 °C in a slope of 1 °C/min, this leads to a resolution of 
~ 16.6 measurements per capillary within one minute and a corresponding 
measurement interval of less than 4 seconds. These long measurement intervals for 
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the Optim setup led to an increased noise level for the raw data in the Optim and 
hence to a more imprecise Tm determination, especially for Tm1 due to the smaller 
unfolding transition (Figure 71 – right). These variations in the calculation of Tm1 
introduce difficulties in the detailed evaluation of stabilizing and destabilizing trends, 
which are in general found to be larger for the first unfolding event. Nevertheless, the 
stability ranking determined for MST and nanoDSF was generally confirmed, although 
the influence of some excipients is covered by the standard deviations and therefore 
remains unresolved. In comparison, the medium resolution MST setup has the 
advantage of more pronounced thermophoresis unfolding peaks, which simplify the Tm 
determination and lead to a higher reproducibility of the results. 
 
Figure 71: Benchmarking of the formulation screening results by using intrinsic FES. Left: 
Thermal unfolding monitored by the intrinsic fluorescence ratio of 350 nm/330 nm over 
temperature. Right: Conformational stability was calculated by determining the inflection points of 
the unfolding curves. All samples were measured at least in quadruplicates (n≥4). 
VIII.2.1.2.3. Differential Scanning Fluorimetry (DSF) 
Comparative measurements of thermal unfolding have been performed for the 
formulation screening by evaluating extrinsic fluorescence emission of the reporter dye 
SYPRO Orange (SO). Unfolding of the mAb resulted in very noisy but still evaluable 
raw data that showed low absolute fluorescence levels and only small melting 
transitions, especially for Tm2 (Figure 72). This low signal to noise ratio is reflected in 
larger standard deviations compared to the thermophoresis evaluation and the other 
benchmark methods. Only the Tm1 values determined by intrinsic FES measurements 
with the Optim instrument showed similar uncertainties as the Tm2 values found in the 
DSF approach. Whereas the large effects of different pH values (F1-F3) are still 
evaluable for both melting transitions, smaller influences, for example from different 
buffer salts or excipients, are covered by the large standard deviations of Tm2 and can 
only be interpreted using the more distinctive and less noisy Tm1 values. However, in 
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this way, the general ranking of conformational stabilities is very comparable and not 
impacted by the addition of a fluorescent dye. Both, the reduced melting point of 
histidine buffer (F4) and the stabilizing effect of sorbitol (F7) and sucrose (F8) can be 
derived and match the benchmark results nicely. Nevertheless, no unfolding 
transitions, and therefore no Tm values were received for the formulations containing 
0.05% Tween 80 (F6) or 1% HP-β-CD (F11) as excipients. This was already observed 
for the rh-GCSF screening (VII.2.1.2) and therefore also expected for the mAb 
formulation screening. In contrast to all other formulations, F11 and especially F6 
expose very high extrinsic fluorescence values from the beginning, which constantly 
decrease with increasing temperatures (data not shown). This fluorescence 
progression, caused by interactions of the excipients (Tween & HP-β-CD) with the dye, 
superimposes all melting transitions and makes the phrasing of a stability statement 
for these particular formulations impossible. 
 
Figure 72: Benchmarking of the formulation screening results by using DSF with Sypro orange as 
unfolding sensitive dye. Left: Exemplary background corrected melting curves. Right: Evaluated 
meting temperatures. n≥4. 
Furthermore, 9-(2,2-dicyanovinyl)julolidine (DCVJ) was investigated as a dye in DSF 
studies. This reporter molecule is described to eliminate the disadvantage of binding to 
certain formulation excipients and consequently enables the analysis of unfolding 
parameters in the presence of surfactants and potentially also other excipients which 
impede the detection of unfolding transitions by SO (e.g. cyclodextrins).20-22 A 
concentration screening was performed using the mAb in order to evaluate the 
feasibility of using DCVJ as a fluorescent probe for stability screenings at low protein 
concentrations. Moreover, the upper measurable concentration limit and the effects of 
different concentrations on the derived melting temperatures were tested. Figure 73 
displays exemplary normalized and staggered melting curves of all concentrations 
(left) and all evaluable melting temperatures (right). In the fluorescence readout, a 
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clear influence of concentration is apparent. For the low mAb concentrations of 0.1 and 
0.5 mg/ml, the fluorescence traces do not considerably distinguish from the buffer 
reference and consequently develop no observable melting transitions. At 1.0 mg/ml, 
small peaks form and melting points were obtained for two out of four replicates. The 
unfolding events get more pronounced at higher concentrations and a reproducible 
and accurate Tm determination is enabled. Above a concentration of 5.0 mg/ml, a clear 
trending of the Tm1 values towards higher, and of the Tm2 values towards lower 
temperatures is received. The effect on the first melting transition could be explained 
by a more distinct peak formation and an appertaining right-shift of the inflection point 
on the ascending curve side. The decrease of Tm2 is observed as a true trend at 
higher concentrations and is attributed to instating protein aggregation and an 
associated discontinuation of fluorescence increase upon unfolding, which is well 
illustrated in the 15 mg/ml melting curve. Recapitulating, this leads to the conclusion 
that concentrations between 2.5 mg/ml and 10 mg/ml are required for a reasonable Tm 
determination. Thereby, an intermediate content of 5 mg/ml was determined to be the 
best compromise between weak signal intensities at lower and potential protein 
aggregation at higher concentrations. With these results, our pH pre-screening and the 
formulation screening are not measureable by using DCVJ as a dye for DSF. 
 
Figure 73: Influence of mAb concentration on DCVJ extrinsic fluorescence over temperature. Left: 
DCVJ fluorescence melting curve comparison. Values were set to 0 A.U. at 30 °C and then plotted 
with individual y-offset. Right: Comparison of the derived Tm values. n≥2.  
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VIII.2.1.3. Differential Scanning Micro-Calorimetry (µDSC) 
µDSC, as the established gold-standard method for studying thermal protein unfolding 
events in high resolution including the possibility of evaluating thermodynamic 
parameters23-26, was used for benchmark measurements in the mAb formulation 
screening. The changes in heat capacity (ΔCp) clearly resolved both unfolding 
transitions of all examined formulations as endothermic peaks, which were shifting 
towards lower temperatures in destabilized formulations and towards higher 
temperatures under stabilizing conditions (Figure 74 – left). The respective peak 
maxima were assigned as transition midpoints (melting temperature, Tm) and 
evaluated in order to rank the formulations according to their conformational stability 
(Figure 74 – right). 
The µDSC results fully confirmed the Tm comparison for the mAb formulation 
screening by MST. In detail, the stronger differentiation by Tm1 in comparison to Tm2, 
the strong stabilizing effect of higher pH values including the pH shift of histidine buffer 
(F4), the destabilization by high salt concentrations (F10), as well as the stabilization 
by sorbitol (F7) and sucrose (F8) were retrieved. Furthermore, high signal quality and 
reproducibility, showing only slight differences for F2, were obtained. 
Additionally to conformational stability, µDSC indicated aggregation of the mAb by a 
sharp exothermal decline of the calorimetric signal at temperatures right above the 
second unfolding endotherm (Figure 74 – left). This aggregation event prevented the 
re-formation of a stable baseline after complete unfolding and present in the 
thermograms of all formulations except F1, F2 and F4. At the same time, these 
formulations showed reduced Tm values for both melting transitions. In comparison to 
all other formulations in the screening, which were adjusted to a pH value of 6.0, F1 
(10 mM phosphate, pH 4.2) and F2 (10 mM phosphate, pH 5.0) were prepared at 
lower pH values, while F4 (10 mM histidine, pH 6.0) bears the property of lowering its 
pKa value at elevated temperatures and therefore acidifying upon heating. 
In conclusion, the only drawbacks of the calorimetric approach for the assessment of 
conformational stabilities and the indication of aggregation are the increased sample 
volume of ~ 600 µl per measurement and the low throughput of maximum three 
samples per day. Both the sample consumption, and the time-consuming handling and 
cleaning procedures are reduced when using the available sample handling robot. 
Nevertheless, the low volume and high-throughput assays like MST, nanoDSF, Optim, 
and extrinsic DSF are playing in an entirely different league. 
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Figure 74: Benchmarking of the formulation screening results by using µDSC. µDSC thermograms 
are displayed with a customized Y offset for each formulation in order to emphasize and visualize 
differences in the curve shapes and peak positions (left). Tm values calculated by determining the 
peak maxima of the thermograms are shown (right, n≥3). 
VIII.2.1.4. Static Light Scattering (SLS) 
The linear aggregation study, simultaneously conducted with the Optim 1000 
instrument, confirmed the impression on the principles of protein aggregation for this 
mAb which were thus far gathered by the MST, nanoDSF and µDSC analyses. 
As Figure 75 illustrates, the changes in the SLS signal detected over increasing 
temperatures clearly emphasize the “low pH” formulations F1, F2 and F4 (after 
temperature induced pH shift) as the most aggregation resistant. Formulation 1 
(10 mM phosphate, pH 4.2) showed neither at the scattering wavelength of 266 nm, 
nor at 473 nm any changes up to 90 °C, therefore no onset temperature of aggregation 
(Tagg onset) was determined. For Formulation 2 (10 mM phosphate, pH 5.0) and 
Formulation 4 (10 mM histidine, pH 6.0), the SLS at 266 nm increased only very 
minimally with Tagg onset values above 74 °C. However, at 473 nm no aggregation was 
observed, which indicates the formation of very small particles, not detectable at the 
higher wavelength. All remaining formulations exhibited strong aggregation with very 
steep scattering slopes for both evaluations. The corresponding Tagg onset values all 
range between 65 °C and 75 °C with slight tendencies of higher aggregation 
propensity for the preparations lacking a stabilizing excipient (F3 and F5) or containing 
low concentrations of Tween 80 (F6) or HP-β-CD (F11). With this said, the Tagg onset 
values at 266 nm for F2 and F4 are indeed comparable with those for F7 (incl. 5% 
sorbitol) and F8 (incl. 5% sucrose), as the onset values are evaluated as the 
temperature, where the 10% of the maximum static light scattering increase is 
reached. However, the drastically increased final scattering level at ~ 80 °C for the 
30 40 50 60 70 80 90
-450000
-300000
-150000
0
150000
R
e
la
ti
v
e
 H
e
a
t 
C
a
p
a
c
it
y
 -
 µ
D
S
C
 -
 Y
 O
ff
s
e
t 
[k
c
a
l/
m
o
le
/°
C
]
Temperature [°C]
 F1    F2    F3
 F4    F5    F6
 F7    F8    F9
 F10  F11
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11
56
58
60
62
64
66
68
70
72
74
76
78
80
 
 
 
 Tm1
 Tm2
M
e
lt
in
g
 T
e
m
p
e
ra
tu
re
 -
 µ
D
S
C
 [
°C
]
MICROSCALE THERMOPHORESIS (MST) 
FOR PROTEIN FORMULATION DEVELOPMENT 
164 
samples at pH 6.0 (F7 & F8) should also be considered in the overall reflection of 
aggregation propensities. 
 
Figure 75: Benchmarking by using static light scattering. All individual measurements of all 
formulations are displayed. In order to easily distinguish between aggregating and non-
aggregating formulations, F1, F2 and F4 are colored in grayscales, while all other formulations are 
shown in red. 
 
 
Figure 76: Benchmarking by using static light scattering. Left: Zoom-in of Figure 75, with only one 
set of formulations selected. Right: Evaluated aggregation onset temperatures for 266 nm and 
473 nm. Formulations that showed no increase in light scattering over the complete temperature 
up-scan are assigned with a theoretical value above 90 °C (dashed line). 
Moreover, the increase in static light scattering was found to be congruent with the 
second unfolding transition of the mAb, both ranging from ~ 70 °C to ~ 80 °C. This 
observation indicates a coherence of both events and a potential dependency of each 
other. For many antibodies, including commercial molecules, the presence of 
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aggregation prone regions (APRs) is described for the Fab part, especially the CDR 
loops.26-28 Thermal unfolding of the Fab fragment potentially leads to the exposure of 
these hydrophobic or aromatic amino-acid rich regions, which in turn enable colloidal 
self-interactions and consequently lead to aggregation and precipitation. Evaluated for 
calorimetry1,7,8,10 and anticipated for the fluorescence based techniques, the most 
prominent and in our case second unfolding transition reflects the above mentioned 
Fab unfolding. In combination with the pH value influencing the net charge of the mAbs 
in solution and therefore altering attractive and repulsive forces29, a Fab unfolding 
induced aggregation by interaction of the APRs may serve as the overall hypothesis 
explaining the observed inversely proportional connection of conformational and 
colloidal stability. 
VIII.2.1.5. Isothermal Chemical Denaturation (ICD) Assay 
Isothermal chemical denaturation (ICD) was used as an alternative approach to 
thermal denaturation for studying the conformational stability of different mAb 
formulations. 
Figure 77 displays the GuHCl induced unfolding curves, which were tracked by 
intrinsic fluorescence, as well as the derived unfolding denaturant concentrations Cm at 
the midpoints of unfolding. On the first impression, the unfolding traces were found to 
be very similar in comparison to the thermal melting curves and changing the pH value 
of the formulation (F1, F2, and F3) expose a high impact on the observed 
conformational stability. Moreover, the stabilizing effect of the added formulation 
excipients is again rather weak, whereas for sucrose (F8) and sorbitol (F7) stabilization 
was indicated. The conformational destabilization for F10, containing 150 mM sodium 
chloride, which was reported for the thermal assays, was not noticeable in the ICD 
approach. However, the main difference between chemical and thermal denaturation 
was observed for Formulation 4 (10 mM histidine, pH 6.0). In the thermal approach, 
lower Tm values were detected for the histidine based formulation in comparison to 
phosphate (F3) and succinate (F5). This observance was linked to the negative shift of 
the buffer pKa value, when exposed to elevated temperatures. This hypothesis was 
recently substantiated by investigations of Svilenov et al.3. As the ICD approach is 
performed at a fixed temperature, this artifact does not occur and comparable 
conformational stabilities were expected for all buffer salts investigated. In fact, the Cm 
values (Figure 77 – right) exceeded all expectations and F4 was found to be suddenly 
the most stable formulation in the whole screening. Without studying an alternative to 
thermal unfolding and aggregation assays the histidine based formulation could have 
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been excluded from further investigations and the potential would have been 
overlooked. These results emphasize the necessity of considering orthogonal 
approaches and the reflecting the potential of chemical denaturation for the 
development of stable protein formulations. 
 
Figure 77: Benchmarking by using chemical denaturation. Guanidine hydrochloride was used as 
chaotropic excipient to unfold the protein without applying a thermal ramp. The unfolding event 
and the unfolding denaturant concentration was detected by using the intrinsic fluorescence ratio 
at 350 nm/330 nm (n=1). For Formulation 9, no Cm1 was detected. 
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VIII.2.1.6. Comparison and Evaluation of MST as a Tool for Unfolding and 
Aggregation Studies 
In the pH pre-screening, MST and nanoDSF provided highly comparable and 
conclusive stability predictions over conformational stability and aggregation 
propensity. The evaluation of a single denaturation cycle by MST already contained 
information on both, protein unfolding and aggregation. In order to obtain a 
comparable information content by nanoDSF, two consecutive up-scans were 
performed and the reversibility of unfolding was analyzed. However, both up-scans by 
nanoDSF were executed within one third of the time, the single MST experiment took. 
Furthermore, instating protein aggregation had a strong influence on the unfolding 
signal in the MST setup, which impeded the calculation of melting temperatures for the 
formulation showing colloidal instabilities already at comparably low temperatures. On 
the contrary, the manifestation of unfolding transitions for the nanoDSF melting curves 
was not perturbed by aggregation and potentially precipitation. However, the Tm1 and 
Tm2 values that were not impacted by aggregation and therefore evaluable for both 
methods expose very high correlations with R² values above 0.99 (Figure 78). The 
acquired stability characteristics show a strong and inversely proportional dependence 
on pH, with decreasing melting temperatures but also reduced aggregate formation in 
acidified solutions. In conclusion, it was possible to determine pH 5.0 as a potential 
lead formulation, combining a minimum aggregation propensity with a maximum of 
conformational stability. 
 
Figure 78: Correlation of the results for MST and nanoDSF within the mAb pH pre-screening. 
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Additionally, an extensive formulation screening benchmarking study was performed 
for the same monoclonal antibody. For the case study presented, the lead formulation 
was chosen only by maximum conformational stability in order to additionally 
investigate moderate stabilizing and destabilizing effects of different buffer salts and 
formulation excipients on the unfolding and aggregation characteristics. The MST 
results were compared to gold-standard methods for thermal denaturation and 
aggregation determination as well as chemical unfolding as a new approach in protein 
formulation development. Figure 79 displays the correlation of melting temperatures 
determined for thermophoresis and t-jump at 350 nm with benchmark results obtained 
by calorimetry, as well as extrinsic and intrinsic fluorescence emission. Thereby, very 
consistent data were obtained for the first unfolding transition (Tm1, R² > 0.970), while 
the correlation for the second unfolding event (Tm2) was found to be substantially 
weaker. The calculated Tm2 values for thermophoresis and t-jump clearly distinguish 
between stabilizing and destabilizing conditions, whereas the melting temperatures for 
the benchmark methods reach a plateau and only discriminate very minimally between 
the different formulations. Considering the lessons learned from the pH pre-screening, 
these deviations could be attributed to the measurement of protein aggregates in the 
MST setup, having a strong effect on the apparent Tm values and the resulting stability 
statement. 
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Figure 79: Correlation of the melting temperatures determined for the mAb formulation screening 
by thermophoresis with t-jump with the benchmark methods microcalorimetry (µDSC), intrinsic 
fluorescence (nanoDSF and FES), and extrinsic fluorescence (DSF). Tm1 (top) and Tm2 (bottom) 
values were correlated individually. 
Chemical denaturation was tested as an alternative approach to the predominant 
thermal unfolding assays. Guanidine hydrochloride (GuHCl) was used as chaotropic 
agent that unfolds the mAb without the necessity of increasing the ambient 
temperature. Thereby, the temperature induced negative pH shift of approximately one 
pH unit, which was observed for the histidine based formulation (F4) during thermal 
denaturation, did not occur and the previously “destabilized” formulation showed by far 
the highest conformational stability among the formulations tested (Figure 80 – left). 
Interestingly, for all other formulations, very good correlations were received in the 
comparison of Tm2 and Cm2 values (Figure 80 – right, R²=0.952). The first unfolding 
transitions showed a slightly reduced overlay for the two methods, which could be 
related to the difficulties in the precise determination of this transition by the limited 
number of data points for isothermal chemical denaturation. Overall, ICD was 
perceived as a valuable orthogonal tool for the assessment of conformational 
stabilities, especially for histidine buffered formulations. 
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Figure 80: Comparison of chemical denaturation (nanoDSF) and thermal denaturation 
(thermophoresis with t-jump) within the mAb formulation screening. Left: Unfolding 
temperature/concentration comparison given relative to the second transition of F3. Right: 
Correlation of the Tm1/Cm1 and Tm2/Cm2 results in two individual fits. For linear fitting, the data 
points for F4 (open symbols) have been removed. 
Thermal protein aggregation was directly measured by the increase in static light 
scattering, which most clearly differentiated between aggregation prone and 
aggregation resistant formulation conditions. Moreover, aggregation propensities were 
indirectly indicated by the emergence of additional peaks for thermophoresis, studying 
the reversibility of unfolding by intrinsic fluorescence and the baseline drop after the 
unfolding event for µDSC. All methods provided a comparable ranking on aggregation 
propensities, elucidating that increased pH values favor protein aggregation. 
As expected, colloidal molecular interaction and the resulting aggregation were found 
to be mainly pH driven and hardly influenced by formulation excipients. Thus, 
approaching the isoelectric point (pI) of the mAb by changing the overall net charge 
could lead to strong molecular attraction and aggregation/precipitation. 
In the following step, either a third round stability screening or storage stability studies 
could be performed. For both options, the lead candidate formulation would be 
optimized based on the present findings by choosing a reduced pH value (e.g. pH 5.0) 
and adding stabilizing excipients (e.g. sucrose or sorbitol). With this starting point, a 
compromise between high unfolding stability and a reduced aggregation propensity 
could be achieved. 
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VIII.2.2. Forced Degradation Studies 
VIII.2.2.1. Thermo-Optical Protein Characterization (TOPC) 
In Figure 81, the measurement of fluorescence changes over time during forced 
degradation in the course of the pH pre-screening is displayed. During the input of the 
IR-laser, the timetraces expose a distinct aggregation pattern by developing different 
fluorescence and scattering levels. The formulations with a pH up to 5.0 exhibited 
neither an increase in fluorescence nor in timetrace scattering and thus showed a high 
resistance to aggregation after unfolding. At higher pH values, the formation and 
accumulation of smaller soluble aggregates lead to a fluorescence enhancement over 
time. After approximately 90 seconds measurement time, the fluorescence scattering 
rapidly increased in the pH range from 5.6-6.2, which is attributed to the generation 
and growth of larger particles and precipitates, periodically flowing through the focal 
volume and blurring the visual appearance of the sample after the measurement. 
Moreover, a trend of earlier scattering onset times with higher pH values was 
apparent. 
 
Figure 81: Normalized fluorescence timetraces over time of thermo-optical protein characterization 
within the pH pre-screening. IR-laser induced unfolding, aggregation and precipitation of 
monoclonal antibody formulations. The area between the horizontal bars (grey background) 
indicates the timeframe of the measurement that was used for further evaluation. 
The chosen timeframe from 125 to 150 seconds as well as the data evaluation of three 
consecutive runs in terms of mean fluorescence values and standard deviations is 
displayed in Figure 82. While increasing mean fluorescence values display the 
formation of small aggregates, increasing standard deviations suggest the generation 
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of larger particles and precipitates. As both aggregation parameters increase at higher 
pH values, the first impressions from the raw data could be confirmed. Therefore, the 
unfolded monoclonal antibody shows a decreased colloidal stability with increasing pH 
values starting from pH 5.2. These observations corroborate the conclusions inferred 
from the thermal unfolding and aggregation investigations. 
 
Figure 82: TOPC data evaluation. Left: Zoom-in of the chosen timeframe of 125-150 seconds to be 
used for further analysis. Right: Mean fluorescence value and standard deviation analysis of the 
thermo-optical protein characterization results. Increasing values precisely indicate protein 
aggregation and particle formation. Error bars were calculated by standard error (n=3). 
In order to further investigate the effect of pH and beyond that target the impact of 
formulation excipients on the stability of the mAb, the formulation screening candidates 
(see page 135) have been included in the TOPC analysis (Figure 83). 
As a first result, the TOPC assay was again able to distinguish rapidly between 
aggregating and non-aggregating samples. In accordance with the pH pre-screening 
results, changing the formulation pH exhibited a tremendous effect on the colloidal 
stability after unfolding, which consequently resulted in a much increased aggregation 
and precipitation propensity for the candidates formulated at a pH value of 6.0 (F3, F5-
11) when compared to the formulations at low pH values of 4.2 (F1) and 5.0 (F2). 
While succinate (F4) and phosphate buffer (F3) expose equal aggregation and 
precipitation characteristics, the histidine formulation at pH 6.0 (F4) is of exceptional 
nature and must – due to its characteristic temperature dependent pH shift (see 
section VIII.2.1.1) – be evaluated with great care. In our selection of eleven 
formulations, F4 shows the highest aggregation resistance with very low fluorescence 
and scattering levels what points towards a strong temperature induced pH shift even 
below pH 4.2. 
For the majority of excipients (F7-F11), a scattering, and therefore precipitation 
reducing effect was observed, when compared to the solely buffered formulation 
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composition (F3). However, this does not hold true for the addition of PS 80 (F6) and is 
surprisingly most pronounced for F10, where 150 mM NaCl were added. While a low 
stabilizing capability of polysorbate was already observed in the thermal unfolding and 
aggregation studies, a stabilizing effect of salt was never detected and the result for 
this formulation might be biased by the high salt concentrations potentially hindering 
the precipitation in this setup. 
 
Figure 83: Normalized fluorescence timetraces over time (left) and data analysis (right) of thermo-
optical protein characterization within the formulation screening. 
VIII.2.2.2. Conventional Stress Testing 
In order to benchmark the findings of the thermo-optical protein characterization 
measurements, we initiated a conventional forced degradation study. Therefore, in a 
first step, the protein formulations of the pH pre-screening were thermally stressed by 
intensive heat exposure and subsequently analyzed for aggregation and particle 
formation by dynamic light scattering (Figure 84 - left), turbidity (Figure 84 - right), and 
visual inspection (Figure 85) against a reference formulation. The study revealed 
corresponding results among each other and in comparison to the high power IR-laser 
heating experiments with pH 4.0 to 5.0 showing no to minimal increases in particle size 
and turbidity. DLS detected soluble aggregate growth in the nm to low µm range from 
pH 5.2 to 5.6 before larger precipitates exceeded the measurement range at higher pH 
values. In contrast, turbidity and visual inspection did not observe protein aggregation 
until pH 5.4 but enabled to detect even large aggregates and precipitates up to pH 6.2. 
Moreover, the latter exposed sedimentation of larger insoluble precipitates for the 
pH 5.8, 6.0 and 6.2 buffered formulations. 
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Figure 84: Benchmarking by forced degradation for the pH pre-screening. After incubation of the 
protein formulations at elevated temperatures, dynamic light scattering (left) and turbidity (right) 
was measured against a reference buffer. Error bars were calculated by standard error (n  3). 
 
Figure 85: Visual Inspection after forced thermal degradation. While the formulation at pH 5.2 
shows neither an increase in turbidity nor visible particles, visible aggregation and precipitation is 
apparent for higher pH values. 
In a second step, stress testing was performed accordingly for the formulation 
screening samples. The analysis of the heat stressed formulations by DLS (Figure 86 
– left) and turbidity (Figure 86 – right) measurements revealed consistent trends when 
compared to the TOPC results. For the formulations F3 and F5-F11 which showed 
elevated fluorescence levels and high scattering during TOPC, much increased Z-
average diameters and turbidity values were received. On the contrary, F1, F2, and 
F4, which were found to be most aggregation resistant in TOPC, exposed only minor 
size and turbidity increases. 
The only deviations between the heat incubated samples were found for the 
formulations F10 and F4. In the comparative forced degradation study, F10 shows a 
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similar stability profile as found for the other excipients, while the aggregation and 
precipitation propensity was reduced for the TOPC measurements. These results are 
congruent with the findings for the thermal unfolding and stability measurements and 
render the significance of TOPC results under widely varying tonicities questionable. 
Furthermore, F4 was ranked the most stable formulation in the TOPC assay, whereas 
this formulation shows a more pronounced size and turbidity increase in comparison to 
F1 and F2 when analyzed after the classical external forced degradation approach 
which is presented here. This variation could be attributed to different assay setups 
and incubation temperatures during heat exposure. In the forced degradation 
approach, the incubation temperature is fixed to 80 °C and the samples are analyzed 
after heat stressing and cooling down to room temperature. However, for the TOPC 
setup, the samples are IR-laser heated to temperatures exceeding the melting 
temperature and aggregation as well as precipitation characteristics are analyzed in-
situ. Given the fact that the pH value of F4 is lowered during incubation at elevated 
temperatures and aggregation was less favored at lower pH values, the aggregation 
propensity is reduced in the TOPC assay when compared to the DLS and turbidity 
analysis at room temperature, where the pH returns to the initial value and the 
equilibrium between native and aggregated species is altered. This cooling step, which 
is necessary for the classical stress testing approach, is one major drawback of the 
procedure, as the molecular properties are prone to change and aggregation, as well 
as precipitation mechanisms could be induced or hindered. 
 
Figure 86: Benchmarking by forced degradation. After incubation of the protein formulations at 
elevated temperatures, dynamic light scattering (left) and turbidity (right) was measured against a 
reference buffer. Error bars were calculated by standard error (n=3). 
Taken all aspects together thermo-optical protein particle characterization revealed a 
comparable aggregation and precipitation profiling in comparison to the forced-
degradation benchmarking, but was able to differentiate more clearly between the 
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aggregating formulations in real-time by using much less time and experimental effort. 
However, it is to mention that the chosen heat stress conditions (storage at 80 °C) 
deviate from standard forced degradation approaches, where incubation usually is 
executed below the melting temperature of the protein. In our case, we wanted to 
mimic the condition during TOPC, where full denaturation of the protein is reached 
before aggregation is induced. 
VIII.2.2.3. Comparison and Evaluation of TOPC as a Tool for Predictive 
Forced Degradation Studies 
The present work introduced an innovative approach for fast and reliable differentiation 
between stabilizing and destabilizing formulation conditions for exemplary pH and 
formulation screenings of a monoclonal antibody (mAb). In the TOPC setup, changes 
in the intrinsic tryptophan fluorescence of the protein were measured during IR-laser-
induced heating of the samples. This temperature increase led to characteristic 
fluorescence changes over time, which were attributed to separable effects of protein 
unfolding, aggregation, and precipitation, depending on the stability of the respective 
formulation. The obtained signals were compared with data from forced degradation 
and thermal stability measurements and correlated well both with the aggregation 
propensity and with the reversibility of unfolding in different formulations. Moreover, the 
most promising formulation in terms of maximal aggregation resistance and thermal 
stability was identified in combination with thermal unfolding measurements as shown 
in section VIII.2.1. These results, gathered with only 4 µL sample volume and 150 s 
measurement time per formulation, demonstrate that our straightforward approach 
facilitates preformulation studies by combining thermal stress testing with 
simultaneous protein aggregation and precipitation detection and therefore makes 
sophisticated instrumentation for temperature control, light scattering and turbidity 
detection redundant. In future investigations, Thermo-Optical Protein Characterization 
should be considered as a competitive orthogonal method for material and time saving 
early formulation and drugability screenings in academic and industrial settings, as it 
has the potential for general applicability in rapid candidate and formulation selections. 
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VIII.2.3. Protein-Excipient Interaction Analysis 
VIII.2.3.1. Binding Studies with Cyclodextrins 
VIII.2.3.1.1. MicroScale Thermophoresis (MST) 
Binding of the mAb with three different cyclodextrins (α-CD, β-CD, and γ-CD) as well 
as two β-CD derivatives (HP-β-CD and SBE-β-CD) was investigated by using MST in 
two different assay buffers by only changing the solution pH. In Figure 87, the titration 
curves in 10 mM phosphate buffer pH 4.2 are shown, while Figure 88 displays the 
results in 10 mM phosphate buffer pH 6.0. For both experiments, data have been 
evaluated for thermophoresis (left) and intrinsic fluorescence (right). 
At pH 4.2, thermophoresis remains constant over the whole concentration range and 
therefore no protein-excipient interaction is observed. However, in the intrinsic 
fluorescence evaluation, a binding event of SBE-β-CD to the mAb seems to occur. 
Binding is indicated by a drop in fluorescence by almost 30% between the titration 
points at 23.3 µM and 468 µM. Though, just after reaching lower thermophoresis 
plateau, the fluorescence intensity increases again and almost returns to the initial 
baseline values at 7500 µM SBE-β-CD. This curve progression could be the effect of 
an association of SBE-β-CD to the antibody at medium excipient concentrations, which 
is followed by a dissociation process taking place at increased concentrations of SBE-
β-CD. 
Increasing the assay pH to 6.0, neither thermophoresis, nor intrinsic fluorescence 
shows any signal change over the whole concentration range of the cyclodextrins, 
including SBE- β-CD. This observation might be caused by a decreased positive net 
charge of the antibody, when approaching the isoelectric point. Including the lessons 
learned from the rh-GCSF-excipient interactions, an ionic binding mechanism was only 
possible with a positively charged protein being able to bind to the strongly negative 
charged SBE-β-CD. 
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Figure 87: Binding studies of the mAb to various cyclodextrins in 10 mM phosphate buffer pH 4.2 
evaluated by thermophoresis (left) and intrinsic fluorescence (right). 
 
Figure 88: Binding studies of the mAb to various cyclodextrins in 10 mM phosphate buffer pH 6.0 
evaluated by thermophoresis (left) and intrinsic fluorescence (right). 
VIII.2.3.1.2. Nano Differential Scanning Fluorimetry (nanoDSF) 
nanoDSF was used to verify the supposed binding mechanism between SBE-β-CD 
and the mAb by comparative thermal unfolding investigations with HP-β-CD in 10 mM 
phosphate buffer pH 4.2. Thus, for every titration step an unfolding scan was 
performed and changes in the unfolding curves, as well as the respective melting 
temperatures were evaluated from the intrinsic fluorescence emission ratio of 
350 nm/330 nm. 
Comparing the derived melting curves as shown in Figure 89, huge differences 
between HP-β-CD (right) and SBE-β-CD (left) are observed, which were also reflected 
in the melting temperature evaluation (Figure 90) Titrating HP-β-CD, both unfolding 
events remain unchanged at values of ~ 63.2 °C (Tm1) and ~ 74.6 °C (Tm2). For SBE-
β-CD, a shift towards lower temperatures was apparent with increasing cyclodextrin 
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concentrations for the complete melting curve, reducing both respective Tm values to 
52.9 °C (Tm1) and 66.7 °C (Tm2). 
With these results an interaction between SBE-β-CD and the mAb in 10 mM 
phosphate buffer pH 4.2 is confirmed. Unfortunately, the binding seems to favor the 
stabilization of the unfolded state and therefore decreases the apparent melting 
temperatures. These findings are in good alignment with the study by Serno et al.30,31, 
where no binding event between and IgG antibody and HP-β-CD could be resolved 
when using intrinsic fluorescence spectroscopy for binding detection. Furthermore, a 
considerable aggregation by SBE-β-CD addition was found for agitation and incubation 
at elevated temperature that was comparable or even deteriorated to a formulation 
without cyclodextrin. However, the adverse effects of agitation were effectively 
prevented by the use of HP-β-CD, while the resistance towards heat stress was 
slightly enhanced. Contrary to the original assumption, more recent studies by Serno32 
and Härtl 33,34 attribute the stabilizing effect of HP- β-CD against interfacial stress to 
weak direct interaction rather than competitive surface displacement. 
 
Figure 89: Thermal unfolding studies of the dilution series of SBE-β-CD (left) and HP-β-CD (right) 
to the mAb in 10 mM phosphate buffer pH 4.2. The unfolding events were tracked by nanoDSF and 
are displayed as the first derivative of the wavelength ratio 350 nm/330 nm. The color code 
corresponds to different cyclodextrin concentrations and changes from yellow over red to blue 
with progressing dilution. 
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Figure 90: Melting temperature evaluation of the mAb thermal unfolding studies in 10 mM sodium 
phosphate buffer pH 4.2 at different concentrations of HP-β-CD and SBE-β-CD. For all excipient 
concentrations, two melting points were detected for the mAb, independent of the cyclodextrin 
titrated. 
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VIII.3. Summary and Conclusions 
In the mAb case study presented, the strength and weaknesses of thermophoresis 
based approaches for protein formulation development were assessed within an 
extended formulation screening comprising a pH pre-screening step and a formulation 
excipient screening. Both, unfolding and aggregation studies by using MST, as well as 
forced degradation testing by using TOPC yielded in conclusive and highly comparable 
stability rankings of the formulations investigated. 
With negligible sample volumes of only 10 µl, rapid assay set-ups, exceptionally short 
hands-on times, and a very broad application range, MST outperformed benchmark 
methods like µDSC, extrinsic DSF and ICD. Generally, the high sensitivity and 
accuracy of intrinsic fluorescence approaches was favorable over the addition of 
extrinsic dyes that led to artifacts and thus impacted the universal applicability. 
However, the gathered results by using MST match the benchmark results precisely 
but do not offer any further insights into conformation and aggregation propensities 
when compared to standard readouts like fluorescence or calorimetry. One drawback 
revealed for all thermal unfolding and aggregation assays was the fallacious 
assessment of stabilities for formulation candidates containing temperature sensitive 
buffer systems like histidine or tris. There, isothermal chemical denaturation (ICD) 
assays, performed at room temperature are beneficial.3 In such assays, automated 
liquid handling and high-throughput fluorescence detection is of great advantage, while 
also MST can be used for evaluation.35-37  
TOPC, as an innovative approach to forced degradation investigation and online 
aggregation monitoring, was compared to conventional stress testing by incubation at 
elevated temperature and subsequent analysis of turbidity and size distribution. Widely 
matching results were achieved in a fraction of the time and by using marginally 
sample volumes by using TOPC. However, the harsh stress condition used for sample 
incubation guaranteed for best comparability with the TOPC approach but deviates 
from standard forced-degradation temperatures, which are typically chosen below the 
unfolding temperature.   
One further limitation of thermal unfolding and aggregation, as well as forced 
degradation is the missing correlation to long-term stability data at quiescent storage 
conditions, which would enable further insights into the predictive power of both short-
term stability testing approaches. 
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Furthermore, the feasibility of rational excipient selection by using MST was 
investigated by targeting the binding of several cyclodextrin variants to the mAb and 
evaluating the stabilizing or destabilizing effect of the addition via thermal unfolding. In 
this study pH dependent binding was detected between the mAb and SBE-β-CD that 
led to adverse stability effects but nevertheless suggest a broader utilization of binding 
assays for excipient screenings. 
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Chapter IX  
Overall Summary and Conclusion 
In this thesis, MicroScale Thermophoresis (MST) was developed and qualified as a 
versatile and reliable orthogonal tool for the high-throughput analysis and stability 
prediction of protein pharmaceuticals. This supports the quest for new straightforward 
analytical approaches in the early stages of biopharmaceutical development and thus 
enables a faster and more efficient lead formulation candidate selection. The 
application range demonstrated comprises investigations of (i) the conformational 
stability, (ii) the aggregation propensity, and (iii) protein-excipient interactions, as three 
major challenges and objectives in the field. 
The main focus of our work was on the assessment of physical protein stabilities by 
using MicroScale Thermophoresis (MST) as a novel label-free high-throughput readout 
technique for thermal unfolding and aggregation investigations. Furthermore, a method 
termed Thermo-Optical Protein Characterization (TOPC) was developed as a 
screening tool investigating non-native aggregation propensities within minutes by IR-
laser induced forced thermal degradation and in-situ intrinsic fluorescence readout. 
Besides innovative physical stability investigations, the commercialized and well-
established MST interaction analysis assay was tested for the rational screening of 
formulation excipients and the examination of interaction mechanisms. 
For both physical stability assessments, namely unfolding and aggregation 
investigations by using MST and forced degradation studies by using TOPC, extensive 
method and assay development was performed (Chapter IV). Prototype setups were 
constructed and steadily optimized in the course of the study, while measurement 
assays and data evaluation routines were developed and validated by the use of proof-
of-principle investigations. 
In the following, all thermophoresis based approaches were investigated as new tools 
for essentially label-free high-throughput stability and interaction analysis during 
formulation development. Four protein stability and formulation screening case studies 
were presented examining (i) engineered antibody derivatives (Chapter V), (ii) the 
model protein human serum albumin (HSA, Chapter VI), (iii) the cytokine recombinant 
human granulocyte colony stimulating factor (rh-GCSF, Chapter VII), and (iv) a model 
monoclonal antibody (mAb, Chapter VIII). All results were comprehensively 
benchmarked with established analytical methods, alternative assays and existing 
literature data. 
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Unfolding and aggregation investigations by using MST in a stepped thermal ramp 
assay (sections V.2.1, VI.2.1, VII.2.1, and VIII.2.1) showed two types of events that 
could be either correlated to protein unfolding transitions or to non-native protein 
aggregation. Protein melting transitions were reflected in distinct broad positive or 
negative peaks in the recorded melting curves for thermophoresis and/or t-jump, which 
were evaluated as apparent melting temperatures (Tm). In the same denaturation 
assay, occurring aggregation (and precipitation) was reflected in very sharp spike-like 
peaks, which were either used to simply indicate the formation of protein aggregates or 
to calculate aggregation onset temperatures (Tagg onset) and rank the formulations in 
terms of their aggregation stability. Thus, MST was capable of reliably detecting 
physical stability changes in the conformational state and aggregation behavior of 
multiple proteins and can be used for the rapid differentiation between stable and 
instable proteins and formulation conditions.  
The derived stability predictions were found to be highly comparable and conclusive 
over conformational stability and aggregation propensity and correlate well with gold-
standard reference techniques as intrinsic and extrinsic fluorescence, static and 
dynamic light scattering as well as calorimetry. Evaluating MST in the context of the 
benchmark methods (Table 25), our technique was classified with a low sample 
volume, short hands-on time and a very broad application range. Furthermore the 
measurement precision, resolution and repeatability were remarkable. However, the 
exceptional data density and resolution of µDSC is even beyond and allows for the 
analysis of even minute and overlapping unfolding transitions with reproducible data 
fitting and evaluation, when operated at an optimal protein concentration. The 
measurable concentration range is, in contrast, many times larger for MST, SLS and 
the intrinsic fluorescence approaches, which resulted in a comparably low noise level 
in the raw data and a smaller replicate deviation for the low concentrations 
investigated. Extrinsic fluorescence approaches (DSF) exclusively showed 
disadvantages compared to label-free assays, only covering a narrow dynamic range 
and additionally bearing the risks of altering the formulation stability and creating 
measurement artifacts by the addition of fluorescent reporter dyes.  
Summarizing our findings for thermal unfolding and aggregation investigations, 
outstanding performance was received from in parallel developed intrinsic 
fluorescence approaches (i.e. Prometheus NT.48) that in the meantime clearly lead 
the field of straightforward, high-throughput and low material consuming stability 
assessments. In the end, no significant added value or benefit could be obtained from 
MST analysis on top of intrinsic fluorescence. 
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Forced degradation studies by using TOPC were utilized for rapid IR-laser heating and 
in-situ intrinsic fluorescence evaluation of emerging aggregation and precipitation over 
time (sections VI.2.2, VII.2.2, and VIII.2.2). Thereby, the accumulation of soluble 
protein aggregates in the focal area was tracked via increasing fluorescence 
baselines, while precipitation resulted in emerging and intensifying signal scattering, 
which is attributed to the periodical flow of particles through the measurement area. 
Our results were found to match the stability rankings from unfolding and aggregation 
investigations and furthermore coincide with conventional stress testing approaches by 
heat incubation and subsequent aggregate analysis. In comparison, TOPC enables 
online detection of protein aggregation and precipitation in real-time. Thus, a robust 
and reproducible stability profiling can be obtained in 150 s measurement time per 
formulation, which clearly outcompetes conventional stress testing approaches. 
The assessment of protein-excipient interactions by using MST was used to further 
investigate molecular stabilization and destabilization mechanisms of excipients in 
protein formulations (sections VII.2.3 and VIII.2.3). The results of protein-cyclodextrin 
interaction studies were confirmed by determining the stability consequences of 
excipient addition by using nanoDSF. Consequently, the titration of binding excipients 
led to alterations in the conformational stability, while for the non-binding excipients no 
effect was observed. Furthermore, protein-surfactant interactions were investigate in 
MST binding studies and suggested a temperature and surfactant concentration 
dependent incorporation into pluronic F-127 micelles. 
In summary, it can be stated that repetitive MST analysis in a stepped thermal ramp 
assay and IR-laser heating induced forced degradation via TOPC were successfully 
established as reliable orthogonal methods for the assessment of unfolding and 
aggregation parameters. Both methods provide multiple advantages over established 
approaches in terms of sample throughput, material consumption, precision, 
reproducibility, and application range. Furthermore, standard label-free MST was 
successfully applied for the fast and easy determination and quantification of protein-
excipient interactions. 
In conclusion, our results gained understanding for protein specific degradation 
pathways and interaction mechanisms, which both helped to derive a protein-specific 
stabilization strategy. For future investigations, this information can be used for a more 
rational excipient selection and to reduce the number of possible formulation 
candidates already in early development phases. A combination of conformation and 
aggregation sensitive analytics is proposed as gold-standard for the predictive stability 
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determination of protein formulations. Our results suggest performing these 
investigations either by using MST as a standalone technique covering both readouts, 
or by a combination of intrinsic fluorescence with an aggregation detecting technique.  
Most useful combinations, as derived from our studies, consist of nanoDSF for 
unfolding analysis and TOPC or SLS for the investigation of protein aggregation and 
precipitation. The lately developed back-reflection aggregation detection optics, which 
was implemented as an add-on technique to nanoDSF within the Prometheus systems 
represents another highly interesting alternative. Furthermore, chemical denaturation 
should be considered as an alternative orthogonal approach to the predominant 
thermal unfolding assays, in order to not run in the risk of eliminating potentially stable 
formulations or selecting potentially instable systems due to pH changes occurring 
under elevated temperatures.  
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Table 25: Comparison of methods used for the determination of unfolding and aggregation 
stability parameters in thermal ramp setups. 
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